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Abstract
Atherosclerosis is a chronic inflammatory disease characterized by thickening of the arterial
wall from accumulation of lipoproteins and immune cells within the vessel intima, forming a
lipid-rich plaque. Macrophages play a central role in atherosclerosis progression through
phagocytic removal of apoptotic cells in a process termed efferocytosis. With disease
progression however, macrophage efferocytosis becomes defective and uncleared apoptotic
cells undergo secondary necrosis and form a necrotic core that increases the risk of plaque
rupture. Despite the importance of defective efferocytosis in atherosclerosis, little is known
about how efferocytosis becomes impaired. The aim of this thesis was to characterize
mechanisms regulating efferocytic clearance of apoptotic cells and to identify potential
mechanisms that contribute to impaired efferocytosis in atherosclerosis. Using a combination
of mass spectrometry and microscopy-based efferocytosis uptake assays, we identified Rab17
as a regulator of apoptotic cargo trafficking to the recycling endosomes. Disruption of Rab17
function using a dominant-negative mutant resulted in mis-trafficking of apoptotic cargo away
from recycling endosomes and into the MHC class II loading compartment. We then examined
the gene expression profile of macrophages from the aortas of patients undergoing open heart
surgery to identify potential mechanisms driving defective efferocytosis. We found over 3,000
differentially-expressed protein-coding genes in these macrophages, with particular
enrichment in pathways involved in cholesterol handling, efferocytosis and efferosome
maturation. Interestingly, we observed upregulation of the hematopoietic transcription factor
GATA2, which has been shown by genetic linkage studies to be associated with coronary
artery disease. By perturbing GATA2 expression in oxLDL-treated THP-1 human
macrophages, we found that oxLDL-induced impairment in efferocytosis and efferosome
maturation is dependent on GATA2. Our findings indicate that exposure to pro-atherogenic
conditions induces upregulation of GATA2 expression, which specifically impairs efferocytic
uptake of apoptotic cells and efferosome maturation. Our data shed new light on the process
of macrophage efferosome maturation and how this process is impaired in atherosclerosis. We
are also the first to describe a role for GATA2 in mediating oxLDL-induced impairment in
efferocytosis. Therefore, GATA2 and other processes involved in dysregulation of efferosome
maturation may be suitable therapeutic targets in human atherosclerotic disease.
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Lay Abstract
Atherosclerosis is a disease of the blood vessels involving the accumulation of cholesterol and
cells of the immune system within the vessel wall. This results in the formation of an
atherosclerotic plaque, which grows over time and may eventually rupture and cause a number
of complications, including heart attack and stroke. A type of immune cell called macrophages
can migrate into the atherosclerotic plaque and remove dying cells and debris from within the
plaque in a process called ‘efferocytosis’. Macrophage efferocytosis helps limit the growth of
the plaque. However, over time efferocytosis within the plaque becomes defective, and
macrophages are no longer able to limit plaque growth leading to faster disease progression.
In this thesis, we studied macrophages isolated from atherosclerotic plaques in human patients
to understand how efferocytosis becomes defective in atherosclerosis. We first identified a new
regulator of efferocytosis called Rab17, which helps the macrophage properly break down the
dead cells and debris it takes up during efferocytosis. We then found that certain genes and
pathways related to efferocytosis were dysregulated in the macrophages from patients. These
included pathways related to how the macrophage processes excess cholesterol and how
macrophages deal with the dead cells they take up. Finally, we identified a transcription factor
(protein that regulates gene expression) that was associated with defective efferocytosis called
GATA2. We found that an increase in the amount of GATA2 in the cell seemed to be required
for macrophages to develop defective efferocytosis. Taken together, these results advance our
understanding of atherosclerosis and uncovers a role for GATA2 in the development of
atherosclerotic disease.
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Chapter 1

1

Introduction

1.1 Efferocytosis and regulation of tissue homeostasis
1.1.1

Overview of efferocytosis

The removal of dying and dead cells in situ is essential in multicellular organisms for
proper growth during embryogenesis and early development, and for maintenance of tissue
homeostasis in adults.1,2 Cells that are senescent, damaged or have otherwise received an
appropriate signal undergo a form of programmed cell death termed “apoptosis”.1,3
Apoptosis involves a series of tightly regulated processes mediated by sequential activation
of caspase enzymes that result in degradation of cellular compartments and packaging of
cellular contents in plasma membrane-contained vesicles known as apoptotic bodies.2,4
Apoptotic bodies must be efficiently removed in order to safely dispose of their contents
and to avoid secondary necrosis, a process whereby uncleared apoptotic bodies leak their
contents, which include a number of pro-inflammatory damage-associated molecular
patterns (DAMPs), into the extracellular milieu and instigate a pathological inflammatory
response.5,6
Apoptotic bodies are removed by other cells through phagocytic uptake and intracellular
degradation of the apoptotic contents.1 This process of phagocytic removal of apoptotic
cells is known as “efferocytosis”.1,2 Efferocytosis is a highly conserved physiological
process that is crucial for the maintenance of tissue homeostasis, play a role in
organogenesis, tissue remodeling (e.g. bone growth, involution of mammary glands, etc.),
tissue repair following injury, and, in certain species, during organ or limb regeneration.7–
9

Efferocytosis is a highly efficient process. Under normal conditions, uncleared apoptotic

cells are rarely detectable in vivo, even in tissues undergoing high rates of cellular turnover
such as the tonsils and thymus.10
The importance of efferocytosis in tissue homeostasis is underscored by fact that defective
apoptotic cell clearance appears to be a central feature of several inflammatory and
autoimmune diseases, including systematic lupus erythematosus and atherosclerosis.10–12
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1.1.2

Types of efferocytes in the body

In higher mammals, including humans, dying cells within tissues are removed by either
cells that are specially adapted for efferocytosis or by neighbouring cells for which
efferocytosis is not a primary function depending on the specific tissue in question and the
circumstances of cellular death.13,14 The professional phagocytes for which efferocytic
removal of apoptotic cells is a primary function include macrophages and dendritic cells,
of which macrophages in particular are thought to carry out the majority of efferocytosis
across a diverse range of tissues within the body.3 However, many other cell types have
been observed to possess limited efferocytic capacity and usually function to remove
neighbouring apoptotic cells under specific circumstances.13 These so-called nonprofessional phagocytes include epithelial cells, endothelial cells and fibroblasts.15–17 Nonprofessional phagocytes are less efficient at apoptotic cell clearance, internalize apoptotic
cells at a slower rate and lack the capacity to clear multiple apoptotic cells in rapid
succession.18
In certain immune-privileged sites where circulating immune cells cannot access, nonprofessional phagocytes play an essential role in apoptotic cell clearance.19,20 One example
of this is within the eye, where specialized epithelial cells known as retinal pigment
epithelial cells efferocytose membrane-bound, rhodopsin-containing disc structures shed
on a daily basis by photoreceptor cells.21 Mutations in efferocytic receptors involved in this
process results in the development of retinitis pigmentosa, a progressive degenerative
disease characterized by loss of photoreceptor cells and resultant visual impairment and
loss.22 Another example of the role non-professional phagocytes within an immuneprivileged site is the clearance of apoptotic germ cells that arise in the process of
spermatogenesis by Sertoli cells within the testes.20 The presence of non-professional
phagocytes within these tissues highlights the importance of apoptotic cell clearance across
all tissues in the body.13
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1.1.3
1.1.3.1

Recognition and uptake of apoptotic cells
Find-me signals

Efferocytosis proceeds through a number of distinct stages, the first of which involves
migration of an efferocyte to the apoptotic cell.23,24 Similar to the migration of immune
cells towards pathogens and sites of infection, migration of efferocytes to apoptotic cells
is dependent on a number of soluble chemoattractants, called “find-me” signals, that guide
efferocyte migration in a concentration-dependent fashion.24 To date, four distinct find-me
signals have been identifying: extracellular adenosine triphosphate (ATP) and uridine
triphosphate (UTP), fractalkine (CX3CL1), lysophosphatidylcholine (lysoPC) and
sphingosine-1-phosphate (S1P).23 These signals are generated following activation of
executioner caspases that cleave a variety of structural components of the apoptotic
cell.23,25
The release of the extracellular nucleotides ATP and UTP occurs early in the execution
phase of apoptosis.26 Caspase 3/7-mediated cleavage of pannexin-1 on the apoptotic cell
surface leads to the opening of pannexin channels and release of cytosolic nucleotides into
the extracellular environment.27 Macrophages and other phagocytes recognize ATP and
UTP in the environment through the G-protein-coupled receptor (GPCR) P2Y2. P2Y2
activation promotes myeloid cell vascular adhesion and motility, and genetic deletion of
P2Y2 in mice delays the kinetics of apoptotic cell clearance in these animals.26
Another find-me signal that is released relatively early on during apoptosis is
fractalkine/CX3CL1.28 Fractalkine is an atypical chemokine that initially exists in a
membrane-bound form and is cleaved to a soluble form through the activity of the metal
metalloproteinases ADAM10 and ADAM17.29 Fractalkine is recognized by the receptor
CX3CR1.28 Truman et al. found that soluble fractalkine is released by apoptotic Burkitt
lymphoma cells and stimulated macrophage chemotaxis.28 In addition to acting as a findme signal for apoptotic cells, the CX3CL1-CX3CR1 signaling axis also appears to play an
important role in promoting monocyte cell survival.30 Absence of either ligand or receptor
results in decreased numbers of circulating monocytes in knockout mice and treatment of
human monocytes ex vivo with fractalkine extended their survival.31,32
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The other two known find-me signals, LysoPC and S1P, accumulate to physiologicallyrelevant levels only later in apoptosis (4-12 hrs following induction).23 LysoPC was first
described as a lymphocyte chemoattractant by Hoffman et al. in 1982.33 Caspase-mediated
activation of phospholipase A2 drives the production of lysoPC from phosphatidylcholine
found on plasma membranes.34 Peter et al. demonstrated that monocytes and macrophages
recognize lysoPC using the GPCR G2A, and that knocking down G2A expression in
macrophages inhibited cell migration in the presence of lysoPC.35 S1P is a lipid signal
mediator with a diverse range of biological functions.23 During the process of apoptosis,
S1P is generated by the activity of S1P kinase 2, which has been shown to be a target of
caspase 1.36 S1P is recognized by five GPCR’s on a range of lymphocytes (S1PR1-S1PR5)
and activation of these receptor drive lymphocyte migration under a variety of
circumstances, including mediating migration of monocytes and macrophages in response
to S1P release from apoptotic cells.24

1.1.3.2

Eat-me signals

Following migration of a phagocyte to the apoptotic cell through the action of find-me
signals, the next step in efferocytosis is recognition of the apoptotic cell by the phagocyte.2
This is achieved through recognition by the phagocyte of specific ligands on the surface of
the apoptotic cells, called “eat-me” signals.23,37 A number of eat-me signals have now been
identified, including exposure of phosphatidylserine (PS) on the outer leaflet of the plasma
membrane, alterations in the glycosylation patterns on the apoptotic cell surface, changes
in ICAM-1 epitopes on the cell surface, and exposure of the endoplasmic protein
calreticulin on the cell surface.2,5
Of these, PS exposure on the plasma membrane outer leaflet has been by far the most
recognized and well-understood eat-me signal.38 In healthy cells, PS is sequestered on the
cytoplasmic face of the plasma membrane through the activity of membrane flippases that
actively shuttle PS from the outer leaflet to the inner leaflet.5,38 Segawa et al. were able to
demonstrate that caspase 3/7-mediated cleavage of the ATP-dependent flippase enzyme
ATP11C is required for PS exposure during apoptosis.39 In contrast, scramblase enzymes
mediate movement of PS to the outer leaflet and Suzuki et al. showed caspase 3/7-mediated
cleavage of the scramblase Xkr8 led to its constitutive enzymatic activity and drove PS
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exposure.40 In a series of experiments using camptothecin- or anti-Fas-induced apoptosis
of Jurkat T cells, Borisenko et al. demonstrated that the amount of PS exposed on the cell
surface increased by >280-fold following induction of apoptosis and that a minimum
threshold of an 8-fold increase in PS levels on the cell outer surface was required before
macrophage-mediated efferocytosis would occur.41 In addition, it is also thought that a
fraction of exposed PS becomes oxidized or otherwise modified and that this may increase
its affinity towards certain efferocytic receptors.38
Despite the requirement for significant PS exposure before efferocytosis can occur, healthy
cells possess an additional means of safeguarding themselves against inappropriate
efferocytosis in the form of so-called “don’t eat-me” signals that inhibit phagocytosis.1,23
To date, just two such signals have been identified: CD47 and the recently recognized β2microglobulin (B2M) component of the major histocompatibility complex (MHC) class I
molecule.42,43 CD47 is a surface protein that belongs to the immunoglobulin superfamily
and interacts in cis with integrins and plays a role in immune cell migration and
proliferation.44 In the context of efferocytosis, CD47 is recognized by the surface
glycoprotein SIRPα expressed on the surface of phagocytes and the CD47-SIRPα signaling
axis serves to inhibit phagocytosis of the CD47-expressing cell through phosphorylation
of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on the cytoplasmic tail of
SIRPα, which leads to the recruitment of the phosphatases SHP1 and SHP2.45,46 The
activity of these phosphatase inhibits the accumulation of myosin II during phagocytic cup
formation to inhibit phagocytosis.46 More recently, Barkal et al. described the expression
of β2M on the surface of a range of human cancer cell lines and found that the level of
β2M expression correlated with the degree of protection against macrophage-mediated
phagocytosis.43 The authors found that β2M was recognized by the inhibitory receptor
LILRB1 expressed on the surface of macrophages and β2M-LILRB1 signaling was
sufficient to inhibit phagocytosis.43

1.1.3.3

Efferocytic receptors

Exposed eat-me signals on the surface of apoptotic cells are recognized by efferocytic
receptors expressed on the surface of efferocytes, either directly or through bridging
molecules that opsonize the apoptotic cell.3,46 Curiously, although there are only a few

6

recognized eat-me signals, these signals can be recognized by a wide range of efferocytic
receptors and opsonins.1,3 The majority of efferocytic receptors function by binding to PS,
either directly or through one or more opsonins. Among the efferocytic receptors that are
capable of binding directly to PS are: member of the TIM family of receptors (including
TIM-1, TIM-3 and TIM-4), brain angiogenesis inhibitor 1 (BAI1), Stabilin-2, members of
the CD300 family of receptors and the receptor for advanced glycation end products
(RAGE).47–51 Opsonin-dependent efferocytosis receptors include integrin αVβ3, the TAM
family of receptors, which includes three members: Tyro-3, Axl and Mer, and integrin αXβ2,
which was recently described by our lab to participate in efferocytosis.52–54 The other eatme signals also have corresponding efferocytic receptors. Modified ICAM3 is recognized
by CD14 on the phagocyte surface, calreticulin is recognized by low density lipoprotein
receptor-related protein 1 (LRP1; CD91) with the complement molecule C1q acting as a
bridging opsonin, while modified phospholipids, including oxidized PS, can be recognized
to a limited extent by the class B scavenger receptor CD36.55–57
Several bridging opsonins that recognize PS have been identified and work in concert with
efferocytic receptors that do not directly recognize PS to mediate recognition of apoptotic
cells.58 Hanayama et al. identified that the secreted glycoprotein milk fat globule-EGFfactor 8 (MFG-E8) could bind to PS on the surface of apoptotic cells.59 The same group
later found that in mice lacking MFG-E8, apoptotic lymphocytes in the spleen and lymph
nodes were not efficiently cleared and the mice went on to develop autoimmune
glomerulonephritis, underscoring the importance of this MFG-E8 in efferocytosis in vivo.60
MFG-E8 is recognized by integrin αVβ3 and mediates αVβ3-dependent recognition of
apoptotic cells.38 Two other opsonins, the vitamin K-dependent proteins Gas6 and protein
S, are recognized by the TAM family of efferocytic receptors and mediate TAM receptordependent apoptotic cell recognition.53,58 Protein S is produced by a wide variety of tissues
across the body and is found as a circulating factor in the blood.53 In addition to its role in
efferocytosis, protein S also plays an important role as a cofactor for protein C in the
inactivation of factors Va and VIIIa in the extrinsic pathway of the coagulation cascade.53
Gas6 is primarily produced by endothelial cells, vascular smooth muscle cells and in the
bone marrow.53 Members of the TAM family have different affinities for each of these
opsonins, with Gas6 preferentially binding to Axl and protein S binding preferentially to
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Tyro-3 and MerTK.53 Two other potential opsonins that have been recently proposed to
function cooperatively with the TAM family of receptors are the signaling proteins tubby
and tubby-like protein 1 (TULP1), both of which are preferentially recognized by
MerTK.61 Mice lacking either tubby or TULP1 have significantly impaired efferocytosis
within the retina and develop a number of vision disorders as a result.62,63 Finally, our lab
has recently identified a soluble form of the transmembrane glycoprotein CD93 (solCD93)
as an opsonin that mediates integrin αXβ2-dependent efferocytosis.54 A summary of findme signals, eat-me/don’t eat me signals and their cognate receptors and opsonins is
presented in Table 1.1.
Table 1.1 List of find-me, eat-me and don't eat me along with their cognate opsonins
and/or receptors.
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1.1.4

Apoptotic cell internalization

Following recognition of the apoptotic cell, it is subsequently internalized by the efferocyte
for degradation and clearance.64 The process of apoptotic cell uptake is complex and there
are probably multiple signaling pathways utilized by different efferocytic receptors. Peter
Henson and others have suggested that the process of apoptotic cell uptake occurs through
two distinct steps: binding of the apoptotic cell to the efferocyte and subsequently its uptake
into the efferocyte in what has been termed the “tether-and-tickle” process.1,23,65 Tethering
holds the apoptotic cell in place while the phagocyte forms an invagination within their
plasma membrane called a “phagocytic cup” to mediate the engulfment of the apoptotic
cell.66 Certain efferocytic receptors are able to mediate both apoptotic cell binding and
uptake, while others, including CD14 and TIM4, are able to tether apoptotic cells but do
not initiate their uptake.1 Indeed, it is believed that many efferocytic receptors that
recognize and tether apoptotic cells require cooperative binding and signaling through
integrins and other canonical phagocytic receptors to mediate apoptotic cell
internalization.67,68 One example of this is the efferocytic receptor TIM-4, which utilizes
β1 integrins as coreceptors in order to induce the necessary signal to initiate apoptotic cell
internalization.69
A complete discussion of the signaling pathways used by efferocytic receptors is beyond
the scope of this thesis, but has been reviewed in detail by Elliot et al., Freeman et al. and
others.46,58 However, signaling from efferocytic receptors appear to converge on the
activation of several Rho guanosine triphosphatases (GTPases): Rac1, Cdc42 and RhoA,
that drive formation of the phagocytic cup required to engulf and then internalize the target
apoptotic cell.37 Rac1 in its active state is a crucial mediator of actin polymerization via the
Scar/WAVE complex, which is required for formation of membrane extrusion and the
phagocytic cup.70 Signaling from efferocytic receptors activate Rac1 through recruitment
of several guanine nucleotide exchange factors (GEFs), in particular the Dock180-Elmo
complex which is crucial for apoptotic cell uptake and highly evolutionarily conserved.37
A number of other factors have also been found to participate in this process and drive
Rac1 activation. Among these is CrkII, a member of the Crk family of adaptor proteins that
are known to associate with Dock180.71 While a direct physical association between
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Dock180 and CrkII appears not to be required for internalization of apoptotic cells, deletion
of the CrkII homologue in C. elegans was sufficient to abrogate efferocytosis.72 An
illustration of efferocytic receptor crosstalk and convergence at Rac1-Dock180-Elmo
complex is presented in Figure 1.1.

Figure 1.1 Convergence of efferocytic receptor signaling onto Rac1 activation.
Efferocytic receptors (BAI1, integrin αVβ5, stabilin-2) utilize distinct signaling pathways
that convergence on the activation of the Rho-GTPase Rac1. Activation of BAI1 results in
recruitment of the Dock180-Elmo GEF complex, which directly activates Rac1. Signaling
from integrin αVβ5 recruits focal adhesion kinase (Fak), which recruits the CrkIIDock180-Elmo complex using the scaffold protein p130Cas as a mediator. Stabilin-2
signaling recruits the adaptor protein Gulp1, which is thought to mediate direct activation
of Rac1 or enable cooperative signaling with integrin αVβ5 to drive Rac1 activation. Figure
adapted from Penberthy & Ravichandran.37

10

Rac1 activity is antagonized by RhoA, which activates the Rac1 GTPase-activating
proteins (GAPs) p190Rho-GAP and FilGAP to drive Rac1 inactivation.73 The contribution
of RhoA to efferocytosis has been somewhat controversial since it plays different roles
during phagocytic cup formation and phagocytic cup closure.70 While impairment of RhoA
function results in impaired apoptotic cell clearance, there is evidence that its activity is
required for phagocytic cup closure and internalization of the apoptotic cell.74,75 Indeed, it
has been demonstrated that RhoA signaling through Rho-associated protein kinase
(ROCK) drives activation of myosin II, which is crucial for actin contraction and functions
to pull the engulfed apoptotic cell into the efferocyte.76 Using fluorescence resonance
energy transfer (FRET)-based biosensors to examine the spatiotemporal dynamics of Rac1
and RhoA activation, Kim et al. found that the ratio of Rac1/RhoA appeared to play a role
in determining whether apoptotic materials were internalized by the efferocyte, with the
authors suggesting that this served as an additional mechanism to prevent inappropriate
efferocytosis.77

1.1.5

Efferosome maturation

Following closure of the phagocytic cup, the apoptotic cell is fully contained within a
plasma membrane-derived vacuole, which then undergoes scission from the cell surface
membrane to form an efferosome.70 The efferosome then undergoes a series of highly
regulated biochemical modifications to efficiently degrade the internalized apoptotic cell
in a remodeling process called efferosome maturation.64,70 Efferosome maturation is
characterized both by sequential fusion with early and then late endosomes along with
progressive acidification of the efferosomal lumen in order to drive the breakdown of
apoptotic cargo.64 The regulation of efferosome maturation is complex but the most welldefined mechanism driving this process is the sequential recruitment of the small GTPases
Rab5 and Rab7 to the efferosome surface (see Figure 1.2).64
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Figure 1.2 Sequential recruitment of the small GTPases Rab5 and Rab7 to the
efferosome surface regulates efferosome maturation.
Following apoptotic cell recruitment, Rab5 is recruited to the surface of the nascent
efferosome, where it drives fusion between the efferosome and early endosomes to form
the early efferosome. Fusion with early endosomes also mediates recycling of efferocytic
receptors to the cell surface. Rab5 is then replaced on the efferosome surface by Rab7,
marking the transition to the late efferosome. The late efferosome undergoes acidification
and fusion with lysosomes, acquiring the lysosomal marker LAMP-1 as a result. Figure
adapted from Kinchen & Ravichandran.64
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One of the earliest maturation events following apoptotic cell internalization is recruitment
of Rab5 to the nascent efferosome, a process that is driven by the Rab5 GEF Gapex-5.78
Initially, activated Rab5 recruits another GEF, Rabex-5, which is thought to further recruit
Rab5 and stabilize Rab5 on the surface of the efferosome.79 A series of Rab5 effectors are
also recruited to the early efferosome, including: EEA-1, Vps-34 and Mon1a/b.79 EEA-1
mediates fusion between the efferosome and early endosomes, which mediates trafficking
to the recycling endosome and receptor recycling back to the cell surface.80 Vps-34
functions as a phosphoinositide 3-kinase (PI3K) and mediates formation of
phosphoinositide 3-phosphate (PI3P), which functions to both enhance Rab5 recruitment
and mediate Rab7 recruitment to the efferosome downstream of Rab5 activation.81
Mon1a/b displaces Rabex-5 and shuts down the Rab5 recruitment loop and also functions
in complex with the vacuolar trafficking protein Ccz1 to recruit the tethering homotypic
fusion and protein sorting (HOPS) complex.82,83 The Vps-39 subunit of HOPS complex
possesses Rab7 GEF activity and this complex mediates the transition between Rab5 and
Rab7 on the efferosome surface.83
Replacement of Rab5 by Rab7 marks the transition from the early efferosome to the late
efferosome.64,83,84 Rab7 effectors have crucial roles in driving remodeling events that result
in apoptotic cell degradation. These mediators include Rab7-interacting lysosomal protein
(RILP) and oxysterol-binding protein-related protein 1 (ORPL1), which together interact
with the dynein/dynactin motor complex to drive trafficking of late efferosome along
microtubules to the perinuclear region of the efferocyte.85–87 This movement is necessary
for efficient fusion between late efferosomes and lysosomes, and the delivery of
degradative lysosomal hydrolases into the efferosomal lumen.87,88 RILP further recruits
V1G1, a subunit of the vacuolar ATPase (v-ATPase), which mediates v-ATPase assembly
on the efferosome surface and drives efferosomal acidification and activation of lysosomal
hydrolases to complete degradation of apoptotic cargo.89

1.1.6

Cellular consequences of efferocytosis

The hallmark of efferocytosis is the lack of an inflammatory response.1,2 Indeed,
efferocytosis is considered to be either immunologically silent—meaning that efferocytes
do not produce pro-inflammatory factors nor do they present apoptotic cell-derived
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antigens or initiate an immunological response—or actively anti-inflammatory.1
Additionally, the efferocyte must effectively deal with the added metabolic stress of
internalizing an entire apoptotic cell and the contents thereof.1,90 In macrophages,
efferocytosis leads to further reinforcement of a tissue remodeling/repair state. This is
achieved through a positive feedback loop whereby engagement of efferocytic receptors
drives the upregulation of the expression of both efferocytic receptors and certain
opsonins.91
Efferocytosis has a well-documented role in restraining the generation of inflammation.92
Many of the receptors involved in efferocyte recruitment and apoptotic cell recognition
themselves have been shown to suppress inflammation.58,92 For example, signaling from
the fractalkine receptor CX3CR1 simultaneously induces production of proinflammatory
cytokines while enhancing expression of both pro-survival signals such as the antiapoptotic protein Bcl-2 and anti-oxidant factors such as hemeoxygenase-1 (HO-1).32,93 In
addition, almost every PS receptor has been shown to exhibit some degree of antiinflammatory activity. Signaling through both TIM-3 and MerTK have been shown to
inhibit nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated
expression of pro-inflammatory genes.94,95 Engulfment of apoptotic cells leads to
activation of several nuclear factor family transcription factors in the efferocyte.96,97
Activation of these transcription factors play a role in generation of an anti-inflammatory
state through increasing the expression of several anti-inflammatory cytokines. Activation
of liver X receptor (LXR)-α/β and peroxisome proliferator-activated receptor (PPAR)-δ
downstream of apoptotic cell internalization drive the expression of TGF-β and IL-10.96,98
Internalization of apoptotic cells imposes a significant metabolic load upon efferocytes,
which must adapt accordingly to deal with this stress.1,90 Activation of LXR-α/β, in
addition to dampening inflammation, also leads to upregulation of ATP-binding cassette
transporter member 1 (ABCA1), which is a major transporter responsible for cholesterol
efflux from the cell.99 Upregulation of ABCA1 (and the related cholesterol transporter
ABCG1) has also been shown by Yvan-Charvet et al. to protect against excessive
production of superoxides as a result of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase 2 activation in response to apoptotic cell internalization.100 In addition
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to cholesterol efflux and anti-oxidant activity, efferocytes are able to cope with cholesterol
and lipid accumulation, which have been shown to exert a pro-apoptotic effect, through
cell survival signaling through the PI3K/Akt axis and activation of anti-apoptotic proteins
such as Bcl-2.101 Finally, due to the intake of excess carbohydrates and lipids from
efferocytosis, mitochondrial function in efferocytes has been shown to be altered postapoptotic cell internalization. Park et al. demonstrated that mitochondrial membrane
potential decreased post-efferocytosis in manner dependent on the mitochondrial
membrane protein mitochondrial uncoupling protein 2 (Ucp2).102 More recently, Wang et
al. demonstrated that dynamin related protein 1 (Drp1)-mediated mitochondrial fission in
response to apoptotic cell internalization was required for increasing intracellular calcium
levels, which the authors found to be required for efficient continuous uptake of multiple
apoptotic cells by professional phagocytes.103 Similarly, Morioka et al. found that
expression of glucose transporter 1 (Glut-1) was upregulated following efferocytosis and
helped drive metabolic reprogramming of the efferocyte towards being glycolysisdominant.104 This transition was found by the authors to also be required for continuous
efferocytosis.104

1.2 Atherosclerosis and the role of macrophages
1.2.1

Atherosclerosis

Atherosclerosis is characterized by thickening of the arterial intima as a result of the
accumulation of modified lipoproteins and immune cells beneath the vessel
endothelium.105 The result of this accumulation is the formation of a lipid-rich plaque
overlaid by a fibrotic cap, referred to interchangeably as an “atherosclerotic lesion” or
“atheroma”.106,107 Atheromas cause stenosis of the arterial lumen, resulting in the
constriction of blood flow to vital organs.105 Significantly, atheroma growth over time can
result in weakening of the fibrotic cap and increased risk of plaque rupture.108 Rupture of
the plaque results in the formation of a thrombus overlying the plaque. Within the coronary
arteries, thrombus formation over a ruptured plaque may result in the occlusion of a vessel
and a subsequent myocardial infarction. The thrombus can also break off from the inciting
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plaque, travel through arteries and potentially lodge in the circulation, resulting in serious
complications including ischemic stroke and critical limb ischemia.105,109 (See Figure 1.3
for a summary of atherosclerotic plaque development). Atherosclerosis is the most
common cause of cardiovascular disease (CVD) such as coronary heart disease and
cerebrovascular disease, which together form the leading cause of death in Canada—
accounting for over 30% of all-cause mortality in the 2013 national census.110

Figure 1.3 Pathogenesis and progression of atherosclerosis.
Stages of atherosclerotic plaque progression. Lesions begin as pre-atherosclerotic fatty
streaks characterized by accumulation of ApoB-containing lipoproteins and a number of
immune cell types within the arterial intima. Next, proliferation of endothelial cells and
smooth muscle cells of the artery results in the formation of a fibrous cap that overlies the
lesion, leading to the formation of the established atherosclerotic lesion. Cell death and
generation of chronic inflammation within the lesion results in the formation of a necrotic
core and the thinning of the fibrous cap, increasing the risk of plaque rupture and forming
a vulnerable plaque. Finally, disruption of fibrous cap integrity through either endothelial
erosion or fibrous cap fissure results in the exposure of lesion contents to the circulation
and the formation of a thrombus. Figure adapted from Moore & Tabas.111
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Atherosclerosis is a prevalent disease and is found almost ubiquitously in individuals living
in

post-industrial

nations.109,112

The

influential

Pathological

Determinants

of

Atherosclerosis in Youth (PDAY) study has reported that among 2,876 U.S. subjects aged
15-34, lesions were identified in all of the aortas and more than half of the coronary arteries
of the youngest age group (15-19 years) and that lesions increased in both prevalence and
extent with increasing age.112 The risk factors for atherosclerosis align closely with those
identified for development of coronary artery disease by the Framingham Heart Study.113
The most important risk factor for atherosclerosis development and progression was age,
with older individuals possessing a greater lesion extent and more lesions that are
considered to be vulnerable and prone to rupture and causing serious complications.112,113
Other risk factors for atherosclerosis include: male sex, race (Southeast Asians are
particularly prone to developing significant atherosclerotic disease), smoking and the
components of metabolic syndrome (abdominal obesity, insulin resistance, hypertension
and high triglycerides/low high-density lipoprotein [HDL] levels).113 Atherosclerosis has
a clear genetic component as well, with certain monogenic disorders such as familial
hypercholesterolemia raising the risk of significant atherosclerotic disease significantly
and a multitude of allelic variants linked to increased risk of atherosclerosis.114
Atherosclerosis is a complex and multi-faceted disease with a number of factors that
contribute to its pathogenesis.105,115 The initiating event in atherosclerosis is thought to be
the retention of apolipoprotein B (ApoB)-containing lipoproteins, in particular modified
low-density lipoproteins (moLDLs) and lipoprotein remnant particles in the arterial
intima.116 Regions of the arterial tree with disturbed laminar flow (e.g. where a single vessel
branches into multiple vessels) are particularly prone to lipoprotein accumulation.117
Damage to the vessel endothelium, for example resulting from decreased nitric oxide
bioavailability and increased adhesion molecule expression on the endothelium as a result
of smoking, is a further potentiating factor for lipoprotein accumulation and plaque
formation.118 Disturbed or damaged endothelium upregulates cell surface adhesion
molecules.118–120 These receptors promote infiltration of circulating immune cells,
especially macrophages and T lymphocytes, into the developing lesion.121,122 There is also
evidence that activated endothelial cells increase their expression of scavenger receptors
that bind to moLDL and drive their trafficking across the endothelium and into arterial
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intima via cholesterol transcytosis within individual endothelial cells.123,124 These
pathological changes within the endothelium together result in accumulation of lipids and
immune cells within the intima.
Retention of lipoproteins in the intima results in increased endothelial activation, which
drives further modification of retained lipoproteins and the generation of sterile
inflammation.108,125 This state of inflammation results in the aberrant production of a
number of chemokines and the recruitment of cells of the innate and adaptive immune
system to the developing atheroma. These immune cells become retained within the
atheroma and contribute to the generation of a highly pro-inflammatory atheroma
microenvironment and a state of unresolved inflammation.115 The development of a
chronic inflammatory state within the atheroma has two major consequences: 1) sustained
endothelial activation resulting in further lipoprotein retention and modification, and 2)
proliferation of vascular smooth muscle cells (VSMCs) into myofibroblasts, which form a
fibrous cap that overlies the plaque.106,119 Persistent inflammation combined with growth
of a necrotic core composed of foam cells and lipid-rich debris over time results in thinning
of the fibrous cap and increased plaque vulnerability to rupture.108 Rupture results from
endothelial fissure or erosion, two distinct processes that result in exposure of the prothrombotic contents of the plaque to the circulation.126 There, phospholipids, tissue factor
and other pro-thrombotic plaque contents react with platelets and fibrin to quickly form
large thrombi that can rapidly occlude entire vessels.127
For decades, a focus of therapeutic intervention in atherosclerosis has been LDL
cholesterol reduction.128 Lowering the level of LDL in patients with a previous coronary
event using statins along with ezetimibe and/or proprotein convertase subtilisin/kexin type
9 (PCSK9) inhibitors has been shown repeatedly to confer a mortality benefit.129 However,
even with reduction of LDL to optimal levels, the rate of further cardiovascular events is
not completely eliminated.129,130 The remaining risk of a recurrent cardiovascular event,
called the residual risk, has widely been believed to be attributable to the inflammatory
component of atherosclerotic disease, which is not adequately addressed with LDL
lowering therapy alone.130 The first indication that inflammation had a role in
atherosclerotic disease in humans came from the Justification for the Use of Statins in
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Primary Prevention: An Intervention Trial Evaluation Rosuvastatin (JUPITER) trial, which
demonstrated that treating patients with low-to-normal LDL levels but high C-reactive
protein (CRP) levels (not causative for atherosclerosis but potentially indicative of ongoing inflammatory processes) lowered their risk of a major cardiovascular event by 0.20.6% over one year.131 More recently, the 2017 Canakinumab Antiinflammatory
Thrombosis Outcome Study (CANTOS) trial was able to definitively show that in patients
with a previous coronary event and optimally controlled LDL levels but high levels of high
sensitivity CRP, treatment with canakinumab, a monoclonal antibody that inhibits IL-1β,
could lower the risk of a recurrent cardiovascular event without affecting lipid levels.132
CANTOS provides strong evidence that targeting inflammation is a viable strategy for
treating atherosclerotic disease in humans.

1.2.2

Role of macrophages in atherosclerosis

Macrophages play a central role in the pathogenesis of atherosclerosis, both in efferocytic
removal of apoptotic debris in early stage of disease and in retention, pathologic
differentiation into lipid-laden foam cells and production of pro-inflammatory factors in
late-stage disease.116,121,133 They are arguably the central inflammatory cell of the
atherosclerotic plaque, acting as the major source of a number of key pathologic proinflammatory cytokines including TNF-α, IL-6 and IL-1β.134 Macrophage content has been
shown to be an indicator of atherosclerotic plaque progression, and in murine plaque
regression models, decrease in lesional macrophage content is observed to correlate with
the degree of disease regression.135,136 The number of circulating monocytes has also been
found to be increased in mouse models of atherosclerosis, suggesting that atherosclerotic
conditions have a systemic impact on hematopoiesis in addition to its local effects in the
vasculature.32,137
It is thought that activation of the endothelium in response to accumulation and
modification (particularly oxidation) of lipoproteins in the underlying intima results in the
release of chemokines such as CCL2 and CCL5 that recruit circulating monocytes to the
site of the lesion.138 Importantly, blockage of either these chemokines or their cognate
receptors abrogate monocyte migration into lesions and inhibit atherosclerosis
progression.111 Simultaneously, activated endothelial cells express a number of cell surface
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adhesion molecules, including P- and E-selectin, which interact with their cognate receptor
on the cell surface of monocytes to induce monocyte rolling.117,139 The monocyte integrins
very late antigen-4 (VLA-4) and lymphocyte function-associated antigen-1 (LFA-1) then
bind to their respective ligands on activated endothelial cells, vascular cell adhesion
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) to mediate
tethering and transmigration of the monocyte into the intima, where they proceed to
differentiate into macrophages.111,121
Initially, these macrophages play a protective role through the efferocytic removal of
apoptotic cells and debris, thereby limiting the size and expansion of the early
atheroma.140,141 However, a certain proportion of atheromas can progress to a more
advanced pathologic state, characterized by a breakdown of the ability to efficiently
efferocytose apoptotic cells (discussed in greater detail in Chapter 1.3).142 The
accumulation of cholesterol within these macrophages, through both uptake of modified
lipoproteins in the intima and efferocytosis of cholesterol-laden apoptotic cells drive the
formation of foam cells, described in greater detail in Chapter 1.2.4.143 Within the lesional
microenvironment, macrophages also experience inflammatory activation as a result of
cholesterol loading and the chronic inflammatory state of the plaque microenvironment,
described in detail in Chapter 1.2.3.13
Within advanced atherosclerotic plaques, macrophages contribute to the development of
necrotic cores and fibrous cap thinning, two features of vulnerable plaques.144
Macrophages contribute to fibrous cap thinning through induction of vascular smooth
muscle cell (VSMC) death through induction of VSMC apoptosis through engagement of
their Fas death receptors and through the production of pro-apoptotic cytokines such as
TNF-α.145 Another mechanism of macrophage-mediated thinning of the fibrous cap is
through production of matrix metalloproteinases (MMPs), which degrade collagen that
stabilizes the cap.144 In particular, macrophage production of MMP-2 and MMP-9 have
been shown to be involved in fibrous cap thinning in mouse models of atherosclerosis.146
Additionally, in mice lacking MMP-13, the collagen content of fibrous caps was found to
be increased.147
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Macrophages also contribute to the generation of necrotic cores, which serve to destabilize
plaques and increase the risk of rupture, through two distinct mechanisms: apoptosis of
advanced lesional macrophages, and a failure of surrounding macrophages to efferocytose
these apoptotic cells.148,149 Macrophage cell death within advanced atherosclerotic lesions
is the result of a combination of factors, including increased oxidative stress, activation of
death receptors by ligands that exist uniquely within advanced lesions and signaling from
Toll-like receptors (TLRs).126,150 Recently, endoplasmic reticulum (ER) stress pathways,
and the unfolded protein response (UPR) pathway in particular, have been recognized as
important contributors to macrophage cell death in atherosclerosis.144,151 Activation of the
UPR mediator C/EBP-homologous protein (CHOP) is associated with lesion progression
and with plaques with vulnerable features.151 Deletion of CHOP in animal models of
atherosclerosis has been shown to protect against lesional cell death and formation of large
necrotic cores.152
An overview of the many roles played by macrophages in the development of
atherosclerosis is provided in Figure 1.4.
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Figure 1.4 Features characteristic of pathologic monocyte/macrophage function in
atherosclerosis.
Monocytes and macrophages play a central role in the pathogenesis of atherosclerosis.
Activation of the endothelium overlying regions of lipoprotein accumulation results in
persistent monocyte influx. Within the lesion, monocytes differentiate into macrophages,
which produce pro-inflammatory cytokines and accumulate cholesterol through uptake of
modified lipoproteins and efferocytosis of cholesterol-laden apoptotic cells. Excessive
cholesterol accumulation results in the pathologic differentiation of macrophages into foam
cells, which are retained within the plaque and fail to egress. In advanced atherosclerotic
lesions, a combination of accelerated macrophage cell death and defective efferocytosis
results in the formation of a large necrotic core. Generation of pro-apoptotic factors and
matrix metalloproteinases by macrophages within advanced lesions also contributes to
fibrous cap thinning. A combination of necrotic core formation and fibrous cap thinning
increase the risk of plaque rupture and contribute to the vulnerable plaque phenotype.
Figure adapted from Tabas (2009).144
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1.2.3

Influence of the plaque microenvironment on macrophages

The presence of a chronic inflammatory state is an important factor in the pathogenesis of
atherosclerosis.115 There is ample evidence from gene expression studies of plaque-resident
macrophages and in knockout mice that the presence of inflammation drives accelerated
lesion progression and the absence or reduction of inflammation slows progression.150,153
Inflammatory activation of macrophages within the plaque appears to be at least partially
driven by signaling through the TLRs.126,154 In particular, TLR4 has been shown to bind
oxidized LDL (oxLDL) cooperatively with CD36 to activate NF-κB signaling and
expression of pro-inflammatory cytokines.155 Another pro-inflammatory pathway in
atherosclerotic macrophages involves accumulation of free cholesterol within the
macrophage cytoplasm which activates the Nod-like receptor pyrin domain containing 3
(NLRP3) inflammasome, driving the subsequent production of IL-1β and IL-18.156 Bone
marrow transplantation experiments using donor mice lacking NLRP3 results in decreased
lesion size compared to transplantation with wild type bone marrow.157 An overview of
pro- and anti-inflammatory signaling with atherosclerotic macrophages is presented in
Figure 1.5.
This aberrant activation of lesion-resident macrophages into an inflammatory phenotype
has important consequences for the progression of atherosclerosis.133 Indeed, analyses of
human atherosclerotic plaques have revealed a greater proportion of pro-inflammatory
macrophages compared to tissue remodeling macrophages within progressing lesions, and
in particular within vulnerable plaques.136 A number of studies have shown that
experimental models of atherosclerosis regression, including delivery of an apoE-encoding
adenovirus vector in Apoe-/- mice and transplantation of atheroma-laden aortic arch from
Apoe-/- mice into recipient C57BL6 mice with varying levels of HDL, demonstrate that
macrophage numbers and polarization state are significantly impacted.158,159 In these
models of atherosclerosis regression, investigators have consistently found lower overall
macrophage numbers within the atheromas and a greater proportion of tissue remodeling
macrophages.135,158,159
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Figure 1.5 Pro-inflammatory and anti-inflammatory signaling within lesion-resident
macrophages.
The atherosclerotic lesion microenvironment activates a number of pro-inflammatory
signaling pathways that converge on NF-κB activation. Simultaneously, inflammatory
activation is counterbalanced by anti-inflammatory signaling that upregulate pathways and
receptors involved in response to cholesterol loading. Lipid ligands within the plaque,
including oxLDL, minimally modified LDL (mmLDL) and lipoprotein(a) (LPa) induce
signaling through TLRs and scavenger receptors to induce the generation of proinflammatory cytokines, including RANTES (CCL5), KC (CXCL1) and MIP-1α (CCL3).
Accumulation of free cholesterol within endosomes result in endosomal damage and
activation of the NLRP3 inflammasome along with generation of IL-1β. Excess cholesterol
also activates the UPR pathway of the ER stress response, leading to further proinflammatory activation and ultimately cell apoptosis. Along with inflammatory activation,
lipoprotein exposure also drives upregulation of ABCA1 and ABCG1, which mediate
cholesterol efflux from the cell. Figure adapted from Moore & Tabas.111
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Beyond the classical paradigm of the simple dichotomy between pro-inflammatory and
tissue remodeling macrophage phenotypes, macrophages in vivo rarely fall nicely into
either subset.160 As such, a number of unique atherosclerosis-associated macrophage
subsets have been identified in murine models of atherosclerosis and in patients. Kadl et
al. identified a Mox macrophage phenotype in murine macrophages treated with oxLDL,
which demonstrated a distinct gene expression pattern characterized by upregulation of
redox-regulatory genes driven by the transcription factor Nrf2.161 Boyle et al. identified
another novel atherosclerotic macrophage subset that is associated with intra-plaque
hemorrhage called hemorrhage-associated (HA)- or Mhem macrophages.162 The presence
of heme and hemoglobin at the site of hemorrhage drives expression of heme oxygenase 1
(HO-1) through activating transcription factor 1 (ATF-1).163 These macrophages also
upregulate gene targets of LXR-α/β, including ABCA1. The net result is a macrophage
subset that is highly resistant to oxidative stress and cholesterol loading.162,163

1.2.4

Cholesterol uptake and foam cell formation

Uptake of lipoproteins by macrophages within the atheroma results in accumulation of
cholesterol esters within the macrophage, which is converted into free cholesterol by
lysosomal acid lipase in the lysosome.164 Free cholesterol must be either removed from the
cell through the cholesterol efflux transporters ABCA1 and ABCG1 or re-esterified and
stored as cholesterol ester intracellularly as neutral lipid droplets.100,143 Excess intracellular
free cholesterol results in macrophage inflammatory activation through the induction of
ER stress, TLR4 signaling and inflammasome activation.151,157,165 Furthermore, delivery of
excess cholesterol into the macrophage leads to enrichment of free cholesterol within the
plasma membrane and may serve to enhance inflammatory signaling through cholesterol
microdomain-mediated activation of pro-inflammatory signaling receptors.166 Thus,
cholesterol loading of macrophages can further contribute to the generation of a chronic
inflammatory state within the lesion.
Accumulation of esterified cholesterol stored in both membrane-bound and free lipid
droplets within the cytoplasm confers unto lesion-resident macrophages the “foamy”
appearance first described by Nikolai N. Anichkov in his classic studies on cholesterol-fed
rabbits in 1913.167 There is also evidence from electron microscopy studies of macrophages
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from advanced atherosclerotic lesions demonstrating the presence of minimally degraded
and fully intact moLDL within foam cell.168

1.2.5

Generation of autoimmunity

Beyond dysfunction of the innate immune system, there is growing evidence that impaired
antigen presentation and autoimmunity also play a role in atherosclerosis.122,169 Strikingly,
autoimmune disorders appear to be an independent risk factor for the development of
atherosclerosis and CVD.11,170 In patients with systemic lupus erythematous (SLE) and
rheumatoid arthritis, the incidence of CVD is significantly increased compared to age- and
sex-matched controls from the general population.170 Similar patterns are observed in nonautoimmune patients, where patients who develop IgG-isotype antibodies against plaque
components develop more severe disease than those who remain immunologically
quiescent.171 In animal models, these athero-reactive antibodies result in immune complex
deposition within the vascular intima, further exacerbating inflammation in the atheroma,
thereby hastening disease and destabilizing the plaque.172 Importantly, presentation of
atheroma-derived antigens on MHC II, by cells such as macrophages, is a pre-requisite for
antibody class-switch to IgG subtypes.173–175 This indicates that mis-presentation of
atheroma antigens following ingestion of plaque components such as apoptotic foam cells
has an important role in atheroma development. Indeed, T-cell-deficient nude mice fed a
high-fat diet developed significantly smaller atheromas than controls.176
The majority of T lymphocytes present within the atheroma are TH1 CD4+ cells.122,177
These cells are likely atherogenic, as inhibition of TH1 polarization in Apoe-/- mice results
decreases plaque burden. TH1 cells infiltrate the atheroma and contribute to the chronic
inflammatory state of the atheroma including through IFN-γ production.122,178
Furthermore, these T cells have a restricted repertoire and appear to respond specifically
to a number of atheroma-specific antigens, including ApoB-100, native LDL and
moLDL—particularly oxLDL.175,178 In advanced atheromas, antigen presentation is
primarily carried out by macrophages and conventional dendritic cells that expression
CD11b and CD11c, and which are pre-disposed to TH1 priming of CD4+ T cells through
production of IL-12 and CCL17.179 Presentation of self-lipid antigens by the CD1 family
of MHC I-like glycoproteins is another potential source of T cell activation in
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atherosclerosis.180,181 CD1 molecules surveil the endocytic pathway and are capable of
presenting both foreign- and self-lipid antigens to CD1-restricted T cells, in particular
CD1d-restricted iNKT cells.182 While the role of endogenous lipid antigens in the
pathogenesis of atherosclerosis is current poorly characterized, investigators have shown
that administration of α-galactosylceramide (a synthetic antigen that activates iNKT cells)
resulted in a 50% increase in plaque size in Apoe-/- mice.181

1.2.6

Impaired inflammation resolution

Resolution of an inflammatory response is a necessary step in maintenance of homeostasis
and avoiding unnecessary tissue damage.65 However, in the setting of atherosclerosis,
resolution of inflammation is impaired and instead a chronic, low-grade inflammatory state
persists within the plaque microenvironment.65,121 Mediators of inflammation resolution
include anti-inflammatory cytokines, other signaling molecules and transcription factors.
The most prominent anti-inflammatory cytokines in atherosclerosis are TGF-β and IL-10.91
IL-10 signaling induces expression of the suppressor of cytokine signaling 3 (SOCS3),
which antagonizes the NF-κB signaling pathway and downregulates expression of a
number of pro-inflammatory cytokines.144 IL-10 also induces expression of signal
transducer and activator of transcription 3 (STAT3), a transcription factor that helps
polarize macrophages into an anti-inflammatory phenotype.9 TGF-β, in contrast, appears
to primarily act on T cells in the context of atherosclerosis and induces the migration and
generation of regulatory T cells.183,184 Within the atherosclerotic plaque, macrophage
production of both IL-10 and TGF-β have been shown to be reduced within advanced
plaques.185 IL-10 levels in the serum are also lower in patients with coronary artery
disease.186
In addition to anti-inflammatory cytokines, inflammation resolution is also mediated by
lipid specialized pro-resolving mediators (SPMs), including lipoxin A4, resolvin D1 and
protectin D1.115 SPMs are generated through the activity of lipoxygenase (LOX) enzymes
on arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA),
and function through several mechanisms including the suppression of lipopolysaccharide
(LPS)-mediated pro-inflammatory signaling.187,188 Variants in LOX enzymes have been
associated with CVD and patients with CVD have lower levels of circulating SPMs
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compared to healthy controls.189,190 Several experiments have shown that SPMs are
produced following efferocytosis and during atherosclerotic lesion regression.144 Direct
administration of a number of SPMs in mouse models of atherosclerosis have been shown
to decrease the rate of plaque progression.191 Fredman et al. showed that SPMs are involved
in atherosclerosis progression by demonstrating the ratio of SPMs, especially resolvin D1,
and pro-inflammatory leukotriene B4 is decreased in advanced atherosclerotic plaques and
in regions of plaque vulnerability in Ldlr-/- mice.192

1.3 Efferocytic removal of apoptotic cells by macrophages
in the atherosclerotic plaque
1.3.1

Apoptosis in the atherosclerotic plaque

Apoptosis is a key feature of progression in atherosclerosis.148 While pre-atherosclerotic
and early atherosclerotic lesions contain few if any apoptotic cells, advanced
atherosclerotic plaques have been shown to be relatively abundant in uncleared apoptotic
cells.142 Several factors drive cell apoptosis within the atherosclerotic lesion, including
oxidative stress, hypoxia, pro-apoptotic cytokines and the cellular response to cholesterol
loading.13,118,149,193 All cells types present within the lesion experience apoptosis, and the
death of these cells have differing impacts on plaque biology. Apoptotic death of
endothelial cells and VSMCs, for example, is thought to destabilize the fibrous cap through
removal of cells and collagen that form the structure of the cap, resulting in increased
plaque vulnerability and risk of rupture.145
The role of macrophage apoptosis on plaque progression appears to be more nuanced and
may indeed exert opposing effects depending on the stage of plaque development (see
Figure 1.6).140 In the early atherosclerotic lesion, macrophage apoptosis is thought to be
protective against disease progression by removing cells from the plaque and reducing the
generation of inflammation.140 Studies that transplanted the bone marrow of mice lacking
the pro-apoptotic factors Bcl-2-associated X (Bax) or apoptosis signal-regulating kinase 1
(Ask-1) into Ldlr-/- mice and feeding a high fat diet for 10-12 weeks resulted in an increase
in total lesion area.194 In contrast, induction of macrophage apoptosis in later stages of
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disease may be detrimental. In experiments using Chop-/- Apoe-/- mice, Thorp et al. showed
that the rate of ER stress-induced apoptosis was decreased, and that plaque apoptosis and
necrotic core formation was reduced in these mice.152 These results suggest that
macrophage apoptosis occurring later during plaque progression leads to additional
necrotic cell burden, potentially due to a lack of functioning efferocytic machinery in later
stages of plaque development.152

Figure 1.6 Macrophage apoptosis and efferocytosis in early and advanced
atherosclerosis. (on opposite page)
Macrophage apoptosis and efferocytosis have different impacts on plaque biology in early
versus advanced atherosclerosis. (a) Within early atherosclerotic lesions, induction of
macrophage apoptosis has a protective role. Apoptotic macrophages are quickly cleared by
neighbouring healthy macrophages, limiting the capacity of that macrophage to contribute
to the generation of inflammation and inducing an anti-inflammatory phenotype in the
efferocyte characterized by release of the anti-inflammatory cytokines TGF-β and IL-10.
(b) In advanced atherosclerotic lesions, in contrast, apoptotic macrophages are not cleared
by neighbouring efferocytes and instead undergo secondary necrosis. This in turn drives
disease progression through contributing to the formation and growth of a necrotic core
within the lesion and the release of pro-inflammatory factors into the plaque
microenvironment. Figure adapted from Tabas (2009).144
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1.3.2

Evidence of defective efferocytosis in atherosclerotic disease

Defective efferocytosis is a hallmark of advanced atherosclerotic lesions and the presence
of impaired efferocytosis is associated with increased plaque vulnerability.195 The lack of
efferocytic apoptotic cell clearance probably contributes more than any other single
mechanism to necrotic core formation.144 Schrijvers et al. demonstrated the presence of
uncleared terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling
(TUNEL)+ necrotic cells within advanced atherosclerotic lesions in human carotid
endarterectomy specimens while in the tonsils—a tissue with comparably high rates of
apoptosis—very few uncleared apoptotic cells could be detected.142 This finding implies
that defective efferocytosis drives the accumulation of necrotic cells in atherosclerosis and
that this is a bona fide feature of advanced atherosclerosis in humans.142
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Complementing observations in human plaque, numerous studies in mouse models of
atherosclerosis have demonstrated that deletion of macrophage efferocytic effectors
increase lesion necrotic core size and total lesional area.196,197 Boisvert et al. found that
Ldlr-/- mice transplanted with bone marrow deficient in transglutaminase 2 (TG2), a coreceptor of integrin αVβ3, had increased atherosclerotic lesion area and necrotic core
size.196 Further evidence for the importance of integrin αVβ3 in efferocytosis within the
atherosclerotic lesion came from studies using Mfge8-/- Ldlr-/- mice. MFG-E8 is the opsonin
used by integrin αVβ3 to bind PS, and Mfge8--/ Ldlr-/- mice develop lesions with larger
necrotic cores and also have higher levels of circulating pro-inflammatory cytokines, in
particular IFN-γ.197 Further studies have also found that C1q, the opsonin used by LRP1 to
bind calreticulin on the apoptotic cell surface, also plays a role in efferocytosis within the
plaque.56,198 Deletion of C1q in Ldlr-/- led to the development of larger and more complex
lesions.198 Finally, Thorp et al. demonstrated that mice expressing a tyrosine kinase
defective MerTK mutant had increased numbers of free apoptotic cells and larger necrotic
cores after 16 weeks of being on a high-fat diet.199 However, deletion of another member
of the TAM family of receptors, Axl, did not appear to impact efferocytosis within the
atherosclerotic plaque or plaque progression.200 A summary of these mechanisms that
mediate macrophage efferocytosis within the atherosclerotic plaque is provided in Figure
1.7.
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Figure 1.7 Known efferocytic receptors and pathways utilized by macrophages in
atherosclerosis.
A number of efferocytic receptors and opsonins have been identified by in vivo studies in
mouse models of atherosclerosis to be involved in macrophage efferocytosis of apoptotic
cells within the atherosclerotic lesion. These include: integrin αVβ3 and its opsonin MFGE8 and co-receptor TG2, LRP1 and its opsonin C1q, and MerTK and its opsonins Gas6
and protein S. Successful clearance of apoptotic cells induces the production of antiinflammatory cytokines by the efferocytosing macrophage, including TGF-β and IL-10.
Figure adapted from Thorp & Tabas.201

1.3.3

Consequences of defective efferocytosis

Beyond insufficient apoptotic cell clearance and the development of secondary necrosis
leading to necrotic core formation and release of pro-inflammatory factors, defective
efferocytosis also has consequences related to a lack of inflammation resolution.65 As
discussed previously in Chapter 1.2.6, efferocytosis induces an anti-inflammatory
phenotype in macrophages that functions to partially counteract the chronic inflammatory
microenvironment of the plaque.116 Impaired efferocytosis removes macrophage-derived
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anti-inflammatory cytokines from the plaque and instead promotes further inflammatory
activation within the lesion.
Defective efferocytosis also leads to a reduction in the production of SPMs that normally
help limit inflammation (discussed previously in Chapter 1.2.6) and increases the
production of pro-inflammatory leukotrienes, which are synthesized from AA, the same
substrate as a number of SPMs.192 Cai et al. found that engagement of MerTK receptor led
to translocation of 5-LOX into the nucleus, where it drives production of the SPM lipoxin
A4.202 The authors found that impaired MerTK signaling in the context of atherosclerosis
reduced the level of lipoxin A4 production and instead increased production of the proinflammatory leukotriene B4.202

1.3.4

Known mechanisms leading to defective efferocytosis

The molecular mechanisms that lead to defective macrophage efferocytosis in
atherosclerosis remain poorly understood. One potential mechanism identified by Cai et
al. involves cleavage of MerTK within the atherosclerotic plaque through the activity of
the metalloproteinase ADAM17.202 The authors found that in Ldlr-/- mice expressing a
cleavage-resistant MerTK variant, atherosclerotic plaques possessed smaller necrotic cores
and thicker fibrous caps. In human carotid atherosclerosis, cleavage of MerTK from the
cell surface of macrophages and the presence of the resultant soluble form of MerTK
correlated with increased plaque necrosis and ischemic symptoms in these patients.203
Separately, the same group found that MerTK cleavage also limited SPM production by
macrophages and led to higher levels of circulating pro-inflammatory cytokines in mice.204
Disruption of anti-phagocytic “don’t eat me” signals has also been shown to have an impact
on atherosclerotic disease.10,205 Kojima et al. showed that blocking the anti-phagocytic
molecule CD47 using antibodies in Apoe-/- mice led to restoration of efferocytosis within
advanced atherosclerotic plaques and a resultant decrease in lesion necrotic core size.205
Within the plaque, elevated levels of TNF-α appears to induce CD47 expression on VSMCs
via activation of NF-κB signaling. In patient carotid endarterectomy specimens, CD47 was
found to be elevated compared to non-atherosclerotic surrounding vascular tissue. This up-
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regulation of CD47 could be reproduced in a mouse model of atherosclerosis through
feeding of a high fat diet in Apoe-/- mice.205
Finally, macrophage cholesterol loading may impair efferocytosis through disruption of
proper efferosome maturation.206 Free cholesterol accumulation in macrophages leads to
the induction of several adaptive processes that could alter the regulation of intracellular
trafficking and efferosome maturation. Huynh et al. showed that inhibition of cholesterol
exit from lysosomes using the small molecule inhibitor U18666A resulted in impaired
phagolysosome formation.206 The authors found that this defect was due to inactivity of
Rab7 recruited to the late phagosome, leading to a failure to recruit the effector molecules
RILP and ORLP1 which are required to drive migration of phagosomes towards the
perinuclear region to permit efficient fusion with lysosomes.87,206 Another example of such
an adaptive process is the increased biosynthesis of phospholipids, in particular
phosphatidylcholine and phospholipid species with polyunsaturated acyl chains.207 Since
the recruitment of many regulators of the maturation process depends on interactions with
phospholipid species present in the efferosomal membrane, alterations to phospholipid
synthesis may result in maturation defects–although this remains to be experimentally
demonstrated.207

1.4 Current limitations in our understanding of
atherosclerosis
1.4.1

Animal models of atherosclerosis and their limitations

Due to the complexity of atherosclerosis and the slow rate of disease progression in
humans, a range of small and large animal models have been developed to study the biology
of this disease.208,209 Each model system carries distinct advantages and drawbacks and are
typically used to study specific components of atherosclerotic disease (e.g. genetics,
lipoprotein profiles, hemodynamics, etc.).208
The most frequently used animal models of atherosclerosis are by far the murine models
of atherosclerosis.210 Although the lipoprotein profile and lesion distribution in mice differ
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from those in humans, many of the critical features of disease are preserved.208,210 The ease
of genetic manipulation in mice and the relatively fast rate at which atherosclerosis develop
in atherosclerosis-prone mice make them an attractive model organism for studying the
impact of specific genes and proteins on disease pathogenesis. Mice are HDL monotypic
animals, meaning that HDL is the dominant lipoprotein in their circulation. This makes
mice naturally resistant to atherosclerosis.211 Mouse models of atherosclerosis therefore
rely on generating a non-HDL based hypercholesterolemia. A number of murine model
systems now exist for studying atherosclerosis, but the most well-known and best-studied
models are the apoE-knockout and the LDLR-knockout animals.210 Deletion of apoE or
LDLR inhibit cholesterol reverse transport and the animals develop hypercholesterolemia
on a high fat diet as a result.208
Despite the widespread use of Ldlr-/- and Apoe-/- mice in experimental investigations into
the biology of atherosclerosis, there are still critical differences between human and mouse
atherosclerosis that call into the question the extent to which the mouse is an accurate
model of atherosclerotic disease.212,213 First, most mouse models of atherosclerosis never
develop the vulnerable, rupture-prone plaque that drives atherosclerotic CVD in humans.210
The distribution of lesions in the vasculature also differs significantly between mouse and
human.117 Importantly, mice rarely develop significant atherosclerosis within their
coronary circulation, instead preferentially developing atherosclerosis within the aortic
root.117 This stands in contrast to humans, where the aortic root and ascending aorta are
usually relatively spared from severe disease.214 Finally, mice do not possess the
cholesteryl ester transfer protein (CETP), a serum transporter of cholesteryl esters and
triglycerides that has been implicated in atherosclerosis in humans.215
The small size of the mouse imposes an additional limitation on the extent to which
important disease parameters such as hemodynamics may be measured in these animals.
As such, a number of large animal models of atherosclerosis have been used.208 A full
discussion of large animal models of atherosclerosis is beyond the scope of this thesis but
is reviewed in detail by Getz & Reardon.208 We will briefly summarize the most important
large animal models of atherosclerosis here. Amongst these are pigs, which spontaneously
develop atherosclerosis on a high fat diet.216 A number of seminal studies on the impact of
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vascular hemodynamics on atherosclerosis development and on endothelial activation in
response to atherogenic stimuli have been performed in pigs.217 Pigs also do develop
complex lesions in their coronary circulation and these plaques do experience vulnerability
and rupture.218 Rabbits have also been used in the study of atherosclerosis. These animals
are extraordinarily sensitive to cholesterol feeding and have been used in a number of
studies on how the body’s circulating lipid profile changes with a high cholesterol diet.219
Finally, non-human primates can also be used to study atherosclerosis. Although they are
expensive and difficult to maintain, non-human primates have the most similar lipoprotein
profile to humans of any model organism.220 Some of the first studies on plaque regression
upon return to a low-fat diet was conducted in Rhesus monkeys.221

1.4.2

Challenges of studying atherosclerosis in humans

The majority of what is currently known about the biology of atherosclerosis and
particularly its pathogenesis and progression is derived from studies in animal models of
disease.128 In particular, studies in mice have generated much insight into the role of
macrophages and other cell types in the atherosclerotic plaque.209 However, the degree to
which these findings may be translated into the human context remains a topic of
controversy.128,222 Indeed, a number of promising therapeutic targets identified through
research on mouse models of atherosclerosis have not been borne out in humans.128 In a
systematic review of disease-causing genes identified in mouse models of atherosclerosis
and the association of the human orthologs of these genes with CVD, Pasterkamp et al.
found few associations between genes found to be important in mice and human disease.213
In contrast, von Scheidt et al. used the same approach but concluded that there was a
significant overlap between genes found to be important for the pathogenesis of
atherosclerosis in mice and genes that have been implicated in atherosclerosis and CVD in
humans.210 To illustrate the stark differences that can be present between atherosclerosis in
the mouse and in humans, a recent study by Gomez et al. found that IL-1β had a protective
effect in advanced atherosclerotic plaques in Apoe-/- mice, which stands in contrast with
the results of the CANTOS trial.223
However, despite the sometimes questionable validity of animal models of atherosclerosis,
it is technically difficult to study this disease in humans for a variety of reasons. First,
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atherosclerosis develops over the course of decades in humans, making it very difficult to
study disease progression.127 Second, obtaining plaque specimens for study in humans is
difficult due to the anatomical location of these plaques.224 The most commonly used
source of plaque material in human studies is plaque obtained from carotid
endarterectomies.225–227 However, it has been established there are significant differences
in macrophage gene expression between plaques isolated from different anatomical
sites.228 Therefore, it is difficult to determine how representative the carotid plaque is of
disease situated in other vessels. Finally, the ubiquitous nature of atherosclerosis in
industrialized nations makes it difficult to identify individuals who are truly free of
atherosclerosis that may be utilized as a control.229 Due to these factors, it is likely that the
field will continue to rely on mouse models of atherosclerosis as the major means of
studying atherosclerosis biology.

1.5 Rationale, objective and aims
1.5.1

Rationale

Defective macrophage efferocytosis is widely acknowledged as a major driver of disease
progression and plaque vulnerability in atherosclerosis. Despite this, relatively little is
known about the molecular mechanisms that drive defective efferocytosis in the setting of
atherosclerotic disease. The few mechanisms that have been identified to date have been
described either in vitro or almost exclusively in mouse models of atherosclerosis.
Therefore, we do not have a clear understanding of how efferocytosis becomes defective
in human atherosclerotic disease.

1.5.2

Objective

The overall objective of this thesis is to explore gene expression in human atherosclerotic
lesion-resident macrophages in order to identify potential genes and pathways that
contribute to defective efferocytosis in human atherosclerosis.
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1.5.3

Aims

Our first aim, described in Chapter 3, was to gain a more complete understanding of how
efferosome maturation is regulated in macrophages under homeostatic conditions. We
employed ectopic expression of fluorescently labelled proteins in combination with beadbased efferocytosis assays and live- and fixed-cell fluorescence microscopy to identify
novel proteins that differentially regulate phagosome and efferosome maturation.
Our second aim, described in Chapter 4, was to study the gene expression profile of human
atherosclerotic macrophages to determine globally which pathways and cellular functions
were dysregulated and specifically which pathways related to efferocytosis and apoptotic
cell clearance were affected. This was accomplished using a microarray to analyze gene
expression in macrophages isolated from aortic punch samples compared to macrophages
derived ex vivo from peripheral blood monocytes from healthy donors.
The final aim, described in Chapter 5, was to validate the role of a transcription factor
identified in the previous aim as being potentially involved in driving efferocytic defects.
This was done through generating stably-transduced macrophage cell lines that
overexpressed or knocked down our protein of interest and using these cell lines in
functional assays that test macrophage efferocytosis and efferosome maturation proceeds
correctly. We also examined the upstream signaling pathways employed to drive
upregulation of our protein-of-interest.

1.6 Importance
Atherosclerosis is the major pathological feature that contributes to CVD. In Canada, the
impact of atherosclerotic CVD is so large that approximately 1 in 3 Canadians will be
affected by atherosclerosis or one of its complications.110 Despite the importance of
atherosclerosis, there are still gaps in our understanding of the biology of atherosclerosis
in humans and a lack of therapeutic agents that completely eliminate the risk of CVD. As
such, identification of specific defects in the efferocytosis of apoptotic cells that forms the
overarching goal of this thesis has the potential to uncover novel therapeutic targets and
approaches for atherosclerosis.
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Chapter 2

2

Materials and Methods

2.1 Reagents, cell lines, plasmids/oligos, and antibodies
2.1.1 Reagents
RPMI, DMEM, Trypsin-EDTA and fetal bovine serum (FBS) were purchased from
Wisent. Recombinant human M-CSF, GM-CSF, IFNγ and IL-4 were purchased from
Peprotech. No. 1.5 thickness 8-mm round coverslips and 16% paraformaldehyde (PFA)
were purchased from Electron Microscopy Supplies. Colloidal Coomassie Blue,
PUREZOL RNA isolation reagent and iScript Select cDNA Synthesis Kit were purchased
from Bio-Rad. Lympholyte-poly was purchased from Cedarlane Laboratories. Cell
Proliferation Dyes eFluor 450 and eFluor 670 were purchased from eBioscience.
Phosphatidylserine (PS), phosphatidylcholine (PC), biotin-phosphatidylethanolamine
(biotin-PE), rhodamine-phosphatidylethanolamine (rhodamine-PE), cholesterol and
BODIPY-cholesterol

were

purchased

from

Avanti

Polar

Lipids.

Salmonella

lipopolysaccharide (LPS), rAPID alkaline phosphatase, Polybrene Infection Reagent,
mammalian protease inhibitor cocktail, Oil Red O, Nile Red, phorbol 12-myristate-13acetate (PMA), methyl-β-cyclodextran, TRITC-dextran, human IgG and the AntiCitrulline (Modified) Detection Kit were purchased from Sigma-Aldrich. Phusion DNA
polymerase, FugeneHD, dithiobis[succinimidyl propionate], dithio-bismaleimidoethane,
Permafluor mounting reagent, Fast SYBR Green master mix, EZ-link NHS-LC-biotin,
CellTrace dyes and nitro blue tetrazolium chloride were purchased from Thermo Fisher.
Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs.
Polystyrene beads, silica beads and silica-functionalized magnetic beads were purchased
from Bangs Laboratories. Tissue-Tek OCT compound was purchased from VWR.
Lipofectamine 3000 transfection reagent was purchased from Life Technologies. Polyjet
In Vitro DNA transfection reagent was purchased from SignaGen Laboratories. Human
plasma oxidized low density lipoprotein (oxLDL) was purchased from Alfa Aesar. Trypsin
Enzymatic Antigen Retrieval Kit was purchased from Abcam. Vector DAB HRP substrate
was purchased from Vector Laboratories. Cytoseal 60 was purchased from Thomas
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Scientific. pHrodo Red Microscale Labeling Kit was purchased from Invitrogen. Normal
rabbit and donkey sera were purchased from Jackson Immunoresearch. All other chemicals
were purchased from Canada BioShop.

2.1.2 Mice, cell lines and bacteria
LDL receptor-deficient C57BL/6J mice were generously provided by Dr. Lillian Barra
(Western University). THP-1 monocytes (ATCC TIB-202) were a gift from Dr. Joe
Mymryk (Western University). Jurkat T cells (ATCC TIB-152) were a gift from Dr. Jimmy
Dikeakos (Western University). J774.2 murine macrophage cells (ATCC TIB-67) were a
gift from Dr. Sergio Grinstein (Hospital for Sick Children). HEK 293 cells (ATCC CRL1573) were a gift from Dr. David Litchfield (Western University). Escherichia coli DH5α
and ML35 strains were gifts from Drs. John McCormick and Susan Koval, respectively
(Western University).

2.1.3 Plasmids and oligos
PM-RFP, Rab5-GFP, Rab7-mCherry, TfR-GFP, TfR-mCherry and LAMP1-mCherry
expression constructs were gifts from Dr. Sergio Grinstein (Hospital for Sick Children).
pBabePuro-GATA2 (Addgene Plasmid #1285) was purchased from Addgene. pLVXIRES-ZsGreen1, pGFP-C-shLenti, pMD2.G and pDR8.2 were gifts from Dr. Jimmy
Dikeakos (Western University). Human Rab17 cDNA was purchased from the Harvard
PlasmID Repository. Primers and shRNA oligos were purchased from IDT. ONTARGETplus siRNA was purchased from Thermo Fisher.

2.1.4 Antibodies
Mouse anti-human LAMP-1 monoclonal IgG1 antibody (H4A3) and mouse anti-human
GAPDH monoclonal IgG1 antibody (2G7) were purchased from Developmental Studies
Hybridoma Databank. Rat anti-mouse MHC class II monoclonal IgG2b antibody
(M5/114.15.2; eBioscience 14-5321-82) was purchased from eBioscience. Rabbit antihuman Rab17 polyclonal IgG antibody (Proteintech 28274-1-AP) was purchased from
Proteintech. Rabbit anti-human CD163 polyclonal IgG antibody (Abcam ab87099), mouse
anti-human CD68 monoclonal IgG1 antibody (KP1; Abcam ab955) and rabbit anti-human
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GATA2 polyclonal IgG antibody (Abcam ab153820) were purchased from Abcam. Rabbit
anti-citrulline polyclonal IgG antibody (Sigma 07-377) was purchased as part of the AntiCitrulline (Modified) Detection Kit from Sigma-Aldrich. All fluorescent secondary
antibodies were purchased as IgG F(ab’)2 fragments from Jackson ImmunoResearch.

2.2 Cell culture
2.2.1 Cell lines
HEK 293 cells were maintained at 37 °C and 5% CO2 in DMEM media supplemented with
10% FBS, L-glutamine and sodium bicarbonate, and buffered with 25 mM HEPES to a pH
= 7.2. Cells were sub-cultured 1:5 by scraping once cells reached 80-90% confluency or
approximately once every 3 to 4 days.
J774.2 murine macrophage cells were maintained at 37 °C and 5% CO2 in RPMI media
supplemented with 10% FBS, L-glutamine and sodium bicarbonate, and buffered with 25
mM HEPES to a pH = 7.2. Cells were sub-cultured 1:5 by enzymatic digestion with 0.05%
trypsin supplemented with 0.53 mM EDTA once cells reached 80-90% confluency or
approximately once every 3 to 4 days.
THP-1 human monocyte-like cells were maintained at 37 °C and 5% CO2 in RPMI media
supplemented with 10% FBS, L-glutamine and sodium bicarbonate, and buffered with 25
mM HEPES to a pH = 7.2. Cells were sub-cultured 1:5 or 1:10 through addition of fresh
media once cells reached a concentration of 1×106 cells/mL. For differentiation into
macrophages, cells are incubated with 100 nM PMA for 48-72 hrs. Differentiated THP-1
cells are washed at least 1× with PBS to remove excess PMA prior to use in downstream
assays.
Jurkat human T lymphocyte-like cells were maintained at 37 °C and 5% CO2 in RPMI
media supplemented with 10% FBS, L-glutamine and sodium bicarbonate, and buffered
with 25 mM HEPES to a pH = 7.2. Cells were sub-cultured 1:5 or 1:10 through addition of
fresh media once cells reached a concentration of 1×106 cells/mL.
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2.2.2 Primary cells
Primary human macrophages and dendritic cells were prepared from monocytes isolated
from whole blood isolated from healthy adult donors with ethics approval from the Office
of Human Research Ethics at Western University Health Sciences Research Ethics Board
(HSREB Reference Number: 104010). Blood was collected through venipuncture into
vacuum tubes coated with heparin and monocytes were isolated using Lympholyte-poly
cell separation media (Cedarlane) according to the manufacturer’s instructions. Briefly,
approximately 4 mL of blood was layered over an equal volume of Lympholyte-poly and
centrifuged for 25 min at 500 ×g at 50% acceleration and zero deceleration. The monocyte
layer was carefully removed using a transfer pipette to a clean 50 mL tube and resuspended
in approximately 50 mL of PBS and subsequently centrifuged for 6 min at 300 ×g at full
acceleration and deceleration. Monocytes were re-suspended in 200 µL of warm RPMI per
well to fill of a 12-well plate. Sterile, acid-washed glass coverslips were placed into 12well plates and the monocyte suspension was pipetted onto coverslips. Cells were
incubated for 1 hr at 37 °C and 5% CO2 to allow monocytes to adhere to glass and
coverslips were washed 3× with PBS to remove any non-adherent cells. Cells were
maintained in culture with RPMI supplemented with 10% FBS, L-glutamine and sodium
bicarbonate, 10,000 U/mL penicillin, 10 mg/mL streptomycin and 25 µg/mL amphotericin
B and buffered with 25 mM HEPES to a pH = 7.2.
To generate dendritic cells, adherent monocytes were additionally supplemented with
1000U/mL rhGM-CSF and 500U/mL rhIL-4 for 48 hrs. To generate macrophages,
adherent monocytes were additionally supplemented with various cytokines and allowed
to incubate for five days to induce cell differentiation and polarization. For M0 or M2
macrophages, adherent monocytes were supplemented with 10 ng/mL rhM-CSF. For M1
macrophages, adherent monocytes were supplemented with 20 ng/mL rhGM-CSF.
Following the five-day incubation, culture media was replaced with fresh complete RPMI
free of antibiotics and supplemented with the following combination of cytokines to induce
specific macrophage polarization: M0 macrophages – 10 ng/mL rhM-CSF; M1
macrophages – 20 ng/mL rhGM-CSF, 250 ng/mL LPS and 10 ng/mL IFNγ; M2
macrophages – 10 ng/mL rhM-CSF and 10 ng/mL rhIL-4.
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2.3 Molecular cloning
2.3.1 Recombinant DNA preparation
Recombinant expression vectors were prepared through restriction enzyme digestion and
subsequent ligation of appropriate insert sequences and vector backbones (see Appendix
A for a complete list of constructs used in this thesis). Briefly, a DNA insert consisting of
the consensus coding sequence (CDS) of the gene of interest or simply the sequence of
interest (in the case of shRNA inserts) were amplified using standard PCR with primers
designed to add flanking restriction enzyme sites compatible with the multiple cloning site
of the vector backbone. A list of all PCR primers used for cloning can be found in
Appendix A. PCR reaction was run for 30 cycles with Phusion DNA polymerase (New
England Biolabs) according to the manufacturer’s instructions.
Subsequently, the insert and backbone were digested with appropriate restriction enzymes
for 1 hr at 37 °C and gel purified using a 1% agarose gel and the Monarch Nucleic Acid
Preparation Kit (New England Biolabs) according to the manufacturer’s instructions.
Optionally, prior to gel purification, backbone DNA sequences can be dephosphorylated
with rAPID alkaline phosphatase (Sigma-Aldrich) according to the manufacturer’s
instructions. Purified cut insert and backbone were ligated at a ratio of 10:1 insert to
backbone overnight at 16 °C with 20,000 U/mL T4 ligase. Ligated vectors were
transformed into chemically-competent Escherichia coli DH5α cells by heat shock for 1
min at 42 °C.
Transformed E. coli were plated on LB agar supplemented with the appropriate selective
antibiotic(s) and incubated overnight at 37 °C. Colonies appearing following incubation
were screened by colony PCR where feasible and propagated in liquid LB media overnight
at 37 °C and shaking at 200 RPM. Following overnight incubation, plasmids were
harvested from cultures using the High-Speed Plasmid Mini Kit (Geneaid) according to the
manufacturer’s instructions. Correct insertion of insert into backbone was confirmed by
Sanger sequencing at the London Regional Genomics Centre.

70

2.3.2 Transfection of cell lines
HEK 293 cells were transfected using Lipofectamine 3000 (Life Technologies) according
to the manufacturer’s instructions. Briefly, cells were seeded at 30-40% confluency the day
prior to transfection. Vector DNA and Lipofectamine 3000 reagent were prepared in
separate tubes in serum-free RPMI media. Equal volumes of DNA and Lipofectamine
reagent were combined and the mixture allowed to incubate for 5 min at room temperature.
The entirety of the mixture was then added dropwise to the desired well of J774.2 cells to
be transfected. The transfection mix was incubated with cells for 5-16 hrs at 37 °C and 5%
CO2, after which it was replaced by fresh complete RPMI media and allowed to incubate
for at least 12 hrs at 37 °C and 5% CO2 prior to use in downstream applications.
J774.2 cells were transfected using FuGENE HD transfection reagent (Promega) according
to the manufacturer’s instructions. Briefly, the DNA to be transfected was diluted in serumfree media and FuGENE reagent was added to 3:1 transfection reagent to DNA ratio. The
mixture was vortexed briefly and allowed to incubate for 10-15 min at room temperature.
Following incubation, the transfection mixture was added to the well to be transfected and
allowed to incubate for at least 16 hrs at 37 °C and 5% CO2 prior to use in downstream
applications.

2.3.3 Viral transduction of cell lines
THP-1 macrophages were transduced using lentiviral vectors to establish cell lines stably
expressing the gene or sequence of interest. Insert sequences cloned into an appropriate
lentiviral transfer plasmid backbone were packaged into lentiviral vectors in HEK 293 cells
using Polyjet In Vitro DNA Transfection Reagent (SignaGen Laboratories) according to
the manufacturer’s instructions. Briefly, HEK 293 cells were seeded at 10-20% confluency
on 10-cm dishes and allowed to proliferate to 50-60% confluency over approximately two
days. A DNA mixture containing 5 µg of the lentiviral vector, 2 µg of the pMD2.G
envelope plasmid and 5 µg of the pDR8.2 packaging plasmid in serum-free DMEM media.
This mixture was combined with an equal volume of Polyjet reagent diluted in serum-free
DMEM and allowed to incubate for 12 min at room temperature. Following incubation,
the transfection mixture was added dropwise to HEK 293 cells. Cells were incubated for
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three days at 37 °C and 5% CO2, with the media being changed with fresh complete DMEM
24 hrs post-transfection. At the end of the three-day period, cell supernatants were collected
and FBS was added to a final concentration of 20%. Supernatants were centrifuged for 5
min at 1,500 ×g and then filtered using a 2-µm filter. Filtered supernatant containing
lentivirus was aliquoted and stored at -80 °C until needed.
THP-1 monocytes were transduced using prepared lentivirus using a Spinfection protocol.
Approximately 1 × 106 cells were re-suspended in 500 µL of lentivirus-containing
supernatant prepared previously. Polybrene Infection Reagent (Sigma-Aldrich) was added
to a final concentration of 8 µg/mL and the mix was centrifuged for 45 min at 800 ×g. Cell
pellet was washed 1× with PBS to remove excess virus and Polybrene reagent and
transferred into complete RPMI media. Transduced cells were incubate for a minimum of
48 hrs at 37 °C and 5% CO2 prior to use in downstream applications.

2.4 RNA preparation and RT-qPCR
2.4.1 RNA preparation
Total RNA was isolated from cells or patient tissues through acid guanidinium thiocyanatephenol-chloroform extraction uysing PureZOL RNA isolation reagent (Bio-Rad). Cells or
tissues were suspended in an appropriate volume of PureZOL reagent (1 mL of reagent per
50-100 mg of tissue or 107 cells), vortexed briefly and allowed to incubate for 5 min at
room temperature. Chloroform was added 1:5 v/v and the mix was allowed to incubate for
another 5 min at room temperature with intermittent agitation. Samples were centrifuged
for 15 min at 12,000 ×g and 4 °C, and subsequently the upper aqueous layer containing
RNA was transferred to a fresh tube. An equal volume of isopropanol and 0.5 µL of 20
mg/mL glycogen were added to the RNA and the mixture was incubated at -80 °C for at
least 30 min. Samples were again centrifuged for 15min at 12,000 ×g and 4 °C to pellet
precipitated RNA. The RNA pellet was washed 2× with 75% ethanol, air dried for
approximately 5 min at room temperature and reconstituted in a minimal amount of RNasefree ddH2O. RNA concentration and quality were measured using a NanoDrop 1000
Spectrophotometer (Thermo Fisher) prior to use in downstream applications.
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2.4.2 RT-qPCR
cDNA was generated from total RNA using the iScript Select cDNA Synthesis Kit (BioRad) according to the manufacturer’s instructions, with an equal amount of starting RNA
an equal mix of the random and oligo(dT)20 primer mixes. cDNA concentration and quality
were checked using a NanoDrop 1000 Spectrophotometer prior to use in qPCR reactions.
qPCR was performed using the Fast SYBR Green Master Mix (Thermo Fisher) an equal
amount of starting cDNA. All qPCR primers used in this thesis can be found in Appendix
A. PCR reactions were run on a QuantStudio 5 Real-Time PCR System (Thermo Fisher)
for 40 cycles. Relative expression of genes of interest was calculated using the ΔΔCt
method with either GAPDH or 18S serving as the reference gene.

2.5 Western blotting
Western blotting was employed to detect proteins of interest in cultured cells. A sufficient
number of cells (at least 5 × 105) was cultured and was 1× with PBS immediately prior to
lysis. Lysis was performed using either Triton X-100 (for cytoplasmic or membrane
proteins; 150 mM NaCl, 1% Triton X-100, 50 mM pH 8.0 Tris-HCl) or RIPA (for nuclear
proteins; 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS and 50
mM pH 8.0 Tris-HCl). Appropriate lysis buffer containing 1:100 v/v mammalian protease
inhibitor was added to the cells and cells were scraped into suspension. The lysate was
transferred to a clean tube and incubated for 40 min at 4 °C on a rotator. The lysate was
subsequently centrifuged for 15 min at 12,000 ×g and 4 °C. Following centrifugation,
supernatants were transferred to a clean tube and 1:4 v/v 4× Laemmli’s buffer (1:5 v/v 1M
pH 6.8 Tris-HCl, 0.08 g/mL SDS, 2:5 v/v glycerol and 0.02% bromophenol blue in ddH2O)
and 1:10 v/v β-mercaptoethanol were added. Supernatants were subsequently incubated for
5 min at 95 °C to fully denature proteins.
Denatured cell lysates were run on a 10% SDS-PAGE gel for 60 min at 120 V or until the
leading edge of the lysates have nearly reached the bottom of the gel. Proteins were
transferred to a nitrocellulose membrane for 1 hr at 100 V or overnight at 40 V on ice or at
4 °C. Following transfer, membranes were washed 1× with TBST prior to processing.
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Membranes were blocked with 5% BSA in TBST for a minimum of 1 hr at room
temperature with gentle agitation. The primary antibody was added to blocking buffer at
an appropriate concentration and allowed to incubate for at least 1 hr at room temperature.
Membranes were washed 3× with TBST and incubated in blocking buffer with an
appropriate concentration of infrared dye-conjugated secondary antibody added.
Membranes were allowed to incubate for at least 30 min at room temperature with gentle
agitation. Subsequently, membranes were again washed 3× with TBST and imaged on an
Odysey CLx Imaging System (LI-COR). If necessary, band densitometry was carried out
using the Analyze Gels tools on ImageJ.1

2.6 Phagocytosis and efferocytosis assays
2.6.1 Preparation of synthetic phagocytic and efferocytic targets
IgG-coated beads were used as synthetic phagocytic targets. An equal mixture of 10 µL of
10% 5-µm polystyrene beads (vortexed and washed 1× with PBS prior to use) and 10 µL
of 10 µg/mL human IgG were combined in PBS. Mixture was incubated for 90 min at room
temperature or overnight at 4 °C rotating. Following incubation, beads were washed 3×
with PBS (3,000 ×g, 1 min per wash) and re-suspended in 100 µL of PBS and stored for
up to two weeks at 4 °C prior to use. If desired, beads may be labelled with 1 µg/mL of a
fluorescently-conjugated secondary anti-human IgG antibody prior to use.
PS-coated beads were used as synthetic efferocytic targets. A lipid mixture consisting of
80% PC and 20% PS was prepared in a glass vial. If desired, a portion of the PS can be
replaced with 0.1% rhodamine-conjugated PE and/or 0.1% biotin-conjugated PE to allow
for fluorescent labelling of the beads. A 10 µL volume of 10% 3-µm silica beads was
washed 1× with PBS (3,000 ×g, 1 min per wash) and then 1× with methanol. Beads were
dried completely by incubating them for 5 min at 60 °C. Dried beads were re-suspended in
100 µL of chloroform and added to the lipid mixture. The lipid/bead mixture was vortexed
well and dried under a stream of nitrogen gas for approximately 10 min or until the
chloroform had completely evaporated. Beads were subsequently washed 3× with PBS
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(3,000 ×g, 20 sec per wash) to completely remove any liposomes. Beads were then resuspended in 100 µL of PBS and stored for up to two weeks at 4 °C prior to use.

2.6.2 Preparation of physiologic phagocytic and efferocytic targets
2.6.2.1 Heat killed bacteria
An overnight culture of E. coli ML35 prepared to provide a sufficient number of bacteria
for the phagocytosis assay. Typically, a ratio between 10:1 to 100:1 bacteria-to-phagocyte
was used. The desired number of bacteria was pelleted for 1 min at 6,000 ×g. Pellet was
re-suspended in 500 µL of PBS. At this stage, if necessary, bacteria were heat-killed by
incubating for 10 min at 70 °C. Bacteria were washed 2× with PBS.
When required, bacteria were surface biotinylated and/or labelled with a covalent
fluorescent dye for downstream applications. Surface biotinylation was performed using
NHS-LC-biotin. Bacteria were re-suspended in 500 µL of pH 8.0 PBS, to which 0.2 mg of
NHS-LC-biotin re-suspended in 10 µL of DMSO was added. The mixture was incubated
for 30 min at room temperature with gentle agitation. Excess NHS-biotin was quenched
using an equal volume of PBS containing 100 mM glycine for 10 min at room temperature
with gentle agitation. Biotinylated bacteria were washed 2× with PBS and re-suspended in
PBS at the desired concentration. Fluorescent labelling was performed using either a
CellTrace dye or an eFluor cell proliferation dye. Bacteria were re-suspended in 500 µL of
PBS and 0.5 µL of the dye was added to the suspension. The mixture was incubated for 20
min at room temperature with gentle agitation away from light. Excess dye was quenched
with an equal volume of PBS containing 100 mM glycine for 10 min at room temperature
with gentle agitation away from light. Labelled bacteria were washed 2× with PBS and resuspended in PBS at the desired concentration. Heat-killed bacteria were stored 4 °C up to
five days whereas live bacteria were used immediately following preparation.
In some experiments, bacteria were opsonized with human serum prior to use. A solution
of 20% human serum was prepared in serum-free DMEM or RPMI media. Equal volumes
of bacteria and opsonin solution were mixed and incubated for 20 min at room temperature
or overnight at 4 °C rotating. Opsonized bacteria were washed 1× with serum-free DMEM
or RPMI prior to use.
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2.6.2.2 Apoptotic cells
Apoptotic Jurkat cells were used as physiologic efferocytotic targets. Jurkat cells were
grown in culture to provide a sufficient number of apoptotic cells. Typically a ratio of 10:1
apoptotic cells-to-phagocytes was used. 1 × 106 Jurkat cells were re-suspended in 1 mL of
serum-free RPMI media, to which staurosporine was added to a final concentration of 1
µM. Cells were incubated for 3-16 hrs (ideally closer to 16 hrs) at 37 °C and 5% CO2.
Apoptotic cells were washed 3× with PBS to remove excess staurosporine and resuspended in complete RPMI media prior to use.
When required, apoptotic cells were surface biotinylated and/or labelled with a covalent
fluorescent dye for downstream applications. Apoptotic cells were re-suspended in 500 µL
of PBS. For surface biotinylation, 0.2 mg of NHS-LC-biotin was re-suspended in 10 µL of
DMSO and added to the apoptotic cells. For direct fluorescent labelling, a CellTracker dye
was added to a final concentration of 2 µg/mL to apoptotic cells. The mixture was
incubated for 20 min at room temperature with gentle agitation away from light. Excess
biotin and/or dye was quenched with RPMI media containing 10% FBS for 5 min at room
temperature with gentle agitation away from light. Labelled apoptotic cells were
centrifuged for 5 min at 500 ×g and cells were re-suspended in an appropriate volume of
complete RPMI or PBS.
In some experiments, apoptotic cells were opsonized with human serum prior to use. A
solution of 20% human serum was prepared in serum-free DMEM or RPMI media. Equal
volumes of bacteria and opsonin solution were mixed and incubated for 20 min at room
temperature or overnight at 4 °C rotating. Opsonized apoptotic cells were washed 1× with
serum-free RPMI prior to use.

2.6.3 Phagocytosis/efferocytosis assay
Phagocytosis and efferocytosis assays were carried out according to our labs previously
published methods (Evans et al. and Taruc et al.).2,3 A desired number of
phagocytes/efferocytes along with the appropriate phagocytic/efferocytic targets were
prepared as specified above. Phagocytes/efferocytes were allowed to equilibrate to room
temperature in order to prevent premature target uptake. The desired number of phagocytic
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and/or efferocytic targets were added and the mixture was centrifuged for 1 min at 500 ×g
to force contact between phagocytes/efferocytes and targets. Assays were incubated for 30
min (IgG-coated beads), 60 min (PS-coated beads or bacteria) or 90 min (apoptotic cells).
Following incubation, assays were allowed to equilibrate to room temperature to prevent
any further target internalization and washed at least 2× with PBS to remove any unbound
targets.

2.7 Immunofluorescence staining
2.7.1 Staining of tissue sections
Immunofluorescence staining was performed on 10-µm thick tissue sections adhered to
glass slides. Sections were immersed in cold 4% PFA for 15 min at -20 °C. Sections were
subsequently washed 3× 5 min with PBS and excess liquid was carefully removed from
slide surface. Tissue sections were demarcated with a PAP pen to facilitate further staining.
Sections were blocked using 200 µL blocking buffer (10% serum from species used for
generation of secondary antibody, 0.3 M glycine, 0.1% Tween-20 and 1% BSA in PBS)
for at least 1 hr at room temperature. For intracellular staining, cells were permeabilized
by supplementing blocking buffer with 0.1% Triton X-100. Following blocking, the
blocking buffer was removed and 200 µL of primary antibody at an appropriate
concentration in blocking buffer was added to the sections. Sections were incubated with
primary antibody for at least 1 hr at room temperature or overnight at 4 °C and subsequently
washed 3× 15 min using 0.1% BSA and 0.1% Tween-20 in PBS. Sections were then
incubated with 200 µL of 1 µg/mL secondary antibody for at least 30 min at room
temperature and subsequently washed 3× 15 min using 0.1% BSA and 0.1% Tween-20 in
PBS. Coverslips were glued to sections using Permafluor mounting reagent and stained
sections were kept at 4 °C until imaging.

2.7.2 Staining of cells
Cells to be stained were grown on 18 mm, #1.5 thickness round coverslips placed into the
wells of a 12-well tissue culture plate. Prior to staining, cells were equilibrated to room
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temperature to prevent membrane turnover and washed 1× with PBS. Cells were fixed with
4% PFA for 20 min at room temperature and subsequently washed 3× 5 min with PBS to
remove excess PFA. Fixed cells were blocked with 5% PBS (supplemented with 10%
serum if the cells to be stained were FcγR-expressing phagocytes) for at least 20 min at
room temperature. For intracellular staining, cells were permeabilized by supplementing
the blocking buffer with 0.1% Triton X-100, and the length of the blocking period
increased to at least 1 hr. Blocking buffer was removed and primary antibody in blocking
buffer was added to the cells and allowed to incubate for 30 min (without permeabilization)
or 60 min (with permeabilization) at room temperature. Cells were washed 3× 5 min
(without permeabilization) or 3× 15 min (with permeabilization). Secondary antibodies in
blocking buffer was added and allowed to incubate for 30 min at room temperature. Cells
were again washed 3× 5 min (without permeabilization) or 3× 15 min (with
permeabilization). Coverslips were mounted onto glass slides using Permafluor mounting
reagent and stored at 4 °C until imaging.

2.8 Patient tissue samples
2.8.1 Human research ethics
Patient tissues used in this study were obtained under a discarded tissue protocol from
patients undergoing elective coronary artery bypass graft (CABG) surgery at London
Health Sciences Centre. This study was reviewed and approved by the Office of Human
Research Ethics at Western University Health Sciences Research Ethics Board (HSREB
Reference Number: 107566). Since this is a discarded tissue study, we did not collect any
personal health information, personal identifying information or clinical data nor were we
required to obtain informed consent from patients’ whose tissues were used in this study.

2.8.2 Surgical specimen preparation
Aortic punch tissue specimens were obtained intra-operatively by a cardiac surgeon using
a 4.0-mm diameter CleanCut RCL Aortic Punch (QUEST Medical) and placed into cold
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saline. Specimens were then bisected evenly using clean surgical scissors, with one half of
the tissue used to prepare frozen sections and the other for preparing paraffin sections.

2.8.3 Tissue sectioning
2.8.3.1 Frozen sections
For laser capture microdissection, tissue specimens used for frozen sections were
immediately embedded in OCT freezing compound and frozen on dry ice over a period of
5-10 min and placed into -80 °C for storage. No more than 30 min was allowed to elapse
between the time at which aortic punch tissue specimens were excised and placement of
the frozen, OCT-embedded tissue into -80 °C for storage. Frozen sections were
subsequently obtained from OCT-embedded tissue on a cryostat at a 10-µm thickness onto
clean, RNase-free glass microscope slides.
For immunofluorescence, Oil Red O staining and all other downstream applications, tissue
specimens were fixed in fresh (< 1 week old) 4% paraformaldehyde for 24 hr at 4 °C. Fixed
specimens were placed into PBS with 15% sucrose for approximately 4 hr (or until the
tissue sinks) and then into PBS with 30% sucrose overnight at 4 °C. Fixed, cryopreserved
tissue specimens were then embedded in OCT freezing compound and frozen on dry ice
over a period of 5-10 min and placed into -80 °C for storage. Frozen sections were
subsequently obtained from OCT-embedded tissue on a Leica CM1900 Cryostat at a 10µm thickness onto clean Superfrost Plus microscope slides (Fisherbrand).

2.8.3.2 Formalin sections
Tissue specimens used for formalin-fixed, paraffin-embedded (FFPE) sections were fixed
in fresh (< 1 week old) 4% paraformaldehyde for 24 hr at 4 °C. Fixed specimens were
stored in 70% ethanol until ready for further processing. For paraffin infiltration, specimens
were dehydrated through immersion in changes of ethanol of increasing concentration
(70% ethanol for 1 hr, 95% ethanol for 1 hr, and four changes of 100% ethanol for
1/1.5/1.5/2 hr), cleared with two changes of xylene for 1 hr each and immersed in two
changes of paraffin wax at 58 °C for 1 hr. Processed tissues were embedded into paraffin
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blocks. FFPE tissues were subsequently sectioned on a microtome at a 5-µm thickness onto
clean glass microscope slides.

2.9 Mouse work
Use of animals for this study was obtained from the Western University Animal Care
Committee under Animal Use Protocol (AUP) 2018-131:1. LDL receptor-deficient (Ldlr/-

) C57BL/6J mice were put on either a high-fat, high-cholesterol (15% fat, 1% cholesterol)

diet or a chow control for a period of 12 weeks. Animals were subsequently sacrificed,
with thoracic aortas being subsequently surgically isolated for further processing.

2.10 Microscopy
Microscopy was used to visualize tissue histology and perform quantification of
fluorescence intensity. In all cases, at least three biological replicates were analyzed. For
measurement of fluorescence within individual cells, a minimum of 30 cells were
quantified. To minimize observer bias, random fields of view were captured whenever
possible.

2.10.1

White light

Tissue section immunohistochemistry, TUNEL assay and Oil Red O-stained cells were
imaged using an inverted-stage white light microscope equipped with a digital camera
running Northern Eclipse image analysis software (EMPIX Imaging) using a 5× or 10×
objective lens.

2.10.2

Epifluorescence

Imaging of immunofluorescently-stained frozen sections and immunofluorescently-stained
cells was performed using a Leica DMI6000B epifluorescence microscope equipped with
a Sedat Quad filter set (Chroma) and operated by Leica LAX software.
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For imaging of Rab protein recruitment to phagosomes and efferosomes or for colocalization experiments, samples were imaged using a 100×/1.40NA objective lens and
an Evolve-512 delta EM-CCD camera (Teledyne Photometrics).
For imaging of phagocytosis and efferocytosis assays, peptide citrullination assays, dextran
fusion assays, nitro blue tetrazolium assays or for confirming the expression of a
fluorescently-tagged protein, samples were imaged using a 63×/1.40 NA objective lens and
the Evolve EM-CCD camera. If needed, z-sections were captured for apoptotic cell
efferocytosis assays across the entire depth of the efferocyte separated by 0.5 µm between
stacks.
For imaging of whole immunofluorescently-stained tissue sections, samples were imaged
using a 40×/1.00NA objective lens and the ORCA-Flash4.0 V3 Digital CMOS camera
(Hamamatsu Photonics) with the Leica LAX Tile Scan Merge function to capture the
entirety of the aortic wall intima.

2.10.3

Live cell

Cells to be imaged were grown on No. 1.5 thickness 8-mm round glass coverslips and
transferred to a Leiden chamber and placed into a heated and CO2-perfused chamber
attached to the piezoelectric stage of a Leica DMI6000B epifluorescence microscope.
Between 5-10 cells of interest were marked using the Mark and Find feature of the Leica
LAX software and live cell acquisitions of each cell were obtained at 0.5-1 frames/min
over a period of 1-8 hrs.

2.11 Image analysis
All image analysis was performed using the FIJI distribution of ImageJ unless otherwise
stated.1,4 Specific methods are described in detail in individual methods sections for each
following chapter.
In general, measurement of fluorescence intensity was performed by forming a selection
around the region of interest (ROI) and using the Measure feature to obtain the area and
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integrated density of the ROI. Background fluorescence was measured by drawing a ROI
around a region free of any cells or other features and measuring the mean. Background
subtraction was performed on fluorescence intensity measurements by subtracting from
integrated density the product of background mean and the measurement ROI area.
Unless otherwise specified, co-localization analysis was performed using the JACoP
plugin on ImageJ to determine Pearson’s coefficient.5

2.12 Statistical analysis
All statistical analysis was performed on GraphPad Prism 6 software. Comparison between
two means made use of an unpaired, two-tailed Student’s t test or Mann-Whitney U test
when the sample distribution was noted to be non-normal. For comparison of multiple
means, we employed 1-way or 2-way ANOVA as appropriate with the Holm-Sidak
multiple comparisons test when comparing multiple means with a single mean or the
Tukey’s range test when comparison multiple means with every single other mean.
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Chapter 3

3

The Small GTPase Rab17 is a Key Regulator of
Efferosome Maturation Under Homeostatic Conditions

3.1 Introduction
3.1.1 Regulation of
conditions

efferosome maturation

under homeostatic

Appropriate regulation of efferocytic clearance of apoptotic cells and subsequent
maturation of the resultant efferosome are crucial for the proper maintenance of tissue
homeostasis.1–3 Much of what is currently known about the regulation of efferosome
maturation is derived from studies in a Caenorhabditis elegans model, where the early
stages of efferosome maturation appears to proceed similarly to canonical phagosome
maturation.4 Efferosome and phagosome maturation is described in detail in Chapter
1.1.5, but briefly, the small GTPase Rab5 is recruited to the surface of the nascent
efferosome, followed by a rapid exchange of Rab5 for Rab7 mediated by the Mon1-Ccz1
complex.5,6 Rab7 subsequently mediates the recruitment of effector molecules such as
RILP and ORPL1, which are required for efferosomal-lysosomal fusion, and VTPases that
drive efferosomal acidification.7–10 The result of this process is the formation of an
efferolysosome where, akin to a phagolysosome, the apoptotic cell cargo is degraded.11

3.1.2 Differential regulation of phagosome and efferosome maturation
Although the mechanisms that govern phagosome and efferosome maturation are similar,
there are drastic differences in the immunological outcomes of phagocytosis versus
efferocytosis.11,12 Whereas phagocytosis is a pro-inflammatory process that results in
inflammation and antigen presentation, efferocytosis is immunologically silent and instead
drives resolution of inflammation.12 The ultimate fate of efferocytic and phagocytic
cargoes must therefore also differ.13,14 Phagocytic cargoes are degraded and subsequently
loaded onto MHC class II molecules for antigen presentation, whereas efferocytosis does
not result in antigen presentation.13
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3.1.3 The Rab family of GTPases
The Rab (“Ras-related in brain”) family is a part of the Ras superfamily of small GTPases
and function as master regulators of intracellular vesicular trafficking.15 Rab GTPases are
found ubiquitously across all eukaryotes studied to date, with more than 60 family
members identified in the human genome alone.16,17 Members of the Rab family all possess
a distinctive set of five α helices surrounding a six-stranded β sheet. This structure is
common to all members of the Ras superfamily and contain structures responsible for
guanine nucleotide binding activity.18 Additionally, Rab GTPases contain two regions
termed switch I and switch II, which contain distinctive RabF regions that can be used to
identify Rab GTPases and undergo conformational changes depending on whether the Rab
is in an active GTP-bound or an inactive GDP-bound state. Finally, individual Rab family
members contain RabSF regions, which are thought to be responsible for binding with
specific effector molecules.15,16 An illustration of the common structural features of the
Rab GTPases is provided in Figure 3.1.

Figure 3.1 Common structural features of the Rab family of small GTPases. (on
opposite page)
Ribbon diagram of the crystal structure of Rab3A complexed with the GTP analog
GppNHp. Purple – bound nucleotide; orange sphere – Mg2+ ion; blue – switch I and II
regions; green – α helices and β sheets; yellow – loops. (a) A consensus amino acid
sequence of the Rab GTPase family. Red – Rab-specific residues (RabF1-5); dark blue –
subfamily-specific motifs (RabSF1-4); cyan – highly conserved nucleotide-binding motifs;
G – guanine base-binding motif; PM – phosphate/magnesium-binding motif. (b) The
secondary structure units (α helices, β strands, and loops, λ) are indicated above the
sequence. Figure modified from Stenmark and Olkkonen.15
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Newly-synthesized Rab GTPases are bound by a Rab escort protein (REP), which first
recruits a geranylgeranyl transferase enzyme that mediates transfer of a hydrophobic
geranylgeranyl group to the carboxyl terminus of the protein.19,20 This post-translational
modification allows the Rab to anchor itself to cellular membranes.20 Specific targeting of
Rab GTPases to the appropriate membrane surface is thought to result from an interaction
between the Rab-REP complex and receptors on the target membrane.21 At this stage, the
Rab is in an inactive, GDP-bound conformation. Inactive Rab’s can become activated via
GTP-GDP exchange mediated by a GEF. The activate Rab is then able to recruit specific
downstream effector molecules. Active Rab’s can be inactivated by a GAP, which cleaves
the bound GTP to GDP.22,23
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Table 3.1 Rab-family GTPases implicated in phagosome maturation. Modified from
Kinchen and Ravichandran.11

Rab GTPases play many key functions in the regulation of almost every component of
intracellular vesicular trafficking.11,22,24 Rab5 and Rab7 are key markers of the early and
late phagosome/efferosome respectively and play crucial functions in the regulation of
proper phagosome and efferosome maturation.6,25 Rab4 and Rab11 are members of this
family that have been implicated in membrane and receptor recycling. Rab4 is required for
the recycling of receptors from the early endosome to the cell membrane while Rab11 is a
marker of the recycling endosome and required for trafficking of receptors from the RE to
the cell surface.26–28 A final example is Rab27, which plays an important role in regulated
secretion across multiple cell types and appears to play a key role in mediating granule
release from secretory cells such as melanocytes, neurons and neutrophils.29–31
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Unsurprisingly, there are a multitude of Rab GTPases involved in the regulation of
phagosome/efferosome maturation (Table 3.1). These include the classical Rab5 and Rab7
but also a number of Rab family members involved in transport between the endoplasmic
reticulum and Golgi and the Golgi and other vesicles.

3.1.3.1 Rab17
One member of the Rab GTPase family of particular interest to us is Rab17 as it appears
as a protein that is uniquely recruited to the efferosomal surface in the mass spectrometry
experiments described below. Rab17 was initially identified in the 1990’s in epithelial cells
and enterocytes as a key regulator of transcytosis and membrane recycling in polarized
cells.32–34
Since then, the presence and function of Rab17 has been described in a number of polarized
and secretory cells, including hepatocytes35,36, neurons37 and melanocytes38. In the liver,
Rab17 appears to play a key role in regulating the basolateral-to-apical transcytosis in
hepatocytes and that sumoylation was required in addition to GTP-binding for Rab17
activity.35,36 In the brain, Rab17 is expressed in neurons of the hippocampus and regulates
formation and post-synaptic growth of dendrites.37 It is also found in brain epithelial cells,
where it again appears to regulate the formation of “sorting tubules” that mediate the
transcytosis of cargoes across the blood-brain barrier.39 In melanocytes, Rab17 is found to
be associated with the RE and Rab17 knockdown resulted in impaired filopodia formation
and melanosome release.38 A detailed mechanistic study of Rab17 involvement in
transcytosis by Striz et al.36 revealed that it is able to associate with transcytotic vesiclespecific VAMP’s and interact with syntaxin 2 at the apical membrane to initiate vesicle
fusion.
Importantly, a dominant-negative (DN) mutant of Rab17 has been previously described
and characterized.32 This mutant contains a single asparagine to isoleucine mutation in the
NKXD motif, which is highly conserved within GTPase proteins and is required for
binding to GTP and conversion to the protein’s active form.40,41 DN-Rab17 does not appear
to interact with syntaxin 2 and cells expressing DN-Rab17 displayed impair trafficking of
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apical proteins via transcytosis, suggesting that expression of DN-Rab17 impairs proper
cargo trafficking.35

3.1.4 Rationale and importance
Despite being a crucial mechanism for the maintenance of tissue homeostasis, efferocytosis
and the mechanisms that regulate efferosome maturation remain poorly understood. Much
of what is known about efferosome maturation is derived from either knowledge of
phagosome maturation or from studies in model organisms such as C. elegans.6 As
phagocytosis and efferocytosis have radically different immunological outcomes, it is
reasonable to expect that phagosomes and efferosomes undergo different maturation
programs.12 To date, we still lack a clear understanding of how phagosome and efferosome
maturation are differentially regulated.
In the present chapter, we use a mass spectrometric approach towards identifying proteins
that are uniquely recruited to phagosomes vs. efferosomes as potential regulators of
differential maturation. We then utilize fluorescence microscopy to track differential
recruitment of regulators to the phagosome and efferosome surfaces and examine the
effects of the knockdown of regulators on phagosomal and efferosomal cargo fate.
Efferocytosis plays an important role in limiting inflammation and promoting
resolution.3,42 Failure of efferocytosis has been implicated in the pathophysiology of a
number of inflammatory and autoimmune diseases, including atherosclerosis,43–45 systemic
lupus erythematosus46,47 and multiple sclerosis.48 Despite this, factors that regulate
efferosome maturation under homeostatic conditions remain poorly understood. A clearer
picture of how efferosome maturation is regulated will allow us to gain a better
understanding of how efferosomal cargo is degraded without antigen presentation and will
form the basis of investigating how this process begins to break down in autoimmune
disease.
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3.2 Methods
3.2.1 Rab17 cloning
Human Rab17 was cloned into pEGFP-C1 and pmCherry-C1 backbones using the method
described in Chapter 2.3.1. A dominant-negative (N132I) Rab17 construct35 was prepared
by amplifying the above construct with DN Rab17-specific 5′ phosphorylated primers
using the standard PCR cycle with a 7 min elongation time. Parental plasmid was removed
by the addition of 1:50 (vol/vol) DpnI to the reaction and incubating for 1 h at 37 °C. The
resulting PCR product was then gel purified, re-circularized by incubating overnight at 16
°C with T4 ligase and subsequently transformed into E. coli as described in Chapter 2.5.1.
See Appendix A for primer sequences.

3.2.2 Phagocytosis/efferocytosis assays
Synthetic IgG- and PS-coated beads were prepared using the methods described in
Chapter 2.6.1 while heat-killed E. coli and apoptotic Jurkat cells were prepared as
described in Chapter 2.6.2. Phagocytosis and efferocytosis assays were performed
following the methods described in Chapter 2.6.3 with proteins of interest labelled
following blocking/permeabilization by addition of primary antibodies (1:1000 anti-MHC
class II, 1:500 anti-LAMP1, 1:200 anti-Rab17) followed by fluorescently tagged Fab’s
(1:1000 to 1:2500).

3.2.3 Quantification of Rab17 recruitment to phagosomes/efferosomes
Quantification of Rab17 recruitment was performed in MATLAB using modified forms of
previously published vesicle-tracking and intensity quantification algorithms.49–51 Briefly,
90-120 min time-lapse videos were captured of macrophages ectopically expressing the
plasmalamellar

marker

PM-RFP,

GFP-tagged

Rab17

and

far-red-labeled

phagocytic/efferocytic targets. TIFF stacks of individual cells were then exported, and a
local threshold applied to the target channel using a local neighborhood 2× the size of the
targets. Targets were then identified using the 'bwlabel' command in MATLAB and the
targets tracked using a robust tracking algorithm.50,52 Image channels corresponding to PMRFP and Rab17 were subjected to a global background subtraction, with no other

90

processing applied, to maintain linearity of intensity data. Internalized targets were defined
as targets that colocalized with a distinct PM-RFP structure that was no more than 1.4×
(beads) or 2× (E. coli or apoptotic cells) the diameter of the phagocytic/efferocytic target,
and the first frame in which the target colocalized with a distinct PM-RFP structure was
set as the 0 min timepoint of phagocytosis/efferocytosis. All tracks were manually curated
to ensure accuracy, with any tracks lasting less than 15 min rejected from subsequent
analyses. Recruitment of Rab17 to the PM-RFP/target structure was then measured at all
subsequent timepoints and normalized to the maximum intensity Rab17 structure in the
cell.

3.2.4 Colocalization analysis
Colocalization of signaling molecules with phagosomes and efferosomes in fixed cells was
also quantified using MATLAB. Z-stack images of cells were captured and deconvolved
using an iterative deconvolution approach. A ROI was manually drawn around each cell
and the mean ± SEM of the fluorescence intensity of each channel within the ROI
determined. Phagocytic/efferocytic targets were then identified using the local background
subtraction and thresholding approach described in the previous subsection but using the
'bwlabeln' MATLAB command to identify targets in the 3D images. Each target was
converted into a 3D ROI by identifying the bounding pixels of each target using the
'convhull' command. These ROIs were then expanded by a factor of 1.4× to ensure that the
bounding PM-RFP and any recruited signaling molecules would be captured without
significant inclusion of cytosolic staining. Targets were scored as associated with a
molecule of interest if the mean intensity of the molecule of interest in each ROI was two
SD higher than the mean intensity of the molecule throughout the entire cell. As with the
Rab17 recruitment analysis described above, no intensity adjustments other than a global
background subtraction were applied to the images of the signaling molecules to preserve
linearity of the image intensity data.

3.2.5 Efferosome mimics quantification
Quantification of mimic-containing efferosomes was performed to measure the formation
of efferosome-derived vesicles (EDVs). Time-to-fragmentation was measured from the
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timepoint of complete efferosome closure to timepoint when fission of the first Rab17+
EDV was observed. The number of EDVs formed from each efferosome was recorded and
the diameter of each EDV was quantified using the line measurement tool.

3.2.6 Efferosome fission, fusion and movement
Efferosomes were tracked in fluorescent images. At the timepoint of complete efferosome
closure an ROI was drawn around the cell using the freehand selection tool, and the x/y
coordinates of the cell barycentre determined with the measure tool. The MTrack2 plugin
was used to track the efferosome, EDVs, and any EDV-interacting Rab17+ vesicles. Track
positions were imported into MATLAB, the timing and location of all fission and fusion
events annotated, and the track divided into pre- vs. post-initial fission segments. Prefission tracks were translated such that all measurements were made relative to a vector
linking efferosome closure site to the cell barycentre, and post-fission tracks translated
such that all measurements were made relative to a vector linking the fission site to the cell
barycentre. The directionality of movement of each track was then quantified as the ratio
between the Euclidian distance covered by the vesicle from its start- to end-point vs. the
total distance traveled.53,54

3.2.7 Efferosome positioning
Efferosome positioning was quantified using the method of Johnson et al.55 Images were
imported into FIJI56,57 and the cell boundary, as defined by the Rab17 staining, traced using
the freehand tool. This ROI was then degraded inwards in 1 mm increments to create 3
shells of 1 mm thickness. The number of EDVs in each shell, EDV diameter (subresolution EDVs were recorded as 0.2 mm in diameter), and colocalization with LAMP or
TfR was quantified in each image using the methods described above.
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3.3 Results
3.3.1 Efferosomes and phagosomes share a common early maturation
pathway
Phagocytic cargos are degraded by a well-characterized maturation pathway in which the
sequential acquisition of Rab5 and Rab7 mediates the sequential fusion of early
endosomes, late endosomes and lysosomes with the phagosome.8 Evidence from C.
elegans and mammalian cell lines indicate that this same maturation pathway degrades
efferocytosed apoptotic cells.4 However, these studies did not use professional antigen
presenting cells (pAPCs), which may use an alternative pathway to avoid antigen
presentation following uptake of apoptotic cells.
To test whether apoptotic cells were trafficked through a novel maturation pathway in
pAPCs, we tracked the recruitment of ectopically expressed Rab5-GFP and Rab7-RFP in
J774.2 macrophages engaged in phagocytosis (Figures 3.2a and 3.2c) or efferocytosis
(Figures 3.2b and 3.2d) of 5 μm diameter synthetic phagocytic or efferocytic targets. Both
efferosomes and phagosomes sequentially recruited Rab5 and Rab7, with efferosomes
transitioning from a Rab5-positive to Rab7-positive compartment with slightly slower
temporal dynamics than phagosomes (Figures 3.2c and 3.2d). To confirm that both
phagosomes and efferosomes were completing maturation, we immunostained human
PBMC-derived M0 macrophages for the lysosomal marker LAMP1 40 min after
engulfment of synthetic phagocytic or efferocytic targets (Figure 3.2e). Significant
LAMP1 accumulation was observed on phagosomes and efferosomes, confirming that
vacuoles containing both types of cargo fuse with lysosomes. Finally, we assessed the
possibility that macrophage polarization may result in the selective uptake of phagocytic
versus efferocytic targets (Figure 3.2f).
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Figure 3.2 Efferosomes and phagosomes share a common early maturation pathway.
(on opposite page)
Fixed and live cell microscopy was used to assess the localization of Rab5, Rab7 and the
lysosomal marker LAMP1 to efferosomes and phagosomes containing 5 μm diameter
bead-based mimics of apoptotic cells and bead-based mimics of pathogens. (a and b)
Recruitment of Rab5 and Rab7 to phagosomes (a) and efferosomes (b) 10, 20 and 30 min
following engulfment by J774.2 macrophages. Ex. Beads indicates noninternalized (i.e.
extracellular) beads. (c and d) Dynamics of Rab5 and Rab7 recruitment to phagosomes (c)
and efferosomes (d). T = 0 is set as the video frame when complete sealing of the
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phagosome/efferosome was observed; data are normalized to maximum Rab5 or Rab7
intensity on each individual phagosome. (e) Immunostaining of LAMP1 accumulation in
phagosomes or efferosomes in human PBMC-derived M0 macrophages. (f) Uptake of
apoptotic cell mimics (Efferosomes) and IgG-opsonized pathogen mimics (Phagosomes)
by human PBMC-derived M0-, M1- and M2-polarized macrophages and DCs, expressed
as the number of beads engulfed per cell. Data are representative of (a, b and e) or
quantifies (c, d and f) at least 30 cells imaged across five independent experiments. Data
are presented as mean or mean ± S.E.M. *p < 0.05 compared with uptake of the same type
of target by M0 macrophages. Scale bars are 5 μm.
M0 and M2 macrophages were highly efferocytic, while M1 macrophages and primary
human dendritic cells were poorly efferocytic. Furthermore, no selectivity was observed
for phagocytic targets, indicating that any capacity to differentially present efferosomal
versus phagosomal antigens must occur following both target engulfment and the canonical
Rab5/Rab7-mediated maturation pathway.

3.3.2 Mass spectrometric identification of late regulators of efferosome
and phagosome maturation
Given that efferosomes and phagosomes shared the same early maturation pathway, any
selective processing of these targets likely occurs at a later timepoint. As such, we
recovered efferosomes and phagosomes using 3 μm diameter magnetic bead mimics of
efferocytic and phagocytic targets from M0-polarized human macrophages, 40 min after
initiation of efferocytosis or phagocytosis. Proteins from the recovered efferosomes and
phagosomes were resolved using SDS-PAGE, revealing several proteins selectively
recruited to efferosomes versus phagosomes (Figure 3.3).
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Figure 3.3 Efferosomes and phagosomes interact with unique subsets of proteins.
Coomassie staining of SDS-PAGE gels of proteins recovered from phagosomes (phago)
and efferosomes (effero) 40 min following phagocytosis or efferocytosis of 3 µm IgG- or
PS-coated magnetic beads. Phagosomes and efferosomes were recovered by magnet from
human PBMC-derived M0-polarized macrophages following cell lysis.
These unique proteins were subsequently excised and identified by liquidchromatography/mass spectrometry. Phagosomes (Table 3.2) contained many of the
proteins expected of a vesicle maturing into an MHC class II loading compartment, notably
MHC class II and indicators of Golgi-to-lysosome trafficking (Rab6b, PIK4). In addition,
phagosomes were enriched in several proteins involved in GTPase and kinase signaling. In
marked contrast, efferosomes (Table 3.3) lacked MHC class II and the markers of Golgito-lysosome trafficking observed on phagosomes. Efferosomes instead recruited proteins
that mediate vesicular trafficking, cytoskeletal organization and ubiquitination/
ISG15ylation. Of particular interest to us were the Rab family GTPases Rab17 and RASEF
(Rab45), both of which have been implicated in trafficking to recycling endosomes and
exocytosis.34,38,58,59 Combined, these results suggest that efferocytic cargos are intercepted
before formation of the MHC class II loading compartment and are redirected to a recycling
or exocytic cellular compartment.
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Table 3.2 Unique proteins recruited to phagosomes 40 min post-phagocytosis.

Table 3.3 Unique proteins recruited to efferosomes 40 min post-efferocytosis.
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3.3.3 Rab17 is persistently recruited to efferosomes but not
phagosomes
To assess the role of Rab17 in phagocytosis and efferocytosis, we performed live cell
microscopy of J774.2 macrophages ectopically expressing the plasma membrane marker
PM-RFP and Rab17-GFP as they engulfed beads mimicking efferocytic or phagocytic
targets. As expected, both phagocytic and efferocytic targets were internalized into plasma
membrane-derived vacuoles demarcated by PM-RFP (Figures 3.4a and 3.4b). Rab17
transiently localized to phagosomes, with dynamics similar to that of Rab5 (Figures 3.4a
and 3.4c). In marked contrast, Rab17 was persistently recruited to efferosomes, displaying
only a modest decrease in recruitment over the hour following engulfment of the
efferocytic target (Figures 3.4b and 3.4c). Close inspection of individual efferosomes
revealed that this recruitment was not constant, and rather that Rab17 is repeatedly
recruited in a series of waves, suggestive of repeat sampling of efferosomes by Rab17
(Figure 3.4d).

Figure 3.4 Rab17 is selectively retained on efferosomes. (on opposite page)
Live cell microscopy was performed on J774.2 macrophages expressing PM-RFP and
Rab17-GFP engulfing apoptotic cell (Efferosomes) or IgG-opsonized pathogen
(Phagosomes) mimics. (a and b) Representative images of Rab17-GFP recruitment to
phagosomes

(a)

or

efferosomes

(b).

Star/arrowhead

tracks

the

same

phagosome/efferosome through successive time points. (c) Dynamics of Rab17
recruitment to phagosomes and efferosomes. (d) Recruitment dynamics of Rab17-GFP to
three representative efferosomes. (c and d) T = 0 is set as the video frame when complete
sealing of the phagosome/efferosome was observed and data are normalized to maximum
Rab17 intensity on each individual phagosome. Data are presented as mean ± SEM (c) or
mean (d). Data are representative of (a, b and d) or quantifies (c) a minimum of 22 cells
imaged over four independent experiments. Scale bars are 5 μm.
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Rab17 expression was observed in primary human PBMC-derived M0-, M1- and M2polarized macrophages as well as primary human PBMC-derived DCs, with late
recruitment of Rab17 observed to efferosomes in M0- and M2-polarized macrophages and
DCs (Figure 3.5). RASEF and Rab6b, the other Rab-family GTPases identified in our mass
spectrometry screen, did not significantly associate with either phagosomes or efferosomes
(Figures 3.6a and 3.6b).
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Figure 3.5 Rab17 is expressed in human phagocytes and is recruited to efferosomes
late in maturation.
Macrophages and dendritic cells were derived by ex vivo differentiation of human PBMC’s
into the respective cell types. Rab17 immunoblot of M0-, M1- and M2-polarized
macrophages and dendritic cells (DCs). (a) Immunostaining of Rab17 30 min following
efferosome closure. (b) Plots indicate the intensity of Rab17 staining along the dashed
yellow line (DC) or horizontally across the center of the insert (M0/M2). Data from M1polarized macrophages are not presented as no efferosomes were observed in these cells.
Images are representative of 3 independent experiments. Scale bars are 5 µm.
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Figure 3.6 Rab6b and Rab45 are not recruited to the maturing phagosome and
efferosome.
Live cell microscopy was performed on J774.2 macrophages expressing PM-RFP and
either Rab6b-GFP engulfing IgG-opsonized pathogen mimics (a) or Rab45-GFP engulfing
apoptotic cell mimics (b) Representative images demonstrating lack of Rab6b and Rab45
recruitment are shown. The arrowhead tracks the same phagosome/efferosome through
successive time points. T = 0 is set as the video frame when complete sealing of the
phagosome/efferosome was observed. Data are representative of a minimum of 10 cells
imaged over three independent experiments. Scale bars are 5 μm.
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Since our model system used non-digestible mimics of bacterial and apoptotic cells, we
could not assess whether Rab17 altered the trafficking of degraded materials derived from
efferosomes or phagosomes. As such, we performed live cell imaging of Rab17-GFP- and
PM-RFP-expressing macrophages as they engulfed E. coli or apoptotic cells covalently
labeled with a degradation-resistant, pH-stable, far-red fluorophore. Bacterial phagocytosis
did not differ from the mimics, with E. coli internalized into a compartment that transiently
colocalized with Rab17 and retained PM-RFP for at least 90 min (Figures 3.7a, 3.7c and
3.7d). In marked contrast, macrophages efferocytosed small fragments (apoptotic bodies)
from apoptotic cells into PM-RFP-demarcated efferosomes, on which Rab17 was retained
for prolonged periods of time (Figures 3.7b, 3.7c and 3.7e). Interestingly, at later time
points, degraded apoptotic cell materials were observed to move into a compartment
negative for PM-RFP (Figure 3.7d), a phenomenon not observed with non-degradable
targets (Figure 3.4b), suggesting that degraded efferocytosed materials were being
directed out of the canonical maturation pathway—a process not observed with E. coli
(Figure 3.7e), indicating that the degraded apoptotic cells and E. coli had been trafficked
into different cellular compartments.
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Figure 3.7 Rab17 is selectively retained on apoptotic cell containing efferosomes.
Live cell microscopy was performed on J774.2 macrophages expressing PM-RFP and
Rab17-GFP engulfing fluorescently tagged apoptotic cells (AC) or E. coli (E. coli or EC).
(a) Representative slice from a z-stack of Rab17-GFP and PM-RFP recruitment to E. coli
containing phagosomes 60 min following phagocytosis. Arrow indicates the phagosome
magnified in the insert. (b) Representative slice of a z-stack of Rab17-GFP and PM-RFP
recruitment to an apoptotic cell containing efferosome 5 min following efferocytosis.
Arrow indicates the same Rab17+/PM-RFP+ efferosome, and arrowhead indicates the same
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Rab17-/PM-RFP+ efferosome, in all panels. (c) Recruitment dynamics of Rab17-GFP to
phagosomes and efferosomes, normalized to the brightest Rab17+ cell structure. (d and e)
Portion of E. coli containing phagosomes (d) or apoptotic cell containing efferosomes (e),
which are positive for PM-RFP only (PM+), positive for PM-RFP and Rab17
(PM+/Rab17+) or positive for Rab17 alone (Rab17+). Scale bars are 5 μm. Small lines
indicate the position of the cross-section shown in the corresponding xy and z images. (c–
e) T = 0 is set as the video frame when complete sealing of the phagosome/efferosome was
observed, and data are normalized to maximum Rab17 intensity observed in each cell and
is presented as mean ± SEM. Data are representative of (a and b) or quantifies (c–e) a
minimum of 52 cells imaged over four independent experiments. *p < 0.05 compared with
the 5 min timepoint for the same group.

3.3.4 Rab17 mediates the trafficking of degraded apoptotic cell
materials to the recycling endosome
The previous data are consistent with a model in which phagocytosed materials traffic
through the canonical maturation pathway, whereas efferocytosed materials are redirected
into another cellular compartment by Rab17. Given that Rab17 has previously been found
to regulate recycling and exocytosis, it was likely that efferocytosed materials were being
trafficked from the efferosome to the recycling endosome.38,58 We therefore assessed the
recruitment of Rab17, a recycling endosome marker (transferrin receptor, TfR) and MHC
class II to phagosomes and efferosomes. Consistent with the canonical maturation process,
90 min following engulfment most phagosomes had recruited MHC class II but not Rab17
or TfR (Figures 3.8a and 3.8b). In contrast, efferocytosed materials did not colocalize with
MHC class II, which remained diffusively distributed throughout the cell (Figure 3.8c).
Instead, efferosomes strongly colocalized with TfR, with a portion colocalizing with both
Rab17 and TfR (Figure 3.8d). We next attempted to knockdown Rab17, but transfection
with siRNA concentrations that reliably knocked down Rab17 expression also inhibited
phagocytosis and efferocytosis (Figure 3.8e). Instead, we transfected J774.2 cells with a
mCherry-tagged dominant negative (DN)-Rab17 at a dose that inhibited ~ 50% of
efferocytosis and phagocytosis (0.5 μg per well; Figure 3.8e). DN-Rab17 was not recruited
to phagosomes and was recruited to a significantly lower fraction of efferosomes compared
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with wild-type Rab17 (Figure 3.8f). Importantly, expression of DN-Rab17 significantly
increased the association of MHC class II, and decreased the association of TfR, with
efferosomes (Figure 3.8f). Combined, these results indicate that Rab17 is selectively
recruited to efferosomes, where it mediates the transfer of degraded apoptotic cell material
into the recycling endosome and away from the MHC class II loading compartment.

Figure 3.8 Rab17 mediates trafficking of degraded apoptotic cell materials. (on
opposite page)
Z-stacks were captured of fixed J774.2 macrophages expressing Rab17-mCherry and either
co-expressing TfR-GFP (TfR) or immunostained for MHC class II (MHCII) 90 min
following engulfment of E. coli (EC) or apoptotic cells (AC). (a-d) Localization of Rab17
and MHC class II (a and c) or TfR (b and d), relative to phagocytosed E. coli (c and d) or
efferocytosed apoptotic cells (a and b). Uptake of E. coli and apoptotic cells by J774.2
macrophages that were untreated/non-transfected (UT), treated with scrambled (Scm) or
Rab17 siRNA (Rab17), or transfected with 0.1–1.0 μg per well of a construct expressing
DN-Rab17, expressed as the number of E. coli or apoptotic cells engulfed per cell. (e)
Quantification of the fraction of phagocytosed E. coli or efferocytosed apoptotic cells that
recruited Rab17, MHC class II and TfR in cells expressing mCherry-tagged wild-type or
dominant-negative (DN) Rab17. (f)

Images are representative of (a-d), and graphs

quantify (e and f), a minimum of 15 images captured in three independent experiments.
Scale bars are 5 μm. Small lines indicate the position of the cross-section shown in the
corresponding xy and z images. *p < 0.05 compared with the same group in untreated cells
(e) or cells expressing wild-type Rab17 (f).
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3.3.5 Rab17 sorts materials on maturing efferosomes
Having demonstrated that Rab17 mediates the transfer of degraded apoptotic cell materials
from the efferosome to recycling endosomes, we next sought to elucidate the mechanism
by which Rab17 mediates the transfer of materials from efferosomes to recycling
endosomes. Firstly, the distribution of Rab17 relative to recycling endosomes (demarcated
by transferrin receptor, TfR) and plasma-membrane derived vesicles (demarcated by PM-
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RFP) was assessed in resting macrophages. PM-RFP was found to be largely excluded
from Rab17+ vesicles (Figure 3.9a and 3.9c). More interestingly, while all but a minute
portion of Rab17+ vesicles were positive for TfR, there was a significant portion of TfR+
vesicles which lacked Rab17 (Figures 3.9b and 3.9c). Therefore, in resting macrophages,
Rab17 demarcates a subset of the recycling endosome system and is not significantly
recruited to plasma membraned-derived vesicles such as endosomes.

Figure 3.9 Rab17 dynamics on efferosome mimics. (on opposite page)
Colocalization of Rab17-GFP and Rab17-mCherry with PM-RFP-derived vesicles or with
TfR-GFP-positive vesicles in resting J774.2 cells. (a and b) Percent of Rab17+ vesicles costaining with TfR (Rab17:TfR), TfR+ vesicles co-staining with Rab17 (TfR:Rab17) and
PM-derived vesicles co-staining with Rab17 (PM:Rab17). (c) Dynamics of Rab17-GFP
and PM-RFP on efferosomes containing non-digestible apoptotic cell mimics. (d) Arrows
indicate Rab17+ vesicles fissioning from the efferosome. Images are representative of (a
and b) or quantifies (c) 47 images captured over 4 independent experiments or is
representative of 12 time-lapse videos captured over 5 independent experiments (d). Data
are presented as mean ± SEM. Scale bars are 5 µm (a and b) or 10 µm (d).
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Next, live cell microscopy was used to quantify Rab17 dynamics during efferocytosis,
using large (5 µm) apoptotic cell mimics to provide higher spatial resolution (Figure 3.9d).
These mimics were internalized into a PM-RFP-demarcated compartment which was
positive for Rab17-GFP. A few minutes following closure, the efferosome vesiculated
through the fission of Rab17+ vesicles, depleting approximately 60% of the Rab17 initially
recruited to the efferosome (Figure 3.9d, Table 3.4). Interestingly, the fissioning vesicles
were devoid of PM-RFP, suggesting that materials were being selectively sorted by
vesiculation of the efferosome. The efferosome remained weakly positive for Rab17
following vesiculation, with the occasional Rab17+ vesicle interacting with the efferosome
during this stage.
Table 3.4 Efferosome fission and fusion characteristics.

3.3.6 Fission and fusion of efferosome-derived vesicles
Our results from the previous section used indigestible apoptotic cell mimics, thus
preventing us from relating Rab17 dynamics to the processing of the efferosomal cargo.
To address this limitation, Rab17 dynamics were quantified on efferosomes containing
labeled apoptotic Jurkat cells in macrophages expressing Rab17-mCherry and PM-GFP.
Macrophages engulfed apoptotic bodies, not intact cells (Table 3.4, Figure 3.10a), with
the level of Rab17 retained on efferosomes and the size of the efferosomes remaining
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constant during the early stages of maturation (Table 3.4, Figure 3.10b). Despite some
photobleaching, it was apparent that newly formed efferosomes migrated toward the cell
center where they then vesiculated into multiple EDV’s (Figures 3.10b and 3.10c).
Interestingly, the intensity of PM-GFP staining on EDV’s was variable, consistent with the
sorting observed during the vesiculation of non-digestible efferosome mimics (Figure
3.10b).

Figure 3.10 Fission, fusion and movement of Rab17-positive efferosomes.
Efferosome and Rab17 dynamics were quantified using live cell microscopy of
efferocytosed fluorescently-labeled apoptotic bodies by macrophages expressing Rab17mCherry and PM-GFP. (a) Fluorescent image of a macrophage immediately following
engulfment of an apoptotic body (arrow/AC). Scale bar is 5 µm. Time-lapse micrograph of
the insert from panel a. (b) The intact efferosome is tracked by the white arrow, colored
arrows track individual EDVs. The staining of the apoptotic body is shown only for the
first and final frames, to emphasize the differential sorting of Rab17 and PM-GFP into
EDV’s. Track of efferosome and EDV’s from panel b. ‘X’ indicates the efferosome starting
position, asterisk indicates fusion between two EDV’s, and diamonds indicate sites of
fusion

with

Rab17+

recycling

endosomes.

(c)

Number

of

fusion

events

between EDV’s, and between EDV and recycling endosomes (RE). (d) Representative
motion tracks of 10 pre-fission efferosomes, measured relative to a vector between the cell
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barycentre and the site of efferosome formation. (e) Representative motion tracks of a
single post-fission vesicle derived from each efferosome in panel e, measured relative to a
vector between the cell barycentre and the efferosome fission point. (f) Directionality of
efferosome movement pre-fission (Pre), Post-fission (Post), and once the EDV’s reach the
periphery (Periph). (g) Data are representative of (a-c, e and f), or quantifies (d and g) 124
efferosomes imaged over 3 independent experiments. *p < 0.05 comparted to Pre, ┼p <
0.05 compared with Post, n.s. p > 0.05 by Students t-test (d) or one-way ANOVA with
Tukey post-hoc (g).
By tracking the fluorescent signal of the apoptotic bodies, we were able to track EDV’s for
prolonged periods of time, revealing that newly vesiculated EDV’s migrated toward the
cell periphery, and once at the cell periphery, ceased moving (Figures 3.10b and 3.10c).
During this migration most EDV’s underwent further vesiculation, as well as fusion with
other EDV’s and with Rab17+ recycling endosomes that were otherwise devoid of
apoptotic bodies (Figures 3.10c-d, Table 3.4), consistent with our previous findings
demonstrating cargo transfer from efferosomes to TfR+ recycling endosomes. Both the
inward movement of the nascent efferosome, and the subsequent outward movement of the
EDV’s were highly linear but became non-directional once EDV’s reached the cell
periphery (Figures 3.10e-g).

3.3.7 Rab17 is required for efferosome-derived vesicle migration
The inward migration of the newly formed efferosome is required for efficient fusion with
lysosomes and cargo degradation,10,60 and indeed, we have demonstrated here that
efferosome-lysosome fusion is concordant with Rab17 recruitment to the efferosome. In
contrast, the subsequent peripheral migration of phagocytosed cargo is, to our knowledge,
previously unreported. To determine if Rab17 was required for peripheral efferosome
migration, we expressed DN- or WT-Rab17-GFP in macrophages and quantified the
intracellular localization of efferosomes, using DN-Rab17 at a modest expression level to
prevent the inhibition of efferocytosis observed when Rab17 siRNA is used (Figure 3.8e).
As expected, a significant fraction of efferosomes were located in the periphery of cells
expressing WT-Rab17, whereas efferosomes remained in the perinuclear region of cells
expressing DN-Rab17 (Figures 3.11a and 3.11b). Efferosomes in DN-Rab17 expressing
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cells underwent limited fission (Figures 3.11c and 3.11d, Table 3.4), but fused normally
with LAMP1-demarkated lysosomes (Figures 3.11e and 3.11g). Consistent with our
findings above, expression of DN-Rab17 significantly impaired the transfer of efferosome
cargos from EDV’s to TfR+ recycling endosomes (Figures 3.11f and 3.11g)

Figure 3.11 Peripheral migration of EDV’s and cargo transfer to recycling endosomes
requires Rab17.
Localization of fluorescently-labeled, apoptotic Jurkat cell-derived EDV’s in macrophages
expressing WT- or DN-Rab17-GFP, and either the lysosomal marker LAMP1-mCherry or
the recycling endosome marker TfR-mCherry, was quantified 90 min post-efferocytosis.
Representative images of EDV location in cells expressing WT- or DN-Rab17. (a) Large
dashed line indicates the cell periphery; fine dotted lines indicate “shells” positioned at 1
µm increments inwards from the cell periphery. Quantification of the fraction of EDV’s
observed in each “shell” of cells expressing WT- or DN-Rab17. (b) Quantification of
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diameter (c) and number (d) of EDV’s in macrophages expressing WT- and DN-Rab17.
Effect of WT- vs. DN-Rab17 on the distribution of EDV’s colocalizing with (LAMP1+) or
lacking (LAMP1-) the lysosomal marker LAMP1. (e) Effect of WT- vs. DN-Rab17 on the
distribution of EDV’s colocalizing with (TfR+) or lacking (TfR-) the recycling endosome
marker TfR. (f) Comparison of the colocalization of efferosomes with LAMP1 and TfR in
cells expressing WT- or DN-Rab17. Data are representative of (a) or quantifies (b-g) at
least 28 cells over 3 independent experiments. *p < 0.05 compared with WT (b, g), LAMP+
in the same group (e) or TfR+ in the same group (f), 2-way ANOVA with Tukey post-hoc
(b, e and f), or Students t-test (d and g). Scale bars are 5 µm.

3.4 Discussion
Proper efferosome maturation is essential for avoidance of self-antigen presentation and
the induction of inflammation and autoimmunity.3 To date, our understanding of the
mechanisms that regulate efferosome maturation has been limited and it has been thought
that efferosome maturation proceeds similarly to phagosome maturation.11 However, it is
apparent that efferosome and phagosome maturation must be differentially regulated
processes since the immunological outcomes of these two processes are diametrically
opposed, with phagocytosis resulting in the initiation of an inflammatory response and
efferocytosis resulting instead in resolution of inflammation.1,3 The ultimate fate of
phagocytic cargo is to be trafficked to the MHC class II loading compartment, where
antigenic peptides from pathogens are loaded onto cognate MHC class II molecules and
trafficked to the cell surface for antigen presentation.61
Some investigators have suggested that the differences observed with efferocytosis in
contrast to phagocytosis is driven by differences in the kinetics of efferosome vs.
phagosome maturation.11,62 Efferosome maturation in macrophages appears to be delayed
in comparison with phagosomes.13,62 It has been suggested that TLR signaling within
phagosomes drive accelerated maturation and subsequent loading of antigenic peptides
derived from phagosomal cargo onto MHC class II molecules.13,62 Indeed, murine
macrophages deficient in either TLR2, TLR4 or MyD88 exhibited a decreased capacity to
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phagocytose either E. coli or Salmonella typhimurium, and phagosome maturation in these
macrophages was significantly delayed.62 However, other studies that have examined the
rate of phagosome maturation in the presence and absence of TLR ligands showed no
difference in the rate of acquisition of late phagosomal and lysosomal markers.63 We
therefore set out to determine whether, in professional phagocytes such as macrophages,
there is an intrinsic mechanism that differentially regulates efferosome maturation and
allows efferocytic cargo to bypass the MHC class II loading compartment.
Our data agree with existing literature that suggest efferosome and phagosome maturation
share a common regulatory pathway.4,6,11 Indeed, we recapitulate the key finding that the
small GTPases Rab5 and Rab7 are recruited sequentially to the maturing efferosome and
phagosome.6 We further demonstrate that the kinetics of Rab5 and Rab7 recruit does not
differ between efferocytosis and phagocytosis. This is perhaps unsurprising as it is well
established that Rab7 is responsible for the recruitment of key downstream effector
molecules that: 1) guide the assembly of a dynein-dynactin complex that drives migration
of the efferosome/phagosome along microtubules towards the cell centre,10,64 and 2)
mediates the fusion of lysosomes to the maturing phagosome, which delivers the vATPses
that mediate efferosome/phagosome acidification.9,65
However, through our mass spectrometry analysis, we identified Rab GTPases that were
differentially recruited to efferosomes vs. phagosomes. Of these, we were particularly
interested in the recruitment of Rab17 to efferosomes, given its established role in the
literature as a key regulator of receptor and cargo recycling34,58. This led to the hypothesis
that Rab17 may mediate trafficking through the recycling endosome as a mechanism by
which efferocytic cargo can bypass the MHC class II loading compartment.34,36 Indeed, we
observe that while Rab17 is transiently recruited to the surface of phagosome, it is
persistently recruited to efferosomes. Consistent with others who have shown that Rab17
regulates trafficking through the recycling endosome,58 we demonstrate here that Rab17+
vesicles containing efferocytic cargo colocalize with TfR, which is a marker of the
recycling endosome system.66 Importantly, we also demonstrate that Rab17+ vesicles
containing apoptotic cell-derived materials do not colocalize with MHC II, suggesting that
Rab17 mediates re-direction of this cargo away from the MHC class II loading
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compartment and to the recycling endosome. Strikingly, when we interfere with Rab17
activity through ectopic expression of a DN-Rab17, efferocytic cargo is then observed to
colocalize with MHC class II. Taken together, these data suggest that Rab17 is an essential
regulator of efferosome maturation and allows antigens derived from efferocytic cargo to
avoid being presented on MHC class II.
Furthermore, we go on to show that the dynamics of efferosome trafficking in macrophages
following internalization of efferocytic cargo differs significantly from that of a
phagosome.

Phagosomes undergo migration towards the cell center during their

maturation process in a dynamin-dependent process.7 This brings phagosomes into close
proximity to lysosomes, which are localized around the nucleus of the cell, and facilitate
phagolysosomal

fusion

and

degradation

of

phagocytic

cargo.55,60

Following

phagolysosome formation, these bodies remain localized perinuclearly to facilitate MHC
class II loading compartment formation.67 While the role of phagosomelysosome position
within the cell is not entirely clear, studies have shown that lysosomes closer to the
perinuclear area have lower pH and greater degradative capabilities.55 We find that in
efferosome maturation, while the efferosome initially migrates towards the cell centre and
undergoes fusion with lysosomes, the efferosome undergoes fission events and generates
multiple EDVs, which then migrate back towards the cell periphery. This is presumably to
facilitate trafficking of degraded efferocytic cargo to the recycling endosomes, which are
located peripherally within the cell.68 Moreover, as the Golgi is a perinuclear organelle,
this may act to decrease the efficiency of Golgi-to-efferosome trafficking, thus limiting the
delivery of newly synthesized MHC II to the efferosome. Remarkably, Rab17 again
appears to be required to facilitate EDV formation and the migration of EDVs back towards
the cell periphery. In macrophages expressing DN-Rab17, initial migration of the
efferosome towards the cell centre and subsequent lysosomal fusion remain unaffected.
However, EDV formation and migration of EDVs towards the cell periphery are abrogated
in DN-Rab17-expressing macrophages, and trafficking of cargo to the recycling endosome
does not occur. Therefore, Rab17 appears to be required for driving efferosomal fission
and subsequent migration of EDVs towards the cell periphery.
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Peripheral migration of EDVs is likely a kinesin-driven process69 and it is tempting to
imagine that Rab17 either directly recruits kinesin or recruits an effector that then recruits
kinesin to mediate peripheral migration of EDVs along the microtubule system. Although
this remains to be demonstrated experimentally, the role of Rab proteins in regulation of
vesicular traffic through recruitment of kinesin has been well documented. Several Rab
proteins, including Rab3, Rab6, Rab9, Rab11 and Rab27, have been shown to be capable
of recruiting kinesin, either director or through adaptor proteins.70 The fate of efferocytic
cargo following trafficking to the recycling endosome also remains unclear. Degraded
efferocytic cargo may be expelled from the phagocyte through exocytosis or it may be
recycled by the cell through nutrient recovery.49,71 Rab17 has been associated with both
transcytosis and exocytosis of melanosomes, which are lysosome-derived organelles, while
the recycling endosome is well established as a nutrient absorption site.38,68 The ultimate
fate of efferocytosed materials remains an open question at this point. Despite these
remaining questions, we propose a model of efferosome maturation whereby Rab17 is
selectively recruited to the efferosome and mediates efferosome fission and trafficking
towards the cell periphery to facilitate escape from the MHC class II loading compartment
and instead mediate trafficking of cargo to the recycling endosome (Figure 3.12).
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Figure 3.12 A model of differential regulation of phagosome and efferosome
maturation.
Phagocytic uptake of pathogen results in the formation of a phagosome that subsequently
undergoes multiple fusions with early endosomes. Rab17 is transiently recruited to the
early phagosome but rapidly lost. Rab5 is a key marker of the early phagosome and is
swapped for Rab7 as part of the process of transition from early to late phagosomes. Rab7
drives migration of the late phagosome towards the cell centre along microtubules, fusion
of the phagosome with late endosomes and phagosomal acidification. At the cell centre,
the late phagosome undergoes fusion with lysosomes to form the phagolysosome where
the phagocytic cargo is degraded by lysosome proteases. MHC class II molecules are
recruited to the phagolysosome from the Golgi and drives formation of the MHC class II
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loading compartment. Antigenic peptides derived from degraded phagocytic cargo are
loaded onto cognate MHC class II molecules and trafficked to the cell surface for antigen
presentation. Efferosome maturation follows a similar pathway, with the additional
recruitment of Rab17 to the efferosome surface. The efferosome undergoes lysosomal
fusion but Rab17 then drives efferosomal fission and trafficking of efferosome-derived
vesicles along microtubules towards the cell periphery where efferocytic cargo is trafficked
to the recycling endosome and subsequently undergoes exocytosis and/or nutrient
recovery. EE = early endosome, LE = late endosome, LY = lysosome.
Our findings in this chapter represent a concrete advancement in our understanding of the
regulation of efferosome maturation under homeostatic conditions. Our data suggest that
in professional phagocytes such as macrophages, there is an intrinsic Rab17-mediated
pathway that acts to prevent improper antigen presentation following efferocytosis. This
supports the idea that the differential regulation of efferosome vs. phagosome maturation
is at least partially independent of Toll-like receptor signaling. These findings may also
have important implications in future studies that examine defects in efferocytosis in the
context of inflammatory and autoimmune diseases. Dysregulation of Rab GTPase function
has previously been implicated in several pathologies. For example, Rab7 function is
impaired in the presence of hypercholesterolemia and results in defects in phagosome
maturation.72 Further studies that examine the role of Rab17 in inflammatory and
autoimmune diseases where efferocytosis has been implicated in disease pathogenesis are
warranted and may indeed demonstrate that Rab17 is a viable therapeutic target in the
treatment of these diseases.
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Chapter 4

4

Macrophages in Early Human Atherosclerosis Exhibit
Dysregulated Expression of Genes Involved in
Cholesterol Metabolism and Efferocytosis

4.1 Introduction
4.1.1 Challenge of studying human atherosclerotic macrophages
The role of macrophages in atherosclerotic disease has been studied intensively for many
years, yet our understanding of macrophage phenotype and function in human
atherosclerosis remains limited.1 This lack of progress can be at least partially attributed to
the inherent challenges of studying atherosclerosis in humans, and the limitations in
available animal models of atherosclerosis (discussed in further detail in Chapters 1.4.1
and 1.4.2).2,3
Much of our understanding of the mechanisms driving macrophage dysfunction in
atherosclerosis has come from animal studies in Apoe-/- or Ldlr-/- knockout mice.3,4 These
mouse models, while widely utilized, have some significant drawbacks and features that
diverge from human disease. Mice are naturally HDL-predominant and are thus resistant
to atherosclerosis.3 Indeed, mice do not naturally develop atherosclerosis when fed a high
fat diet and mouse models of atherosclerosis rely on genetically perturbing LDL
homeostasis to generate disease.4 The anatomical distribution of atherosclerotic lesions is
also dramatically different in mouse models when compared to human disease.5,6 Mice
rarely develop atherosclerotic plaques within the coronary arteries, and differences in
mouse hemodynamics means that they have greatest atherosclerotic burden in the aortic
root and ascending aorta.5
On the other hand, studying atherosclerosis in humans is challenging for several reasons.
First, atherosclerosis in humans takes decades to develop into clinically significant
disease,7 making it challenging to study the underlying disease pathogenesis.2
Atherosclerosis is also ubiquitous amongst people living in developed, post-industrial
nations.8,9 The PDAY study, which examined the burden of atherosclerotic disease from
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young people who died between the ages of 15 and 34 at 15 centres in the United States,
found that atherosclerotic lesions at the early stages of disease were present starting in the
15-20 age group, and that lesions that occupied > 5% of intimal surface area were present
in the aorta at rates in excess of 95% across all subjects.9,10 This makes it difficult to identify
subjects who can be considered “disease-free” when studying atherosclerosis in humans.
Finally, the site of disease—the atherosclerotic plaque—is difficult to access. The most
common source of atherosclerotic plaque used to study macrophage phenotype and gene
expression has been carotid plaque.11,12 While carotid plaque can be obtained following
carotid endarterectomy procedures and carotid plaque is involved in ischemic stroke,
findings from carotid plaque may not be entirely translatable to coronary and aortic
plaques. Transcriptomics studies that have examined plaque-resident macrophage gene
expression in lesions from different anatomical sites have shown site-specific changes in
gene expression patterns.13 It is difficult to access coronary and aortic plaque material
outside of autopsy studies, and as a result atherosclerosis in these vessels remain poorly
studied. More creative approaches to studying atherosclerosis at these anatomical sites are
needed. A recent study by Sulkava et al. was able to make use of left internal thoracic
arteries obtained in the course of CABG surgery,13 highlighting the need to leverage
collaboration with surgical colleagues to advance our understanding of human
atherosclerotic disease.

4.1.2 Cholesterol metabolism in macrophages
Macrophage cholesterol metabolism is well established as being dysregulated in
atherosclerosis.14,15 Formation of cholesterol-laden macrophages, known as foam cells, is
perhaps the most well-established feature of atherosclerosis—having first been described
by the Russian pathologist Nikolai Anitchkov in 1914.16
A summary of cholesterol metabolism in macrophages is provided in Figure 4.1.
Macrophages recognize and take up modified lipoproteins through the scavenger receptors
SR-A, CD36 and the lectin-like low-density lipoprotein receptor 1 (LOX-1).17 Following
uptake, these modified lipoproteins are trafficked into the lysosome, where lysosomal acid
lipase (LAL) releases free cholesterol from the lipoprotein.18 Free cholesterol within the
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lysosome is transported out of the lysosome and into the ER through the concerted activity
of the membrane-bound cholesterol transport proteins Niemann-Pick disease, type C1
(NPC1) and Niemann-Pick disease, type C2 (NPC2).19 In the ER, acyl coenzyme
A:cholesterol acyltransferase 1 (ACAT1) catalyzes the conversion of free cholesterol into
cholesterol esters, which are stored as lipid droplets within the ER and cytoplasm of the
macrophage.18,20 Neutral cholesterol ester hydrolase (NCEH) catalyzes the hydrolysis of
these cholesterol esters back into free cholesterol.19 This free cholesterol can subsequently
be removed from the cell through the efflux activity of the transporters ABCA1 and
ABCG1, upon which they are shuttled onto the cholesterol acceptors HDL and ApoA1 for
transport to the liver for further processing and removal.20

Figure 4.1 Cholesterol uptake, metabolism and efflux by macrophages.
Overview of cholesterol metabolism in macrophages. SR-A1 = scavenger receptor-A1,
LOX-1 = lectin-like low-density lipropotein receptor-1, LAL = lysosomal acid lipase,
NPC1/2 = Niemann-Pick disease, type C1/2, ACAT1 = acyl coenzyme A: cholesterol
acyltransferase-1, NCEH = neural cholesterol ester hydrolase, ER = endoplasmic
reticulum, HDL = high-density lipoprotein. Figure modified from Chistiakov et al.20
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In atherosclerosis, pro-inflammatory stimuli and hypercholesterolemic stress induce
increased expression of scavenger receptors and ACAT1, along with downregulation of
cholesterol transporters required for cholesterol efflux.21 This results in accumulation of
lipid droplets and intracellular free cholesterol, giving the macrophage it’s characteristic
“foamy” appearance.1,21 Additionally, accumulation of free cholesterol within the
cytoplasm of these macrophages induces a pro-inflammatory response that results in
production of TNF-α, IL-1β and IL-6, thus contributing to the maintenance of the
inflammatory plaque microenvironment.22,23

4.1.3 Efferocytosis and efferosome maturation
Efferocytic removal of apoptotic cells (primarily apoptotic macrophages) within the
atherosclerotic plaque is a crucial mechanism for limiting plaque progression and
vulnerability.24,25 In early atherosclerotic disease, it is thought that macrophage
efferocytosis of apoptotic cells contributes to the generation of anti-inflammatory
cytokines such as TGF-β and IL-10, which function to induce generation of a protective
fibrotic cap and restraint of inflammation within the plaque microenvironment.24 In the late
stages of atherosclerosis, macrophage efferocytosis becomes defective, contributing
secondary necrosis of uncleared apoptotic cells that contributes to generation of large
necrotic cores that increase the likelihood of plaque rupture and thrombosis.24
Mechanisms leading to defective efferocytosis remain poorly defined, especially in human
disease. Macrophages recognize apoptotic cells through efferocytic receptors that
recognize specific signals on the cell surface of apoptotic cells (such as
phosphatidylserine), usually through an intermediary opsonin.25,26 These efferocytic
receptors are thought to then function in cooperation with cell surface integrins (including
the integrin αx and β2)27 to mediate internalization of the apoptotic cell.26 Activation of
integrins results in the induction of several cell signaling pathways, including signaling
through the Src family kinases and integrin-linked kinases to drive actin remodeling,
efferocytic cup formation and efficient efferocytosis.26,28 Following internalization, the
nascent efferosome undergoes a series of maturation steps that result in efficient
degradation of apoptotic cell contents without generation of inflammation or antigen
presentation (discussed in detail in Chapter 3).
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Available evidence supports the notion that both efferocytic uptake and efferosome
maturation may be dysregulated in the setting of atherosclerosis. Cardiac and vascular
macrophages utilize the TAM family of receptors in binding to apoptotic cells through their
opsonin Gas6. Linkage studies in humans have demonstrated that SNPs in MERTK and
TYRO3, but not AXL or GAS6, are associated with carotid atherosclerosis.29,30 In
particular MerTK appears to play a critical role in mediating efferocytic clearance of
apoptotic cells within the atherosclerotic plaque.31 Mutations in MerTK reduce efferocytic
efficiency and increases necrotic core size in mouse models of atherosclerosis,32 and
ADAM17-mediated cleavage of MerTK also reduced atherosclerotic burden in Ldlr-/mice.33 Dysregulation in efferosome maturation in atherosclerosis has been studied to a far
lesser extent. However, there is some evidence that Rab GTPase activity and antigen
presentation are altered in atherosclerotic macrophages.34,35

4.1.4 Rationale and importance
Several decades of intensive study into the mechanisms of atherogenesis have yielded a
wealth of knowledge on potential mechanisms that drive atherosclerosis initiation,
progression and reversal. However, translation of these findings into clinical interventions
that better diagnose, monitor and treat atherosclerotic disease has remained limited.2 One
reason for this lack of clinical translation is that the vast majority of these mechanistic
studies have been done either in vitro or in animal models of atherosclerosis. These model
systems, while extremely useful, fail to capture the whole complexity of human disease
and, as a result, mechanisms that drive human atherosclerotic disease remain poorly
understood.2,3 Evidence from both animal and human studies implicate macrophages as
key players in the pathogenesis of atherosclerosis.24 However, macrophage dysfunction in
atherosclerosis is challenging to study due to the inaccessibility of human plaque tissue and
the inherent challenges of separating out a pure macrophage cell population from the
plaque for analysis.
In this chapter, we describe a novel approach towards studying macrophage dysfunction in
the setting of human aortic atherosclerosis. In collaboration with cardiac surgeons, we were
able to collect small punch biopsies of the wall of the ascending aorta that are routinely
obtained by the surgeon during CAGB operations. We proceed to obtain macrophages from
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the atherosclerotic lesions present on these aortic punch samples by laser capture
microdissection (LCM) and use these macrophages in a gene expression study to examine
dysfunction in macrophage cholesterol metabolism and efferocytosis in the setting of
human atherosclerotic disease.
A clearer picture of macrophage dysfunction in human atherosclerosis will provide us with
a better understanding of which pathological mechanisms established from in vitro and
animal work may be of importance in human atherosclerotic disease. Furthermore,
uncovering changes in gene expression patterns in pathways related to efferocytosis and
efferosome maturation will provide new insight into how critical function of macrophage
efferocytosis becomes defective in the setting in atherosclerotic disease.

4.2 Methods
4.2.1 Histology
All histology was performed by Caroline O’Neil at the Robarts Research Institute
Molecular Pathology Core Facility. Prior to staining, all frozen sections were fixed in 10%
buffered formalin for 20 min and washed in ddH2O. FFPE sections were deparaffinized by
immersion in two changes of xylene for 10 min each and subsequently rehydrated by
immersion in three changes of 100% ethanol, two changes of 95% ethanol and one change
of 70% ethanol. Slides were then immersed in ddH2O for 5 min.

4.2.1.1 Hematoxylin and eosin
Hematoxylin and eosin (H&E) staining was performed on both frozen and FFPE sections.
Slides were first immersed in Mayer’s hematoxylin solution for 3 min, followed by a brief
wash in ddH2O. Slides were the immersed in 0.2% ammonia water solution for 30 sec to
allow for bluing and washed in ddH2O. Slides were dipped briefly into 95% ethanol and
stained in eosin Y solution for 3 min, followed by a brief wash in ddH2O. Slides were then
dehydrated by immersing in 95% ethanol for 1 min, and then in three changes of 100%
ethanol for 10 dips each. Slides were mounted onto glass coverslips.
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4.2.2 Oil Red O
Oil Red O staining was performed only on frozen sections. Slides were allowed to air dry
at room temperature for 30 min prior to fixing in 10% buffered formalin. Slides were air
dried again for 30 min at room temperature and washed in three changes of ddH2O. Slides
were transferred into 100% isopropanol for 5 min and then stained in per-warmed Oil Red
O solution (3 parts 1:200 w/v Oil Red O powder 100% isopropanol to 2 parts ddH2O) for
10 min at 60 °C. Following Oil Red O staining, slides were immersed in 85% isopropanol
for 5 min and then washed in two changes of ddH2O. Slides were then immersed in Mayer’s
hematoxylin solution for 30 sec and washed with ddH2O for 5 min. Slides were mounted
onto glass coverslips.

4.2.3 Movat’s stain
Modified Russell-Movat pentachrome staining was performed on both frozen and FFPE
sections. Slides were immersed in Verhoeff’s elastic stain (2:1:1 5% hematoxylin in 100%
ethanol, 10% ferric chloride, Verhoeff’s iodine solution – 2% w/v iodine and 4% w/v
potassium iodide in ddH2O) for 30 min and subsequently washed with ddH2O for 5 min.
Slides were immersed in three changes of 2% ferric chloride solution for 10 sec each,
immersed in 5% sodium thiosulfate solution for 1 min and washed with ddH2O for 5 min.
Slides were then immersed in 3% glacial acetic acid for 3 min, then 1% Alcian blue
solution for 15 min, and finally washed with running ddH2O for 10 min. Slides were then
immersed in Crocein scarlet-acid fuchsin solution (0.08% w/v Crocein scarlett, 0.02% w/v
acid fuchsin and 0.5% v/v acetic acid in ddH2O) for 2 min, washed in two changes of
ddH2O for five dips each and then in one change of 1% acetic acid for five dips. Next,
slides are immersed in 5% phosphotungstic acid for 1 min, and washed in one change of
1% acetic acid, one change of ddH2O and one change of 100% ethanol for five dips each.
Slides are dehydrated in two changes of 100% ethanol for 3 min each and then immersed
in alcoholic saffron solution (6% w/v Saffron du Gatinais in ethanol) for 15 min. Finally,
slides are dried in two changes of xylene for 3 min each and mounted onto glass coverslips.
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4.2.3.1 TUNEL stain
TUNEL staining was performed on FFPE sections only to assess the number of uncleared
apoptotic cells present.36,37 Following deparaffinization, sections were digested with 20
µg/mL proteinase K for 15 min at room temperature to permeabilize tissue. Slides were
rinsed with two changes of PBST for 2 min each. Slides were then immersed in 3% H2O2
in PBS for 10 min and washed again with two changes of PBST for 2 min each. Slides
were then immersed in TdT reaction mixture (1:9 terminal transferase enzyme, biotin-16UTP prepared according to the manufacturer’s instructions) for 2 hr at 37 °C in a humidity
chamber. The labelling reaction was stopped by incubation in a buffer containing 300 mM
NaCl and 30 mM sodium citrate for 10 min. Following washing with PBST, slides were
immersed in streptavidin-HRP for 20 min at room temperature and then DAB chromogen
with a PBST wash in between. Slides were rinsed in running tap water for 30 sec and
counterstained with Mayer’s hematoxylin solution for 30 sec. Slides were washed in
running ddH2O for 5 min and then dehydrated through subsequent immerse in one change
of 95% ethanol and two changes of 100% ethanol for 3 min each. Sections were cleared by
immerse in two changes of xylene for 5 min each and mounted onto a glass coverslip.

4.2.4 Laser capture microdissection
Patient aortic punch frozen sections as described in Chapter 2.2 on Superfrost Plus
Microscope Slides (Fisher Scientific) and stored at -80 °C prior to use. Immediately prior
to beginning tissue staining and dehydration, slides were removed from -80 °C storage and
allowed to thaw briefly (~ 30 sec) at room temperature to completely remove condensation.
Slides were fixed in ice-cold acetone for 2 mins, followed by air drying for 30 sec to remove
excess acetone. A PAP pen was used to circumscribe each tissue section adhering to the
slide. In a humidity chamber, sections were washed with 200 µL of PBS and 100 µL of 3060 µg/mL anti-CD163 antibody (Abcam, polyclonal Ab ab87099) was applied for 3 min
at room temperature. Sections were washed 2× with PBS and 100 µL of 1:100 diluted
secondary antibody was applied for 3 min at room temperature. Sections were again
washed 2× with PBS and then sequentially dehydrated with application of 200 µL of 75%,
95% and 100% ethanol for durations of 30 sec each. Slides were dried by immersion in
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xylene for 5 min and excess xylene was allowed to evaporate under a fume hood. Processed
slides were used immediately for LCM.
LCM was performed on an ArcturusXT Laser Capture Microdissection System (Applied
Biosystems) running ArcturusXT Operating Software (Applied Biosystems). Due to the
small size of the sections in question, CapSure HS LCM Caps (Applied Biosystems) were
used to capture dissected samples. Samples were captured using IR capture laser of 15 µm
diameter at 70 mW, 1,500 µsec and 1 hit per capture. A minimum of 200 captures per
section across four consecutive sections was performed to obtain sufficient cell numbers
for downstream analysis. Following laser capture microdissection, dissected samples were
immediately processed in TRIzol reagent to stabilize RNA. Total RNA was extracted from
dissected samples using the protocol described in Chapter 2.6.1.

4.2.5 Microarray
RNA quality checks, cDNA preparation, array hybridization and microarray data analysis
(in part) were all performed by David Carter and Jen Biltcliffe at the London Regional
Genomics Centre.
Total RNA for microarray was prepared from patient aortic punch macrophages prepared
according to Chapter 4.2.4 and control peripheral blood monocyte-derived macrophages
prepared according to Chapter 2.4.2. Prior to the microarray, RNA quality was checked
using a 2100 Bioanalyzer Instrument (Agilent) and a minimum A260/280 of 1.5 and
minimum RIN of 7 was required before the RNA could be used in the microarray. A
minimum of 2.0 µg of total RNA was from each sample was used in the microarray.
RNA samples were prepared for array hybridization using the GeneChip WT Pico Reagent
Kit (Applied Biosystems) according to the manufacturer’s instructions with 12 cycles of
pre-in vitro transcription amplification. Poly-A RNA standards provided by the
manufacturer were used as exogenous positive controls. Samples were analyzed on the
GeneChip Human Gene 2.0 ST Array chip (Applied Biosystems) hybridized on the
GeneChip Scanner 3000 7G System (Applied Biosystems) according to the manufacturer’s
recommended instructions.
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4.2.6 Identification of differentially expressed genes
Raw microarray data were analyzed using the Partek Genomics Suite platform (Partek).
Reads were normalized using the Robust Multi-array Average (RMA) procedure with
quantile normalization. Subsequently, a mixed-model ANOVA was used to identify
differentially expressed genes with a foldchange cutoff of 2.0 and p-value cutoff of p<0.05.
Unsupervised hierarchical clustering of all differentially expressed genes was performed
to generate a heat map of differential gene expression.
Results were verified using open-access tools in R Statistical Software (R Project for
Statistical Computing) available through the Bioconductor project.38 The oligo package
was used to read in raw microarray data files and perform RMA normalization.39 The
limma package was used to identify differentially expressed genes using a linear models
approach along with an empirical Bayes method to better estimate errors in log-fold
change.40,41

4.2.7 GO term enrichment analysis
Gene ontology (GO) term enrichment analysis was performed on the Partek Genomics
Suite (Partek) using the GO ANOVA feature, with analysis restricted to functional groups
with more than two and fewer than 150 genes. The top 100 GO biological function terms
were used for GO term visualization using the REVIGO online software platform (Rudjer
Boskovic Institute), where terms were visualized by both uniqueness and connectivity.42

4.2.8 Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was performed using the Gene Set Enrichment
Analysis software platform (Broad Institute) with publicly-available annotated gene sets
(cholesterol_homeostasis, antigen_processing_presentation, fcr_mediated_phagocytosis,
phagosome_maturation) obtained from the Molecular Signatures Database (MSigDB).43,44
Analysis run at 10,000 permutations using default settings with FDR < 0.25.
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4.2.9 KEGG pathway analysis
Pathway enrichment analysis was performed using the Partek Pathway software platform
(Partek) using public-available Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways (Phagosome, Oxidative Phosphorylation, Antigen Processing and Presentation).

4.3 Results
4.3.1 Quantification of mean wall and intimal thickness in patient aortic
punch samples
In order to study human aortic atherosclerosis, we utilized aortic punch tissue that is
routinely obtained and discarded by cardiac surgeons during procedures that involve
cannulation of the ascending aorta. The surgeon creates a full-thickness, circular punch
through the aortic wall. The resulting tissue sample contains all the features of a typical
artery, including the tunica intima, tunica media and tunica adventitia. An example of a
patient aortic punch cross-section is shown in Figure 4.2.

Figure 4.2 Cross-section of a typical patient aortic punch sample.
H&E staining of a sectioned patient aortic punch tissue sample demonstrating the intact
layers of the aortic wall. Following excision during surgery, aortic punch tissue was
embedded and frozen in OCT. 10 µm-thick frozen sections were obtained and stained using
hematoxylin and eosin and imaged under white light. The section shown is representative
of the appearance of a typical patient aortic punch sample. Scale bar is 500 µm.
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As there are relatively few studies that have examined atherosclerotic plaques in the human
aorta, we sought to assess the average wall and tunica intima thicknesses of our patient
aortic punch samples. To differentiate between intima and media on histology, we utilized
the Movat pentachrome stain, which allows visualization of the elastin layer that separates
the intimal and medial layers as a thin black line immediately below the intimal layer
(example shown in Figure 4.3a). Average wall thickness of our patient aortic punch
samples was approximately 3.7 mm (Figure 4.3b) while average intimal thickness was
approximately 0.2 mm (Figure 4.3c).

Figure 4.3 Quantification of wall and intimal thickness in patient aortic punch
samples.
Following excision during surgery, patient aortic punch tissue samples were formalin-fixed
and embedded in paraffin. (a) 10 µm-thick sections were obtained, stained using a modified
Russell-Movat pentachrome stain and imaged under white light. From images, (b) wall
thickness and (c) intimal thickness were directly measured. Image is representative (a), and
graphs quantify (b,c) four punches from four separate patients. Data are shown are mean ±
SEM. White arrows indicate the elastin layer. Scale bars are 100 µm.
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The literature reports varying mean ascending aortic wall thickness in healthy individuals.
Biancari et al. report that an ascending aorta wall thickness of greater than 1.8 mm
increases the risk of post-operative mortality following CABG,45 while Erbel and
Eggebrecht state that a wall thickness of less than 4 mm should be considered to be normal
in healthy adults.46 Our finding of 3.7 mm in older individuals with significant
atherosclerotic burden therefore lies between these two reported values. Discrepancies in
reported measurements may be a result of the methodology used to assess wall thickness,
with both ultrasound and direct measurement on histology being utilized.47,48 In general,
aortic wall thickness varies according to anatomical location, with the ascending aorta
having the greatest thickness.48 The size of the aorta also increases with age, with the
diameter increasing by 1-2 mm/year on average.46

4.3.2 Patient aortic punch samples exhibit early stage atherosclerotic
disease
Upon examination of H&E staining of patient aortic punch tissue sections, we observed
minimal evidence of advanced atherosclerotic disease (e.g. significant accumulation of
lipids, large necrotic cores, etc.). As a result, we sought to better characterize the degree of
atherosclerotic disease present in our aortic punch samples by examining: 1) sub-intimal
lipid accumulation, 2) intimal thickening and fibrosis, and 3) sub-intimal macrophage
accumulation. Serial frozen sections of aortic punch tissue were stained with H&E to assess
tissue morphology, Oil Red O to assess lipid accumulation, Movat’s stain to assess intimal
thickening and fibrosis, and αCD163 antibody to assess macrophage accumulation.
CD163 was used as a marker of macrophages within the atherosclerotic plaque because the
most commonly used human macrophage marker, CD68, is problematic in atherosclerosis
because smooth muscle cells exposed to the atheroma microenvironment can also express
this marker.48–50 Indeed, Allahverdian et al. demonstrated that up to 40% of CD68+ cells in
advanced coronary atheromas are of smooth muscle cell origin.50 The hemoglobinhaptoglobin scavenger receptor CD163 is uniquely expressed in cells of the monocyte/
macrophage lineage and was therefore selected as a highly specific marker of macrophages
within the human atherosclerotic plaque.51 It is well-established that CD163 is highly
expressed in macrophages that have been exposed to intraplaque hemorrhage, which adopt
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an unique phenotype termed MHem (or HA-mac) that is characterized by ATF-1-driven
up-regulation of CD163 and the HO-1 enzyme.52,53 Originally believed to be
atheroprotective, a recently seminal study from Guo et al. has demonstrated that MHem
macrophages actually increase inflammation in human atherosclerotic plaques via
induction of intraplaque angiogenesis, vascular permeability and inflammatory cell
recruitment.54 In our hands, CD163 expression can be reliably detected on human M0-,
M1- and M2-polarized macrophages differentiated in vitro from peripheral blood
monocytes (Figure 4.4a). We were able to further demonstrate that in our patient aortic
punch tissue sections, CD163 and CD68 expression are highly correlated (Figure 4.4b and
4.4c).
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A representative example of serial sections of patient aortic punch tissue stained using the
strategy described previously is provided in Figure 4.5a. We observed while there was a
lack of extracellular lipid pools or necrotic core formation, our patient aortic punch tissues
were characterized by lipid droplet accumulation beneath the intima, along with some
intimal thickening and fibrosis. Furthermore, we could detect the presence of discrete
macrophage populations within the intimal layer. Upon quantification of the degree of lipid
accumulation, intimal thickening and macrophage accumulation, we could demonstrate
that there was a significant positive correlation between the degree of lipid accumulation
and number of macrophage cells (Figure 4.5b). Positive correlations were also observed
between intimal thickness and number of macrophage cells (Figure 4.5c) and between
intimal thickness and lipid accumulation (Figure 4.5d). Referencing the classic
classification system for atherosclerotic plaque progression developed by Stary and
colleagues in 1994, these features are characteristic of Types I-III lesions .55

Figure 4.4 CD163 is a reliable marker of macrophage cells. (on opposite page)
Immunofluorescence staining of cultured macrophages and aortic punch sections was used
to determine whether CD163 expression can be reliably detected on macrophage cells. (a)
Macrophages differentiated in vitro from peripheral blood monocytes from healthy human
donors and polarized to M0, M1 and M2 phenotypes were immunostained for CD163.
Images are representative of three independent replicates. Scale bars are 20 µm. (b) Aortic
punch sections were co-immunostained for CD163 and CD68 and (c) Pearson’s correlation
coefficient between CD163 and CD68 was calculated for both clearly identifiable
macrophage cells (MAC) and random regions of the intima (INT). Images show two
representative fields of view (FOV#1 and FOV#2) (b) or quantifies five fields of view as
mean ± SEM (c). **p < 0.01 by unpaired two-tailed Student’s t test. Scale bar is 10 µm.
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Figure 4.5 Patient aortic punch tissue samples exhibit features of early atherosclerotic
disease.
Serial sections of patient aortic punch tissues were obtained and treated with a number of
histological stains to characterize the degree of atherosclerotic disease present in the
samples. (a) 10 µm-thick frozen sections were stained with hematoxylin and eosin (H&E),
Oil Red O (ORO), modified Russell-Movat’s pentachrome stain (Movat) and
immunostained for CD163 (CD163). (b-d) The degree correlation was assessed between
lipid accumulation and number of macrophages per high-power field (b), intimal thickness
and number of macrophages per high-power field (c) or intimal thickness and lipid
accumulation (d). Linear regression was calculated, with line of best fit and r2 values being
provided in each graph. Pearson’s correlation coefficient was also calculated (p < 0.01 for
b, n.s. for c and d). Images are representative of (a) and graphs quantify (b-d) seven
separate aortic punch samples. Dotted line indicates the normal intimal thickness in healthy
adults. Scale bar is 50 µm.
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Finally, we aimed to assess the extent of necrotic cell accumulation within the intima in
our aortic punch tissues. Uncleared apoptotic cells that have undergone secondary necrosis
is a hallmark feature of advanced atherosclerotic disease. In accordance with our previous
results, we found only a few necrotic cells could be observed (Figure 4.6a and 4.6b), again
indicating an earlier stage of disease progression.

Figure 4.6 Minimal necrotic cell accumulation in patient aortic punch tissue.
TUNEL staining was used to measure the degree of necrotic cell accumulation within
patient aortic punch tissues. (a) TUNEL staining of a 10 µm-thick frozen section of aortic
punch tissue, and (b) quantification of the number of TUNEL stain-positive necrotic cells
per low power field. Image is representative of (a) and graph quantifies (b) eight random
fields of view from three separate aortic punch samples. Data are shown are mean ± SEM.

4.3.3 Isolation of a pure macrophage cell population from patient tissue
After establishing that CD163 immunostaining as a reliable means of identifying
macrophage cell populations in the intima of our patient aortic punch samples (example
shown in Figure 4.7a), we proceeded to isolate a pure macrophage cell population using
LCM. Aortic punch frozen sections were rapidly immunostained for CD163 and used
immediately for LCM, with CD163 staining guiding the capture of at least 800 cells per
sample from four successive serial sections.
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RNA was immediately isolated from captured macrophage cells and expression of the
monocyte/macrophage-specific marker CD14 and the smooth muscle cell-specific ACTA2
in captured cells compared to whole sections to assess the purity of captured cell
populations. Captured cell samples were significantly enriched in CD14 expression
(Figure 4.7b) whereas they expressed ACTA2 at significantly lower levels than whole
section controls (Figure 4.7c), suggesting that a relatively pure macrophage cell population
was successfully isolated by LCM.

Figure 4.7 Isolation of a pure macrophage cell population from aortic punch tissue by
LCM.
LCM was used to selectively isolate macrophage cell populations and the purity of LCM
dissected macrophages was confirmed by RT-qPCR. (a) Patient aortic punch tissue
sections were immunostained for CD163 and imaged using the fluorescence microscopy
system built into the LCM System. Borders between the intima (I), media (M) and
adventitia (A) are denoted by dashed lines. (b, c) RT-qPCR analysis of the expression of
CD14 (b) and ACTA2 (c) in LCM-captured macrophages and whole section controls. The
image is representative of (a) and graphs quantify (b, c) three independent sets of captured
macrophages and whole section controls. Data are presented as mean ± SEM. *p < 0.05 by
unpaired two-tailed Student’s t test. Scale bar is 200 µm.
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4.3.4 Gene expression profiling of macrophages isolated from patient
aortic punch tissue
To better understand the properties of macrophages within the early pre-atherosclerotic
lesions identified in our patient aortic punch tissue, gene expression profiling by microarray
was performed on LCM-captured patient macrophages. As a control we utilized peripheral
blood monocytes isolated from healthy age- and sex-matched donors were differentiated
in vitro to M0-polarized macrophages. In total, three patient macrophage samples and three
controls were analyzed by microarray. Concentration and integrity for each sample are
reported in Table 4.1.
Table 4.1 Concentration and RNA integrity of samples used for microarray.

Microarray analysis was performed using the GeneChip Human Gene 2.0 ST Array at
London Regional Genomics Centre (London, Ontario). This chip provides comprehensive
coverage of protein-coding and long intergenic non-coding RNA (lncRNA), although for
the purposes of this study, lncRNA was not included in subsequent analyses because they
remain poorly annotated. Gene expression profiling demonstrated significant differences
in gene expression between patient and control macrophages. Principal component analysis
(PCA) showed clear segregation and separation of patient and control macrophages, with
the first two principal components accounting for 65.9% of variability between the two
groups (Figure 4.8a). Following RMA normalization (Figure 4.8b) and differentially
expressed gene identification using a mixed-model ANOVA, 3,374 protein-coding genes
met the pre-specified cutoff criteria of log-foldchange > 2.0 and adjusted p value < 0.05
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(Figure 4.8c). Compared to control macrophages, the majority of genes in patient
macrophages were down-regulated (Figures 4.8c and 4.8d).

Figure 4.8 Microarray analysis of pre-atherosclerotic macrophages demonstrates
profound differences in gene expression.
Microarray analysis was performed on LCM-captured patient macrophages with ex vivo
monocyte-derived macrophages from healthy donors as controls. Three patient samples
and three controls were used for microarray. (a) PCA of gene expression profiles from
patient and control macrophages. (b) Average read intensities of patient and control
macrophage samples pre- and post-RMA normalization. (c) Volcano plot demonstrating
overall changes in gene expression in patient macrophages compared to controls. Each
individual dot represents one gene, with red dots representing differentially expressed
genes that met the pre-specified cut-offs of log-foldchange > 2.0 and adjusted p value <
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0.05. In total, 3,374 protein-coding genes met cut-offs. (d) Heatmap generated through
unsupervised hierarchical clustering of all differentially expressed genes in patient
macrophages compared to controls, with colour scheme reflecting gene expression z-score.
AP – patient aortic punch macrophages, CT – healthy donor control macrophages.
From the complete list of differentially expressed protein-coding genes, we manually
curated a list of genes of interest on the basis of either known association with
atherosclerosis or involvement in pathways of interest. These pathways of interest
included: 1) phagocytosis and efferocytosis, 2) cholesterol metabolism, 3) antigen
presentation, 4) peptide citrullination, and 5) regulation of gene expression. Using this
method, we identified 10 differentially upregulated genes of interest and 10 differentially
downregulated gene of interest (Table 4.2). A list of the top 100 upregulated and
downregulated genes can be found in Appendix B.
Table 4.2 Differentially expressed genes with potential relevance to dysregulated
macrophage function in atherosclerosis
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The set of genes that were differentially upregulated in patient macrophages in comparison
to controls was limited. However, this set of genes did significantly include a number of
transcription factors (FOXF2, YAP1, GATA2, E4F1 and RARG). This was of interest to
us because these transcription factors may drive part or all of the differences in gene
expression observed in our patient macrophages. Of these five transcription factors,
GATA2, E4F1 and RARG have previously been implicated in atherosclerosis. Briefly,
SNP’s in GATA2 have been found to be associated with CAD in genome-wide association
and linkage studies.56,57 E4F1 is an estrogen-responsive gene that is up-regulated in the
aortas of postmenopausal women with atherosclerotic disease.58 Finally, activation of
RARG in vitro has been shown to induce up-regulation of ABCA1, which encodes a
protein that plays a key role in transport of cholesterol out of the cell.59 Interestingly,
another gene that is upregulated in patient macrophages is PADI3, which encodes the type
III peptidyl arginine deiminase – an enzyme that is responsible for peptide citrullination
and plays a role in the pathogenesis of rheumatoid arthritis.60 Peptide citrullination has
been reported to occur in atherosclerosis and is thought to be involved in the acceleration
of atherosclerotic disease development in patients with rheumatoid arthritis.61

4.3.5 Confirmation of changes in gene expression by RT-qPCR
Since microarray data is inherently noisy, we next sought to confirm that the changes in
gene expression identified in the microarray analysis could be reproduced by RT-qPCR.
Furthermore, to control for the possibility of bias from using a limited number of patients
and controls, we assessed gene expression in five independent patient and control
macrophage samples. Genes assessed included those involved in regulation of gene
expression: GATA2, E4F1, RARG (Figure 4.9a); those involved in cholesterol
metabolism: ABCA1, NPC1, NPC2 (Figure 4.9b); and those involved in phagocytosis/
efferocytosis (Figure 4.9c).
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Figure 4.9 RT-qPCR validation of key microarray results. (on opposite page)
RT-qPCR analysis was performed on independent patient macrophage and control
macrophage samples to validate microarray results. Genes assessed included those
involved in regulation of gene expression (a), cholesterol metabolism (b) and
phagocytosis/ efferocytosis (c). Graphs quantify five independent patient and control
macrophage samples that had not been used in the microarray. CT – control macrophages
from healthy donors, AP –macrophages from patient aortic punch tissue. Data are
presented mean ± SEM. *p < 0.05, **p < 0.01, ****p < 0.001 by Mann Whitney U test. ns
= not significant, n.d. = not detected.
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As expected, we observed upregulation of GATA2 and downregulation of ABCA1, NPC2,
ITGAX and RAB7A in the patient macrophages in comparison to the controls. There was
no difference in the expression of ILK between patients and controls, which may be due to
inter-individual differences between the subjects used in the microarray study versus for
RT-qPCR or random variability in the original microarray data. Unexpected, neither E4F1
nor RARG was detectable in our RT-qPCR assay. Conversely, we found that GATA2 was
upregulated in excess of 50-fold in patient macrophages.

4.3.6 Functional analysis of gene expression data reveals potential
defects in cholesterol metabolism and in phagocytosis/
efferocytosis
To translate differences in gene expression profile determined by microarray to altered
patient macrophage function within the pre-atherosclerotic environment, we took
functional and pathway-based approaches to assigning biological significance to
differences in gene expression. We first examined GO classifications that were
significantly enriched in our gene expression dataset. Using the 100 most significantly
over-represented biological processes in our dataset, we generated plots of GO terms on
the basis of uniqueness (Figure 4.10a) and connectivity (Figure 4.10b).

Figure 4.10 Highly over-represented GO terms from microarray data. (on opposite
page)
The 100 most highly significant biological processes GO terms from the microarray dataset
were visualized on the basis of uniqueness (a) or connectivity (b) using the REVIGO online
GO term analysis platform. Plots assign x and y coordinates to terms by semantic similarity
such that GO terms representing processes similar in function are grouped closer together
(a) or by connectivity between terms such that similar GO terms are connected pairwise,
with the line width indicating the degree of similarity (b). Colours represent p values and
the size of each circle represents the number of differentially expressed genes from the
microarray dataset that are categorized as part of that particular GO term (a, b).
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From this basic analysis of GO term enrichment data, a number of key biological processes
that involve differentially expressed genes can be identified. These processes include:
cellular metabolism, intracellular transport, antigen presentation and cellular stress
response. We proceeded to validate these observations through gene set enrichment
analysis looking at over-representation of differentially expressed genes in the following
processes with defined gene sets: cholesterol homeostasis (Figure 4.11a), Fcγ-mediated
phagocytosis (Figure 4.11b), phagosome maturation (Figure 4.11c), and antigen
processing and presentation (Figure 4.11d). Indeed, we found that all four gene sets were
significantly enriched in our microarray results (false discovery rate [FDR]-adjusted pvalue = 0.083664).

Figure 4.11 Gene set enrichment analysis of differentially expression genes in patient
macrophages.
GSEA was performed to analyze genes sets enriched in patient macrophages compared to
controls. Enrichment plots were generated for all gene sets tested. All four gene sets tested
were found to be significantly enriched using a FDR-adjusted p-value cutoff of 0.25. (a)
Cholesterol metabolism (adjusted p-value = 0.083664), (b) Fcγ-mediated phagocytosis
(adjusted p-value = 0.083664), (c) Phagosome maturation (adjusted p-value = 0.083664)
and (d) Antigen processing and presentation (adjusted p-value = 0.083664). NES =
normalized enrichment score.
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Finally, we mapped differentially expressed genes onto several key pathways of interest in
order to visualize the potential impact of altered gene expression in patient macrophages
on the function of biological pathways. Specifically, we examined pathways related to
phagocytosis and phagosome maturation (Figure 4.12a) and antigen processing and
presentation (Figure 4.12b). Both phagocytosis and antigen processing were pathways that
were previously implicated by the results of our GO term enrichment and gene set
enrichment analyses. As expected, we found that key components of both of these
pathways were significantly downregulated in the gene expression profile of patient
macrophages. Looking at phagosome maturation, several key components of this process
appear to be impaired, including Rab7, the vacuolar ATPase, and several components of
the NADPH oxidase complex. As for antigen processing and presentation, components of
this pathway appear to be almost universally affected, with expression of the key regulators
calreticulin

and γ-interferon-inducible lysosomal thiol reductase (GILT) being

significantly downregulated (Figure 4.12a and 4.12b).

Figure 4.12 Visualization of differentially expressed genes on KEGG pathways. (on
opposite page)
Differentially expressed genes obtained from microarray results were mapped onto KEGG
pathways using the Partek Pathway software platform. Pathway data for phagocytosis (a)
and antigen presentation (b) were obtained from the Kyoto Encyclopedia of Genes and
Genomes. Red indicates downregulation of gene expression in the microarray dataset, with
darker shades indicating greater magnitudes of downregulation.
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4.4 Discussion
Macrophages play a complex and multifaceted role in the development and progression of
atherosclerosis.62,63 Studying gene expression in human atherosclerotic plaque-resident
macrophages poses challenges in both accessing the relevant tissues in patients and in
isolating the macrophage cell population from the rest of the plaque. To date, there have
been a limited number of studies that have examined gene expression in human
atherosclerotic plaques.11,13,64–70 The majority of these studies have focused carotid
plaques, which can be obtained following carotid endarterectomy.11,65,68,70 Significantly
fewer studies have examined coronary arteries64,67,69 and only a select number of these have
actually taken the additional step of separating the macrophages from the rest of the plaque
tissue prior to analysis.65,66
To the best of my knowledge, the current study is the first to examine gene expression
profiles in isolated macrophages from atherosclerotic plaques located in the human aorta.
Histopathological examination of the aortic punch tissue samples demonstrated that the
aortic wall is characterized by early pre-atherosclerotic lesions that fall under type III
lesions or earlier in the classic Stary classification scheme of atherosclerotic plaque
progression.55,71 At this stage of plaque development, there is moderate intimal thickening
and fibrosis, along with accumulation of small populations of macrophages and limited
amounts of intracellular and extracellular lipid deposits, which aligns well with our
observations.55 This was not completely surprisingly to us because atherosclerotic burden
in humans is predominantly focused in the coronary and carotid vessels, along with the
abdominal aorta and common iliac arteries.6,72 The ascending aorta, where our punch
samples originated, in comparison is relatively spared of severe atherosclerotic disease.3,5
While the lack of advanced plaques precluded us from studying macrophage gene
expression in late atherosclerotic disease, when efferocytosis is already impaired, it offered
us the opportunity to instead focus on early stages of atherosclerotic plaque development
and characterize macrophage phenotype in early pre-atherosclerotic disease. This
represents another novel aspect of our approach, since the existing literature has focused
almost exclusively on late-stage, established disease that is present in the majority of
clinical specimens recovered. At these later stages of disease development, the mechanisms
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that drive the development of efferocytic defect may be masked by changes induced by the
complex interactions between macrophages and the late plaque microenvironment,
including prior plaque rupture and thrombosis and intra-plaque hemorrhages – both of
which have been previously shown to induce distinct macrophage phenotypes.11,52,73
The isolation of a pure macrophage cell population from the pre-atherosclerotic lesion
presents another challenge. While some previous gene expression studies have utilized
whole plaques, a number of cell types besides macrophages exist within the plaque. This
includes large populations of smooth muscle cells, fibroblasts and endothelial cells that
comprise the plaque,7,63 as well as smaller numbers of infiltrating immune cell populations
including CD4+ and CD8+ lymphocytes, NKT cells and dendritic cells.74–76 It is therefore
difficult to attribute any observed changes in gene expression to macrophages alone when
whole plaques are used in gene expression profiling studies. However, isolation of
macrophages from plaques is not a trivial task. The traditional approach of enzymatic
digestion followed by magnetic- or FACS-based cell separation presents a challenge when
the goal is to analyze gene expression because the conditions under which macrophages
cells are subjected to during these procedures (e.g. enzymatic digestion, separation from
the atheroma microenvironment) may contribute to significant changes in their gene
expression profiles due to the incredible plasticity of these cells and their ability to rapidly
adapt to new external environments.77 Indeed, recently single-cell RNA sequencing studies
have demonstrated that murine microglia cells removed from the brain and placed into
culture ex vivo exhibited dramatic changes in gene expression within six hours.78
Therefore, we opted to immediately freeze our tissue samples and isolate macrophages by
LCM. While freezing subjects RNA to some level of degradation, it carries the important
advantage of preserving the integrity of overall gene expression profile.79 Several previous
studies have used LCM to isolate macrophages from within atherosclerotic plaques.
Following labelling of macrophages by CD163, we were able to selectively isolate
macrophage cells from pre-atherosclerotic lesions and isolate enough RNA of sufficient
quality to perform both microarray and RT-qPCR analysis.
We examined gene expression changes in patient macrophages by microarray using M0polarized macrophages differentiated in vitro from peripheral blood monocytes as a
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control. The lack of a more comparable source of control macrophages is a significant
drawback of this approach, yet a suitable source of control cells is difficult to identify. In
the healthy artery, there is not a substantial population of sub-intimal macrophages that
could act as a control. Several groups have identified a population of “arterial
macrophages” that are associated with arteries throughout the body, these are primarily
located within the adventitia or in close association with the smooth muscle rather than the
intima.80,81 Ensan et al. found that in C57BL/6J mice, only 2% of all arterial macrophages
could be found in the intima.81 Further, studies have demonstrated that these macrophages
are entirely tissue resident cells with an embryonic origin.81 In contrast, atherosclerotic
plaque-resident macrophages are thought to be mostly derived from circulating monocytes,
although they do exhibit limited self-proliferative potential.63,82 Some studies that have
examined apoptotic cell clearance in human atherosclerotic plaque have used the tonsils as
a control tissue with a highly active efferocytic activity.36 However, it is questionable in
our particular situation whether tonsillar macrophages would serve as a superior control to
monocyte-derived macrophages. Nevertheless, since our control macrophages are derived
from a different source than patient pre-atherosclerotic macrophages, that should be taken
into account when interpreting the results of our gene expression profiling study.
From the results of our microarray study, it is apparent that even in the early stages of
atherosclerotic plaque development, lesion-resident macrophages have a very different
gene expression profile. We observed that over 3,000 protein-coding genes are
differentially expressed in patient macrophages in comparison to controls. Undoubtedly,
some of this difference we observe can be attributed to the comparison between lesionresident macrophages and monocyte-derived macrophage controls. However, many of the
features that we identify as unique in the pre-atherosclerotic lesion-resident macrophage
population are not obviously connected to inherent differences between macrophages
isolated from a tissue and macrophages cultured in vitro. These features include marked
downregulation of genes involved in cholesterol homeostasis, phagocytosis and
phagosome maturation and antigen processing and presentation but not inflammatory
activation. Rather, we contend that these features define a novel macrophage phenotype
associated with early, pre-atherosclerotic lesions (Figure 4.13). Within the early
atherosclerotic lesion, the dominant microenvironmental factor that drives macrophage
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dysfunction is probably an excess of lipids and modified lipoproteins rather than the
chronic inflammation that characterizes advanced plaques. Hypercholesterolemia has been
previously described by Huynh et al. to impair phagosome maturation by interfering with
the activity of Rab7,34 which, as described in the previous chapter, is a key regulator of
proper phagosome and efferosome maturation. Rab7 regulates phagosome acidification
and phagolysosomal formation and its downregulation in pre-atherosclerotic lesionresident macrophages suggests that phagosome and efferosome maturation may be
impaired in these cells.

Figure 4.13 Novel macrophage phenotype associated with early, pre-atherosclerotic
lesions.
We defined a novel macrophage phenotype associated with early, pre-atherosclerotic
lesions located in the human ascending aorta. Upon histological examination, the vessel
intima is observed to possess diffuse thickening in combination with accumulation of lipids
and small, discrete macrophage cell populations. These intima-infiltrating macrophages are
characterized by dysregulated gene expression in pathways related to cellular cholesterol
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handling, intracellular vesicular trafficking and phagocytosis/efferocytosis. Specifically,
we observed downregulation in the expression of the cholesterol efflux genes NPC1 and
ABCA1, downregulation of genes encoding components of the vATPase, NADPH oxidase
(gp91, p22phox), and downregulation of Src kinases and integrins involved in pathogen
and apoptotic cell internalization. We observed upregulation of several transcription
factors, notably the hematopoietic transcription factor GATA2 and upregulation of the
PADI3 enzyme.
The phenotype we have described herein appears to be distinct from any other previously
established macrophage phenotypes. Defining a consistent phenotype for atherosclerotic
macrophages has been difficult and the precise phenotype varies on the basis of whether
investigators studied human or animal plaques, the location of the plaque and the stage of
plaque development. In general, it is thought that atherosclerotic macrophages in later
stages of disease are predominantly M1-like and proinflammatory in nature.83 Indeed,
immunohistochemistry studies of advanced atherosclerotic plaques show an increase in the
proportion of pro-inflammatory macrophages and an association between these
macrophages and sites of plaque instability.84 Additionally, in animal models of
atherosclerosis regression, decrease plaque size is associated with an increase in the
number of M2-like macrophages.85,86 In advanced atherosclerosis, macrophages are shaped
by the inflammatory microenvironment of the plaque to adopt a pro-inflammatory
phenotype and contribute to inflammation, cytokine production and plaque instability.24,87
The M1-M2 paradigm however fails to capture the full complexity of macrophage
behaviours within the atherosclerotic plaque. Non-classical macrophage phenotypes have
also been described in the setting of atherosclerosis.88 For example, Boyle et al. describe a
heme-induced macrophage polarization stated (Mhem) that is associated with intraplaque
hemorrhage.53 These macrophages upregulate ATF-1 and heme oxygenase-1 and are able
to efficient clear excess hemoglobin.53 Kadl et al. describe another unique macrophage
characterized by upregulation of Nrf2 in response to oxidized phospholipids, which express
high levels of redox-regulating genes such as Srxn1 and Txnrd1 to control the oxidative
stress induced by oxidized phospholipids.89 In contrast, our pre-atherosclerotic
macrophages do not appear to overexpress markers of the macrophage M1-polarization,
nor is there a particularly strong effect in genes involved in iron metabolism or redox
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regulation. In contrast, we observe a non-inflammatory phenotype in our preatherosclerotic macrophages along with features suggestive of ER stress and regulation of
proteasome activity.
Macrophage efferocytosis undoubtedly plays a critical role in the pathogenesis of
atherosclerotic disease. Work to date has indicated that defective efferocytosis is a feature
of advanced, late-stage atherosclerotic disease. While the mechanisms that drive defective
efferocytosis remain poorly defined, there is some evidence to suggest that the
inflammatory microenvironment of the atheroma drives matrix metalloproteinasemediated cleavage of efferocytic receptors, thereby impairing efferocytic uptake of
apoptotic cells. Our findings here challenge these paradigms in two key ways: first, we find
that defects in phagocytosis and efferocytosis are present (at least at the level of gene
expression) very early on in atherosclerotic disease; second, we find that in addition to
impairments in phagocytic and efferocytic uptake, phagosome/efferosome maturation may
also be implicated in impaired macrophage efferocytosis. Critically, these findings are
based on analysis of isolated macrophage cell populations from human disease and are
therefore potentially more indicative of clinically-relevant macrophage dysfunction in
atherosclerosis than what has been previously identified in animal models of disease or
studies that have examined whole plaques.
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Chapter 5

5

The Hematopoietic Transcription Factor GATA2 is a
Master Regulator of Defective Macrophage Efferocytosis
in Atherosclerosis

5.1 Introduction
5.1.1 In vitro models of atherosclerotic macrophages
Studying atherosclerotic macrophages in vitro is a challenging task because the complexity
of the atherosclerotic plaque microenvironment is difficult to re-capitulate in culture.1 We
know that at a minimum, atherosclerosis involves cross talk between three cell types:
macrophages, endothelial cells and VSMCs.2,3 Indeed, a number of investigators have
attempted to create models of atherosclerosis through co-culture of some combination
endothelial cells, VSMCs and monocytes in the presence of various components of the
extracellular matrix (ECM).4–6 These models can successfully re-capitulate certain aspects
of atherogenesis, including SMC proliferation and migration of monocytes into the subendothelial cell space and their subsequent differentiation into macrophages.4 However,
due to the presence of multiple cell types, extra care is required in order to study
macrophage cell biology in isolation using these approaches and it is difficult to discern
how individual pro-atherogenic stimuli (such as the presence of modified lipoproteins) act
directly on macrophage cells.
Another approach that has been commonly employed is the isolation and ex vivo culture of
macrophages from patients, or more commonly, mice with atherosclerosis.1 One strategy
is to isolate macrophages from the peritoneum of atherosclerotic mice and subsequently
activate and study them in vitro.1 This has been key in studying the effects of various proatherogenic agents, cytokines and drugs on macrophages conditioned to the
hypercholesterolemic environment of the atherosclerotic animal.1,7,8 For example, Yu et al.
used this approach to establish that treatment with rosuvastatin in Apoe-/- mice had the
direct effect of inhibiting macrophage apoptosis,7 while Kanters et al. found that
atherosclerotic macrophages isolated from Ldlr-/- mice lacking a component of the NFκB
signaling complex exhibited decreased IL-10 production following stimulation with LPS.8
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However, while this approach is powerful and re-capitulates the systemic effects of
atherosclerosis on macrophage function, it become less feasible in humans given the lack
of a source that can provide large numbers of viable macrophages. Furthermore, unlike
with mice or immortalized cell lines, it is very difficult to perform genetic manipulations
on human macrophages cultured ex vivo, limiting our ability to study the effects of
perturbing the expression of specific genes on macrophage phenotype.9
Perhaps the simplest in vitro model of atherosclerotic macrophages is to treat cultured
macrophage with oxLDL,10 a similar modified lipoprotein,11 or LDL in the presence of an
ACAT inhibitor.12 The literature disagrees somewhat with the precise concentration of
oxLDL to use and the duration of treatment, with studies using a range of concentrations
between 25-100 µg/mL and a duration between 1-3 days.13,14 While a very simple model,
oxLDL exposure is able to re-capitulate some of the earliest pathologic features exhibited
by macrophages within atherosclerotic lesions. Uptake of oxLDL has a number of
consequences for macrophage. Cholesterol recovered from the lipoprotein particle
accumulates within the macrophage, as both neutral cholesterol esters sequestered within
lipid droplets and as free cholesterol that accumulates within the cytoplasm and lipid
plasma membrane of the cell.11 Cholesterol ester buildup as lipid droplets creates the
classic “foamy” appearance of macrophage-derived foam cells.15 Free cholesterol within
the cytoplasm aggregate as cholesterol crystal, which can induce a number of biological
responses within the macrophage, including UPR and activation of the UPR effector
protein CHOP, which can induce apoptosis.16,17 Cholesterol crystals also contribute to
activation of the NRLP3 inflammasome and generation of IL-1β, which plays a key role in
driving inflammatory responses within the atherosclerotic plaque.18 Furthermore, oxLDL
can activate endosomal Toll-like, which in addition to generating a pro-inflammatory
response, also inhibits the macrophage’s capacity to engage in efficient efferocytosis.19

5.1.2 GATA family of transcription factors
The GATA family of transcription factors is comprised of six members that have master
regulatory roles during development, specifically in progenitor differentiation and renewal,
and in cell lineage specification.20,21 GATA transcription factors are highly-conserved and
are evolutionarily ancient proteins, being found among animals, plants and fungi.20 They
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are characterized by the presence of two highly-conserved zinc finger domains that
recognize the consensus sequence (A/T)GATA(A/G).22 In vertebrates, there are six
members of the GATA transcription factor family (GATA1-6; see Figure 5.1).20
Classically, these six paralogs have been divided into two subfamilies on the basis of
function. GATA1/2/3 were thought to be primarily involved in development of the
hematopoietic system while GATA4/5/6 were thought to be involved in cardiac
development.21 However, more recent evidence suggests that various members of the
GATA family play important roles in the development of many other tissues, including the
kidneys (GATA2/3), breast (GATA3) and testes (GATA1) among others.20 The role of
GATA transcription factor during development has been discussed in detail in two recent
reviews from Lentjes et al. and Tremblay et al.20,21
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GATA family members are transcription factors with pleiotropic effects, capable of
cooperative binding with a wide range of other transcription factors.20,23 In fact, multiple
members of the GATA family have demonstrated ability to act as pioneer transcription
factors, binding to heterochromatic DNA sequences and promote chromatin opening to
allow for other transcription factors to bind.20 For example, GATA2 is able to regulate
androgen receptor binding by recognizing and opening sections of chromatin containing
androgen receptor-target genes. GATA family members typically bind cooperatively with
other, tissue-specific transcription factors to regulate gene expression.23 They are capable
of regulating the activity of other transcription factors through a variety of molecular
mechanisms (see Figure 5.2).20 In particular, during lineage specification, pairs of GATA
transcription factors tend to negatively regulate each other, where the exchange of one
GATA family member for another drives cell fate commitment in a process called a
“GATA switch”.20

Figure 5.1 The GATA family of transcription factors. (on opposite page)
The six members of the GATA family of transcription factors found in vertebrates
(GATA1-6). Members of the GATA family exhibit a high degree of sequence conservation
within the DNA binding domain, which is comprised of two zinc finger domains that allow
binding to the (A/T)GATA(A/G) consensus DNA binding sequence. Sequence
conservation in the N-terminal and C-terminal regions is markedly lower. The percentage
similarity of the protein sequence is calculated using the Matrix Global Alignment Tool
(MatGAT).24 AD = activation domains, Zn = zinc finger, NLS = nuclear localization signal.
Figure is modified from Tremblay et al.20
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Figure 5.2 GATA transcription factor mechanisms of action.
Molecular mechanisms of action employed by members of the GATA family of
transcription factors to regulate gene expression. (A) GATA transcription factors can act
as pioneer factors and open up chromatin to allow for binding of other transcription factors.
(B) They are able to loop chromatin to bring distant enhancer regions in closer proximity
with the genes they regulate. (C) The replacement of one GATA factor for another is
termed a “GATA switch” and has been implicated in regulating cell lineage specification.
GATA transcription factors are also able to recruit mediators that affect epigenetic
modification, either activating (D) or repressing (E) chromatin opening. (F) Finally, GATA
transcription factors directly enhance or repress binding of other transcription factors.
Figure is modified from Tremblay et al.20
GATA transcription factors regulate both primitive and definitive hematopoiesis. During
definitive hematopoiesis, GATA factors are required for both progenitor renewal and cell
lineage specification.23 Hematopoietic stem cells require continued GATA2 expression to
maintain their capacity for self-renewal.23 Disturbing GATA2 expression, either through
over-expression or knockdown, perturbs the ability of these stem cells to engage in selfrenewal.23,25 GATA factors are also markers of specific lineages of hematopoietic cells.
GATA1 is expressed in erythrocytes and megakaryocytes, GATA2 is a marker of
monocytic and dendritic cells, while GATA3 is only expressed in cells of the lymphoid
lineage.20
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5.1.2.1 GATA2
Of the GATA family of transcription factors, GATA2 is of particular interest to us. GATA2
was one of three non-cell cycle transcription factors found to be upregulated in patient
atherosclerotic macrophages from our gene expression profiling study (see Chapter 4).
Available evidence in the literature suggests that GATA2 could be involved in the
pathogenesis of atherosclerosis in humans. Mature monocytes and macrophages do not
normally express GATA2. A previous genome-wide association study (GWAS) and a
linkage study have found a positive association between mutations in GATA2 and earlyonset familial CAD and several risk factors associated with CAD, including obesity, low
HDL and hypercholesterolemia.26,27 Furthermore, a study that examined miRNAregulation of gene expression in CAD patients found that GATA2 was involved in a miR92a regulatory pathway associated with CAD.28 GATA2 appears to regulate expression of
the long non-coding RNA CDKN2B-AS, which in turns regulates miR-92a levels.28 miR92a has previously been identified as driving the production of inflammatory cytokines in
endothelial cells under pro-atherogenic conditions.29
GATA2 has also been implicated in several regulatory pathways associated with
inflammation. In a cohort of cardiac transplant patients receiving re-transplantation as a
result of graft rejection, SENP1-mediated deSUMOylation of GATA2 in the coronary
arteries was associated with graft atherosclerosis and inflammation.30 SENP1-mediated
deSUMOylation increased GATA2 stability and ability to bind DNA, thereby increasing
its activity.30 There is also evidence that GATA2 expression is regulated by inflammatory
PAMP’s, including LPS. Yang et al. show that LPS induces myeloid-derived suppressor
cell formation in mice in a GATA2-dependent fashion,31 while Wu et al. demonstrate that,
at least in vitro, LPS stimulates GATA2 migration into the nucleus and activations
transcription of IL-1β.32
Along with GATA1, GATA2 is absolutely required for both primitive and definitive
hematopoiesis. GATA1/2 knockout mice die during E10-11 due to severe hematopoietic
defects. GATA2 is required for proper development of the lymphatic system. In mice,
complete GATA2 knockout is embryonically lethal due to lymphatic collapse, whereas
partial knockouts result in lymphatic system mis-patterning.33 In patients with loss-of-
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function GATA2 mutations, lymphatic valves do not properly develop and these patients
exhibit lymphedema as a result.34 Mutations in GATA2 are also associated with diseases
of the hematopoietic system, including both chronic and acute myeloid leukemia,
Emberger syndrome, and MonoMAC (monocytopenia and mycobacterial infection)
syndrome (also referred to as Immunodeficiency 21).34–36 These syndromes are
characterized by profound deficiencies of dendritic cells, monocytes, B cells and natural
killer cells, resulting in severe immunodeficiency and increased susceptibility to infection
by human papillomaviruses and nontuberculous mycobacteria.37 Simultaneously, patients
with GATA2 mutations are at increased risk of AML, pulmonary alveolar proteinosis and
lymphedema. The mutations within GATA2 that give rise to these clinical manifestations
are heterogeneous but can be roughly divided into three groups: missense mutations,
frameshift mutations and in-frame deletions of the C-terminal zinc finger, mutations and
large deletions resulting in a null allele, and mutations within the regulatory region of the
GATA2 gene.37
GATA2 mutations have been identified in patients with chronic myeloid leukemia (CML)
that have experienced progression into the blast crisis phase of disease.20,25 In many of
these patients, a distinctive L359V mutation results in increased DNA binding and
coactivator recruitment, as well as repression of the transcription factor PU.1 through
aberrant binding and sequestration of this protein.25 PU.1 is a major regulator of myeloid
cell proliferation and GATA2-mediated repression of PU.1 function in vitro appears to be
sufficient to induce maturation arrest of myeloid precursor cells at the myeloblast and
monoblast stages.38 Disruption of GATA2 expression and function can also lead to
AML.20,35 In this case, both GATA2 overexpression and knockdown/loss-of-function can
lead to leukemogenesis.20 In particular, high levels of GATA2 expression correlate with
poorer outcomes in pediatric AML and activation of GATA2 through a Ras-MAPKGATA2 axis is sufficient to induce CXCL2-dependent AML proliferation.39,40

5.1.3 Processes involved in efferosome maturation
Efferocytosis is a complex process of removing apoptotic cells in order to prevent
secondary necrosis and maintain tissue homeostasis.41,42 We discuss efferocytosis and its
regulation in detail in Chapter 1.1 and Chapter 3. Broadly speaking, efferocytosis can be
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divided into three distinct stages: recognition of the apoptotic cell, apoptotic cell binding
and uptake, and processing and degradation of the internalized apoptotic cell.42 In the
context of atherosclerosis, a great deal of effort has gone into understanding the first two
stages of efferocytosis but the final stage of efferocytosis—proper degradation and
processing of internalized apoptotic cargo through regulated efferosome maturation—
remains poorly understood.43,44 Although the regulation and end result of efferocytosis is
distinct, efferosome maturation utilizes the same fundamental processes to degrade
apoptotic cells as phagosomes utilize to degrade pathogens. These processes include:
superoxide generation within the efferosome, efferosome acidification, and fusion between
efferosomes and lysosomes.45
The generation of superoxides within the phagosome is an efficient mechanism of pathogen
killing.46,47 In macrophages, phagosomal superoxides are generated by the phagocyte
NADPH-oxidase (NOX) complex. NOX is capable of generating superoxide anions within
the phagosome, which in turn can form hydrogen peroxide, a potent antimicrobial agents.46
This mechanism is so efficient that human macrophages polarized in vitro to the proinflammatory M1 phenotype actually favour superoxide formation and hydrogen peroxide
formation at the expense of consuming protons within the phagosome and delaying
phagosome acidification.48 The NOX complex is composed of two transmembrane
proteins: gp91phox, p22phox; three cytosolic regulators: p40phox, p47phox and p67phox; and a
Rho GTPase (either Rac1 or Rac2).46,49 The gp91phox and p22phox subunits together
assemble into an inactive flavocytochrome on the membrane of nascent phagosomes. The
regulatory subunits exist in the cytoplasm as a complex, which translocates to the
phagosome membrane upon stimulation and, together with Rac1 or Rac2, activates the
flavocytochrome complex. The activated flavocytochrome is able to reduce oxygen
molecules to generate superoxide anions within the pathogen and engage in pathogen
degradation.49 NOX activity has also been recently demonstrated to be critical in efficient
degradation of apoptotic cargo. Bagaitkar et al. demonstrated that efferocytosis of
apoptotic neutrophils by murine macrophages was sufficient to induce NOX activation.50
Using macrophages from mice with one of the NOX subunits deleted, the authors further
demonstrated that superoxide generation was essential for the rapid degradation of
apoptotic cargo and to prevent aberrant presentation of self-antigens to T cells.50
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A second mechanism contributing to efficient degradation of apoptotic cargo within
efferosomes is efferosome acidification. Acidification is crucial for phagosome and
efferosome function.45,51 Many proteases that serve to degrade pathogens or apoptotic cells
only become active at a pH below 6.0 In the context of phagocytosis specifically, cathepsin
D, which plays a crucial role in the loading of peptide onto MHC class II molecules for
antigen presentation, requires a sufficiently low pH to function efficiently.45 Acidification
of phagosomes and efferosomes is mediated by the v-ATPases, which serve as pumps to
move protons into the efferosome.51 The v-ATPase is comprised of two subunits, V1 and
V0. The V1 subunit performs ATP hydrolysis and provides the energy for movement of
protons across the efferosome membrane, while the V0 subunit forms a membranespanning channel to direct movement of protons inwards.51 V-ATPase-mediated
acidification plays several important roles in efferosome maturation. The low pH
environment is necessary for activation of certain degradative proteases, protons within the
efferosome participate in the formation of reactive oxygen species that enhance apoptotic
cell degradation, and the A1 subunit of the v-ATPase appears to be required for further
fusion of efferosomes with lysosomes to complete apoptotic cargo degradation.51,52
Recruitment of the V-ATPase to the efferosome and proper regulation ofv-ATPase activity
appear to depend at least in part on the activity of the small GTPase Rab7 and its effector
protein RILP.52,53 Interestingly, under hypercholesterolemic conditions, Rab7 is recruited
to the phagosomes but remains inactive, with phagosomal acidification impaired as a
result.54
One final mechanism that is involved efferosome maturation is fusion between the
efferosome and lysosomes. This delivers lysosomal enzymes to the efferosome that aid in
the degradation of apoptotic cargo.55 As we have demonstrated in Chapter 3, following
internalization of apoptotic bodies, efferosomes ultimately go on to acquire lysosomal
markers such as LAMP-1, indicating that fusion with lysosomes has taken place. Active
Rab7 is again required for efferolysosomal fusion. RILP, along with another key Rab7
effector ORP1L, serve to recruit a dynein-dynactin complex and drive efferosomal
migration towards the cell centre along microtubules.53,56 This serves to bring the
efferosomes into close proximity with lysosomes, which are concentrated in the perinuclear
region.53 The importance of Rab7 in the regulation of this process is underscored by the
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fact that hypercholesterolemia-induced Rab7 inactivity inhibits the capacity of
phagosomes to undergo migration towards the cell centre and fuse with lysosomes.54 There
is also some evidence that LC3-associated phagocytosis (LAP), which involves
translocation of some components of the cellular autophagy machinery to the efferosome,
is also required for efficient efferolysosomal fusion.57

5.1.4 Rationale and importance
As described in Chapter 4, gene expression profiling of macrophages isolated from earlystage human pre-atherosclerotic lesions located in the proximal aorta from patients
undergoing open-heart surgery revealed profound dysregulation in both cholesterol
metabolism and in efferocytosis and efferosome maturation. The challenge is now to
identify potential regulatory transcription factors that could account for part of all of this
unique macrophage phenotype. We found just three non-cell cycle transcription factors to
be upregulated in patient macrophages, with only GATA2 being confirmed to be
upregulated by RT-qPCR.
GATA2 is of interest over RARG and E4F1 since of the three, only SNPs in GATA2 are
associated with increased risk for CAD.26,27 Mutations in GATA2 are also strongly
associated

with

immunological

and

hematological

abnormalities,

including

myelodysplasia and an elevated risk of leukemia.23,35 Intriguingly, Jaiswal et al. have
recently shown that certain mutations associated with the development of leukemia, in
particular mutations in TET—another transcription factor involved in hematopoiesis—also
increase the risk of developing atherosclerosis and cardiovascular disease.58 Gain-offunction mutations in GATA2 are associated with blast crisis in CML and increased
GATA2 expression is a marker of worse outcomes in AML.25,40 There is therefore some
biological plausibility in GATA2 being a master regulator of the dysregulation observed
in patient macrophages. Further connecting GATA2 and defects in efferosomal maturation,
Lasbury et al. have shown that in the context of Pneumocysitis carnii infection of the
airways, GATA2 upregulation suppresses the phagocytic capacity of alveolar macrophages
in response to infection.59
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In this chapter, we utilize an in vitro model of atherosclerotic macrophages and genetic
manipulation of GATA2 to study the effect of perturbing GATA2 expression on
cholesterol homeostasis, efferocytosis and efferosome maturation, and on peptide
citrullination in these cells. GATA2 is an attractive candidate for a master regulatory factor
that could drive some or all of the defects observed in patient macrophages. Determining
to what extent perturbation of GATA2 expression affects macrophage cholesterol handling
and efferocytosis would add significantly to our understanding of the mechanisms driving
macrophage dysregulation in early atherosclerotic disease and development of defective
efferocytosis. GATA2 and its downstream targets could also represent potential therapeutic
targets for development of novel atherosclerosis treatments targeting the inflammatory
component of atherosclerotic disease.

5.2 Methods
5.2.1 Generation of atherosclerotic macrophages
J744.2 and THP-1 macrophage cell lines were cultured as described in Chapter 2.4.1.
Primary human macrophages were prepared as described in Chapter 2.4.2. Prior to oxLDL
treatment, THP-1 cells were differentiated into adherent macrophages by treatment with
100 nM PMA for 72 hrs. Cells were incubate with human oxLDL at a concentration of 50
µg/mL for 48 hrs (J744.2 cells13 and primary human macrophages14) or 100 µg/mL for 72
hrs (THP-1 cells10). oxLDL-treated cells were washed with PBS to remove excess oxLDL
and were placed into fresh, oxLDL-free media prior to use in downstream assays.

5.2.2 Measurement of cholesterol accumulation
Cholesterol accumulation in oxLDL-treated macrophages was measured by staining with
either Oil Red O or Nile Red. For Oil Red O staining, stock Oil Red O solution (1:250 w/v
Oil Red O power in 100% isopropanol) was diluted 3:2 in ddH2O to a working
concentration, mixed by vortexing, allowed sit for 20 min at room temperature, and filtered
through a 0.2 µm filter. The cells to be stained were washed 1× with PBS and then fixed
with 4% PFA for 20 min at room temperature. Fixed cells were washed 3× 5min with PBS
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to remove excess PFA. Cells were then washed briefly with a 3:2 v/v mixture of
isopropanol and ddH2O and allowed to dry completely. Cells were covered with the
minimum volume of Oil Red O working solution to ensure complete coverage and allowed
to incubate for 5 min at room temperature. Cells were washed 3× 5 min with PBS to remove
excess Oil Red O. If desired, Oil Red O-stained cells may be prepared for imaging under
white light at this point by mounting coverslips on glass slides using Permafluor.
Otherwise, Oil Red O can be extracted by treating cells with 100% isopropanol for 10 min
at room temperature with gentle agitation. Oil Red O concentration can be quantified by
measurement of absorbance at 460 nm using an Eppendorf BioPhotometer Plus (Thomas
Scientific).
For Nile Red staining, stock Nile Red solution is prepared by dissolving Nile Red power
in acetone at a concentration of 1 mg/mL. Cells to be stained are washed 1× with PBS and
fixed with 4% PFA for 20 min at room temperature. Fixed cells were washed 3× 5min with
PBS to remove excess PFA. Stock Nile Red is diluted 1:100 in PBS to generate a working
solution. Fixed cells are covered with Nile Red working solution for 5 min at room
temperature. Cells are then washed 3× 5 min with PBS to remove excess PBS and prepared
for imaging by mounting coverslips on a glass slide using Permafluor. For Nile Red
staining of live cells, cells are prepared for live cell imaging in a Leiden chamber as
described in Chapter 2.10.2 with time-lapse images captured on white light and Nile Red
channels at 630× magnification every 15 min for 8 hrs. Nile Red fluorescence is measured
using a solid-state white light source in conjunction with a 550/570 nm bandpass excitation
filter and a 605/52 nm bandpass emission filter. Nile Red stock solution is added 1:100 v/v
directly to the culture media and live cell imaging is performed as usual. If desired, cells
can be incubated for 3-5 hrs in serum-free media prior to staining to remove background
lipid deposition.

5.2.3 Cholesterol efflux assay
Cholesterol efflux was measured using a high-sensitivity assay initially described by
Sankaranarayanan et al.60 To prepare labelling media, BODIPY-cholesterol and unlabeled
cholesterol were mixed together at a ratio of 1:5 v/v in a glass bottle and dried under
nitrogen away from light. The cholesterol mixture was solubilized with MEM-HEPES
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(MEM media with 10 mM HEPES, pH 7.4) containing 20 mM methyl-β-cyclodextran
(MβCD) at a molar ratio of 1:40 cholesterol to MβCD in MEM-HEPES. The mixture was
agitated in a sonicating water bath at 37 °C for 30 min. The sonicated suspension was
placed on a stirring hot plate pre-heated to 37 °C and kept stirring with a sterile stir bar for
3 hrs. This labelling media can be used immediately or stored at 4 °C away from light until
ready to use. Immediately prior to use, labelling media is again sonicated in a sonicating
water bath at 37 °C for 30 min and filtered through a 0.45 µm filter.
ApoB-depleted human serum is used as the cholesterol acceptor. To prepare ApoBdepleted serum, 1M CaCl2 is added to whole human plasma at a ratio of 1:40 v/v. The
plasma is allowed to incubate for 1 hr at room temperature to allow for clotting, after which
serum is separated from the clotted plasma proteins by centrifugation for 5 min at 1,000
×g. ApoB was precipitated from the serum through addition of PEG solution (20% PEG
8,000 in 200 mM glycine buffer, pH 7.4) to serum at a 2:5 v/v ratio. The mixture is allowed
to incubate for 20 min at room temperature and then centrifuged for 30 min at 10,000 ×g
and 4 °C. The supernatant, containing apoB-depleted serum, is transferred to a fresh tube.
To perform the cholesterol efflux assay, THP-1 cells were cultured in a 48-well plate to a
density of 75,000 cells/well. At 24 hrs prior to starting the assay, cells are differentiated
into adherent macrophages through addition of 100 nM PMA. Cells are washed 1× with
PBS and incubated with 250 µL/well of labelling media for 1 hr at 37 °C and 5% CO2.
Cells are washed 2× with MEM-HEPES to remove excess labelling media. Cells are then
incubated with incomplete RPMI containing 0.2% BSA for 16 hrs at 37 °C and 5% CO2.
Cells were again washed 2× with MEM-HEPES and then incubated with fresh MEMHEPES containing 10% apoB-depleted serum for 4 hrs at 37 °C and 5% CO2. A negative
control where cells are incubated with MEM-HEPES lacking apoB-depleted serum should
also be prepared at this point. Media from each well was collected, filtered through a 0.45
µm filter and fluorescence intensity (ex. 482 nm, em. 515 nm) was recorded using a Gemini
Fluorescence Microplate Reader running SoftMax Pro (Molecular Devices). The cells used
in the negative control were solubilized with the addition of 4% cholic acid and incubated
for 4 hrs at room temperature with gentle agitation. Supernatants were collected, filtered
through a 0.45 µm filter and fluorescence intensity was recorded and used as the baseline
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value for total cholesterol present within the cells. The percent cholesterol efflux was
calculated as fluorescence intensity of media divided by fluorescence intensity of cholic
acid.

5.2.4 Nitroblue tetrazolium assay
A microscopy-based nitroblue tetrazolium (NBT) assay protocol was used to assess
macrophage NADPH oxidase activity.61 Apoptotic Jurkat cells were prepared according to
Chapter 2.8.2.2 and added at a multiplicity of infection (MOI) of 10 to PMA-differentiated
THP-1 cells and briefly centrifuged for 1 min at 400 ×g to force contact between the
macrophages and apoptotic cells. NBT was added to a final concentration of 100 µg/mL
and the assay was allowed to incubate for 1 hr at 37 °C and 5% CO2. Following incubation,
cells were washed 3× 5 min to remove unbound apoptotic cells and excess NBT reagent.
Cells were fixed with 4% PFA for 20 min at room temperature. Cells were then washed 3×
5 min with PBS and coverslips were mounted onto glass slides using Permafluor for
imaging. Fluorescence of diformazan deposits formed were imaged on an epifluorescence
microscope at 630× magnification using a solid-state white light source in conjunction with
a 650/670 nm bandpass excitation filter and a 700/50 nm bandpass emission filter.

5.2.5 Dextran fusion assay
Dextran fusion assay to quantify phagolysosomal fusion was performed according to the
protocol of Flannagan et al.62 PMA-differentiated THP-1 macrophages were treated with
100 µg/mL 10,000 MW TRITC-conjugated dextran for at least 16 hrs at 37 °C and 5%
CO2. Dextran-loaded macrophages were washed 3× with PBS to remove excess dextran
and then incubated in serum-free RPMI for 1.5 hrs at 37 °C and 5% CO2 to allow for
loading of the dextran onto the lysosomal compartment. IgG-coated beads prepared
according to Chapter 2.8.2.1 were added to macrophages at a MOI of 10 and the mixture
was briefly centrifuged for 1 min at 400 ×g to force contact between macrophages and
beads. The assay was allowed to incubate for 30 min at 37 °C and 5% CO2. Following
incubation, cells were washed 1× with PBS to remove unbound beads and labelled 1:1,000
with a Cy5-conjugated anti-human IgG secondary antibody to label bound but
uninternalized beads. Cells were subsequently washed 3× 5 min with PBS and fixed with
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4% PFA for 20 min at room temperature. Following fixation, cells were washed 3× 5min
to remove excess PFA and coverslips were mounted onto glass slides using Permafluor.
Assays were imaged under epifluorescence microscopy at 630× magnification with a
550/570 nm bandpass excitation filter and a 605/52 nm bandpass emission filter (TRITCdextran) and a 650/670 nm bandpass excitation filter and a 700/50 nm bandpass emission
filter (Cy5-conjugated anti-human IgG).

5.2.6 Phagosome acidification assay
Human IgG was labelled using a pHrodo Red Microscale Labeling Kit (Invitrogen) as per
the manufacturer’s instructions. 5 µm polystyrene/DVB beads were coated with a 50:1:1
ratio of unlabeled:pHrodo-conjugated:AF647-conjugated human IgG as per our published
protocols.63,64 Beads were added to PMA-differentiated THP1 macrophages at a MOI of
10 and time-lapse images on the white light, pHrodo (ex. 550/570 nm bandpass filter, em.
605/52 nm bandpass filter) and AF647 (ex. 650/670 nm bandpass filter, em. 700/50 nm
bandpass filter) channels were recorded at 630× magnification, 1 frame-per-minute, for 60
min. At the end of the imaging period, the cell culture medium was replaced with
calibration buffers of known pH (140 mM KCl, 1 mM MgCl2, 0.2 mM EGTA, 20 mM
NaCl with either 20 mM MES (pH 4 and 5) or 20 mM HEPES (pH 6 and 7)). Images were
captured on the pHrodo and AF647 channels after each pH change. Using FIJI,65,66
phagocytosed beads were identified in the DIC channel, and the intensity of the pHrodo
and AF647 signal on individual beads recorded at each time point starting immediately
prior to phagosome closure through to the end of the time-lapse. For each phagosome, at
each time point, the pHrodo signal was normalized using the AF647 channel, and then the
calibration curve for the phagosome used to determine the pH of the phagosome at each
time point.

5.2.7 Anti-modified citrulline staining
Anti-modified citrulline (AMC) staining was employed to detect citrullinated peptides in
patient aortic punch tissue sections, according to the protocol developed by Vossenaar et
al.67 From FFPE sections prepared according to Chapter 2.2.3.2. Sections were deparaffinized through sequential exposure to: xylene 2× 5-10 min, 100% ethanol 2× 5-10
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min, 95% ethanol 2× 5-10 min, 75% ethanol 2× 5-10 min, ddH2O 2× 5-10 min and PBS
1× 20 min. Follow de-paraffinization, the citrulline modification step was performed using
the Anti-Citrulline (Modified) Detection Kit (Sigma-Aldrich) according to the
manufacturer’s instructions for 3 hrs at 37 °C. Antigen retrieval was performed using the
Trypsin Enzymatic Antigen Retrieval Solution (Abcam) according to the manufacturer’s
instructions with a 30 min room temperature incubation period. Following modification,
sections were incubated for a further 30 min with 3% H2O2 to block endogenous
peroxidases. Sections were washed 3× 5 min with PBS and blocked with 10% goat serum
for 30 min at room temperature. Sections were then incubated with either 1% goat serum
(negative control), 1µg/mL normal human IgG (isotype control), or 1:1,000 anti-peptidylcitrulline antibody (Sigma-Aldrich, clone F95) overnight at room temperature. Excess
antibody was removed by washing 3× 5 min with PBS and 1:2000 of 0.8mg/mL goat antihuman HRP conjugate was applied to the sections for 1 hr at room temperature. Sections
were then developed with Vector DAB HRP substrate (Vector Laboratories) was applied
for 2-10 min until staining reaches an appropriate level. Sections were rinsed with PBS to
stop the reaction and then washed a further 2× 10 min with PBS. Sections were then
counterstained with haemotoxylin for 5 min, rehydrated with increasing concentrations of
ethanol followed by xylene. Sections were then mounted on glass coverslips using Cytoseal
60.
AMC staining of cultured THP-1 macrophages was performed using a modified version of
the procedure outlined above. To label individual cells, 1mg/mL Cy5-conjugated wheat
germ agglutinin was added 1:200 to cells for 10 min protected from light and washed 3× 5
min with PBS. Cells were then fixed in 2% PFA for 15 min at room temperature, washed
3× 5min with PBS, and then permeabilized with 0.2% Triton X-100 for 10 min at room
temperature. Citrulline modification step was performed as described above. Cells were
washed 3× 5 min with PBS and blocked with 5% fetal bovine serum for 3 hrs at room
temperature. Thereafter, cells were incubated with 1% goat serum (negative control),
1µg/mL normal human IgG (isotype control), or 1:1,000 of 1mg/mL anti-peptidylcitrulline antibody (Sigma-Aldrich, clone F95) for 1 hr at room temperature. Cells were
again washed 3× 15 min with PBS and then incubated with 1:1,000 of 1mg/mL Cy3-
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conjugated goat anti-human IgG for 30 min at room temperature. Cells were washed 3× 15
min with PBS and mounted onto glass slides using Permafluor.

5.3 Results
5.3.1 Confirmation of GATA2 expression in patient aortic punch
macrophages
We observed a significant upregulation of GATA2 expression in patient aortic punch
macrophages in our microarray dataset (Chapter 4.3.4) and subsequently verified this in a
set of independent patient and control macrophage samples by RT-qPCR (Chapter 4.3.5).
Our results from qPCR indicated that not only was GATA2 significantly upregulated in
patient macrophages, it was expressed at much higher levels than detected by microarray.
To confirm that GATA2 is specifically expressed in lesion-resident macrophages, we
performed immunofluorescence imaging of sectioned patient aortic punch tissues stained
for human GATA2 and the human pan-macrophage marker CD68 (Figure 5.3a).
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Figure 5.3 Co-localization of GATA2 expression with patient lesion-resident CD68+
macrophages.
Patient aortic punch tissue sections were stained for GATA2 and the pan-macrophage
marker CD68. Sectioned were subsequently imaged using a fluorescence microscope to
examine co-localization between GATA2 and CD68+ cells. The image is representative of
(a) and the graph quantifies (b) localization of GATA2 within CD68+ across N = 3 patients
shown as mean ± SEM. LUM = lumen, INT = intima. ***p < 0.001 by unpaired, two-tailed
Student’s t test. Scale bar = 20 µm.
We observed co-localization of GATA2 with approximately 50% of CD68+ cells within
the intima (Figure 5.3b), indicating that expression of GATA2 is heterogenous across the
population of lesion-resident macrophages. It is also possible that a number of these CD68+
cells are smooth muscle cells that have adopted a foam cell-like phenotype,68 however this
experiment was not designed to be able to discriminate between these two cell populations.
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5.3.2 Generation of an in vitro model of atherosclerotic macrophages
To study the effects of GATA2 on macrophage function, we first generated an in vitro
model of atherosclerotic macrophages through exposure of human monocyte-like THP-1
cells to oxLDL following PMA-differentiation based on the method of Seo et al.14
Characterization of Oil Red O accumulation in THP-1 macrophages incubated with 100
µg/mL oxLDL by white light microscopy (Figure 5.4a) or quantification of Oil Red O
content extracted from cells by measurement of absorbance at 420 nm by
spectrophotometer (Figure 5.4b) demonstrated a linear increase in intracellular lipid
content over a period of 24 hrs, resulting in cells that resemble cholesterol-laden foam cells
in appearance. Due to the kinetics of GATA2 expression in THP-1 cells exposed to oxLDL,
we also examined sustained exposure of THP-1 cells to oxLDL over a period of 72 hrs and
again demonstrated a significant increase in intracellular lipid content in these cells as
compared to cells cultured for 72 hrs without exogenous oxLDL (Figure 5.4c).
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Figure 5.4 Exposure to oxLDL induces an increase in intracellular lipid content in
THP-1 macrophages. (on opposite page)
THP-1 monocyte-like cells were incubated with 100 µg/mL human oxLDL over a period
of 48 (a, b) or 72 hrs (c). (a) Cells were stained with Oil Red O following 0, 12, 24 and 48
hrs incubation with oxLDL and imaged under a white light microscope. (b) Cells were
incubated with oxLDL for the time points specified previously and stained with Oil Red
O. Intracellular Oil Red O was quantified at 420 nm as a proxy of total intracellular lipid
content. (c) Cells were incubated with oxLDL for 0 or 72 hrs and intracellular Oil Red O
content was quantified at 420 nm. Data are presented as mean ± SEM of N = 3 replicates.
*p < 0.05 compared to Time = 0 hrs by 1-way ANOVA with Sidak multiple comparison
test (b) or compared to oxLDL concentration = 0 µg/mL by unpaired, two-tailed Student’s
t test. Scale bar = 10 µm.
Accumulation of intracellular lipid droplets is perhaps the most important feature of lesionresident atherosclerotic macrophages and foam cells. We demonstrate here that incubation
of THP-1 macrophages with human oxLDL for at least 48 hrs is sufficient to induce
significant amounts of intracellular lipid accumulation in these cells, suggesting that we
are able to re-capitulate at least part of the lesion-resident atherosclerotic phenotype in
vitro.

5.3.3 Exposure to oxLDL induces GATA2 expression in THP-1 and
primary human macrophages
After confirming that exposure to oxLDL in vitro can induce an atherosclerosis-like
phenotype in THP-1 macrophages, we went on to determine whether oxLDL exposure is
sufficient to induce upregulation of GATA2 expression in both THP-1 cells and primary
human macrophages. We incubated THP-1 cells with 100 µg/mL oxLDL and primary
human macrophages with 50 µg/mL oxLDL (100 µg/mL oxLDL resulted in toxicity in
these cells, data not shown) over 72 hrs and quantified GATA2 expression by RT-qPCR
over this time period (Figure 5.5).
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Figure 5.5 Exposure to oxLDL is sufficient to induce upregulation of GATA2
expression in macrophages.
Quantification of relative GATA2 expression in macrophage cells following exposure to
oxLDL. PMA-differentiated THP-1 macrophages (a) or ex vivo monocyte-derived primary
human macrophages (b) were incubated with 100 or 50 µg/mL human oxLDL respectively
for up to 72 hrs. GATA2 expression levels were measured by RT-qPCR at various time
points and normalized to GATA2 expression at Time = 0 hrs. Data are shown as mean ±
SEM from N = 3 biological replicates. *p < 0.05 compared to Time = 0 hrs by 1-way
ANOVA with Sidak multiple comparisons test.
Incubation with oxLDL resulted in a linear increase in the level of GATA2 expression in
THP-1 macrophages but this increase was not significant compared to baseline until 72 hrs
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post-oxLDL exposure (Figure 5.5a). With respect to primary human macrophages, we did
not observe an increase in GATA2 until 72 hrs of incubation with oxLDL but we did not
find this increase to be significantly different compared to baseline (Figure 5.5b). This
may be a result of the lower concentration of oxLDL used in the primary human
macrophage experiments or it could be that a longer incubation period is required.
However, on the basis of this data and the previous section, incubation with oxLDL for a
period of 72 hrs is sufficient to induce cholesterol accumulation within THP-1
macrophages accompanied by a significant increase in GATA2 expression.

5.3.4 Generation of GATA2 overexpression and knockdown cell lines
To study the effect of perturbing GATA2 expression both in the presence and absence of
oxLDL, we generated stable GATA2 overexpression and knockdown THP-1 cell lines. To
generate a GATA2 overexpression vector, the human GATA2 consensus coding sequence
was cloned into a pLVX-IRES-ZsGreen1 backbone, a lentiviral expression vector that
allows simultaneous expression of GATA2 along with the ZsGreen1 fluorophore under a
CMV promoter (see Figure 5.6a for cloning strategy and Appendix A for sequences of ).
To generate a GATA2 knockdown vector, shRNA sequences targeting human GATA2
were generated using the siRNA Wizard Software 3.1 (InvivoGen). Each shRNA generated
was cloned into a pGFP-C-shLenti backbone, a lentiviral shRNA expression vector that
allows simultaneous expression of a GATA2 shRNA and the TurboGFP fluorophore under
a SV40 promoter (see Figure 5.6b for cloning strategy for most effective shRNA
sequence). See Appendix A for the sequence of the most effective shRNA sequence.

Figure 5.6 Cloning strategy for GATA2 overexpression and knockdown vectors. (on
opposite page)
Cloning strategy employed to create the (a) GATA2 overexpression (pLVX-IRESZsGreen1 GATA2) and (b) knockdown (pGFP-C-shLenti GATA2 shRNA1) vectors.
Diagrams were created using SnapGene Version 4.3 (GSL Biotech).
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The GATA2 overexpression vector was packaged into a lentivirus and stably transduced
into THP-1 cells. Transduced cells were sorted to contain only successfully-transfected cell
populations by a fluorescence-activated cell sorting strategy using a FACSAria III Flow
Cytometric Cell Sorter (BD Biosciences) and gating on the 10% of live cells expressing
the highest levels of green fluorescence (data not shown). Immunofluorescence imaging
demonstrated that in ZsGreen1+ cells that were successfully transduced with the
overexpression vector, GATA2 is significantly overexpressed (Figure 5.7a). As expected,
controls transduced with an empty pLVX-IRES-ZsGreen1 vector did not show any
GATA2 expression (Figure 5.7a). We examined this at the protein level, measuring
GATA2 protein expression by Western blot in stably-transduced THP-1 cells. GATA2
protein levels were increased in the transduced THP-1 cells as compared to a untransduced
control, as demonstrated by the Western blot (Figure 5.7b) and densitometry quantification
thereof (Figure 5.7c). Finally, we confirmed upregulation of GATA2 expression in
transduced THP-1 cells by RT-qPCR (Figure 5.7d).

Figure 5.7 Generation of a stably-transduced THP-1 GATA2 overexpression cell line.
(on opposite page)
A stably-transduced THP-1 GATA2 overexpression cell line was generated through
lentiviral transduction of the pLVX-IRES-ZsGreen1 GATA2 vector into THP-1 cells and
a pure GATA2-overexpression THP-1 population was obtained through FACS sorting of
ZsGreenbright cells. (a) Stably-transduced THP-1 were immunostained for human GATA2,
using THP-1 cells transduced with an empty pLVX-IRES-ZsGreen1 vector as a negative
control. (b) Demonstration of GATA2 protein production in stably-transduced THP-1 as
compared to a negative control transduced with the empty vector by Western blotting, and
(c) quantification thereof by band densitometry analysis. (d) Measurement of GATA2
overexpression in stably-transduced cells by RT-qPCR compared to cells transduced with
an empty vector control. Images and graph are representative of (a-c) or quantifies (d) N
=3 biological replicates. Data are shown as mean (c) or mean ± SEM (d). **p < 0.01 by
unpaired, two-tailed Student’s t test. Scale bar = 10 µm.
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Since THP-1 cells do not produce appreciable levels of endogenous GATA2, it was not
possible to test the efficiency of shRNA constructs on knocking down GATA2 expression
in these cells directly. Instead, we adopted a strategy of co-transfecting the GATA2
overexpression and the shRNA vectors into HEK cells. This allowed us to determine the
degree to which each shRNA construct created could inhibit GATA2 overexpression. We
demonstrated that the most effective shRNA construct (hereafter referred to as shRNA1)
could reduce GATA2 protein expression by approximately 50% (Figure 5.8a, 5.8b). The
shRNA1 sequence was used to generate the GATA2 knockdown vector, which was stablytransduced into THP-1 cells and sorted by FACS to generate a pure GATA2 knockdown
THP-1 cell population (data not shown). Analysis of GATA2 mRNA levels in stablytransduced THP-1 cells following oxLDL exposure showed a significant reduction in
GATA2 levels in the cells expressing the GATA2 shRNA compared to cells transduced
with a scrambled shRNA control (Figure 5.8c).
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Figure 5.8 Generation of a stably-transduced THP-1 GATA2 knockdown cell line.
A stably-transduced THP-1 GATA2 knockdown cell line was generated through lentiviral
transduction of the pGFP-C-shLenti GATA2 shRNA1 vector into THP-1 cells and a pure
GATA2-knockdown THP-1 population was obtained through FACS sorting of
TurboGFPbright cells. (a) Demonstrating that co-transfection of HEK cells with the GATA2
overexpression and knockdown vectors results in a decrease in GATA2 protein levels
compared to co-transfection of HEK cells with the overexpression vector and a scrambled
shRNA control by Western blotting, and (b) quantification thereof by band densitometry.
Empty = empty pLVX-IRES-ZsGreen1 vector, scr = scrambled shRNA vector. THP-1
GATA2 knockdown cell line was generated through lentiviral transduction of the pGFPC-shLenti GATA2 shRNA1 vector into THP-1 cells and a pure GATA2-knockdown THP1 population was obtained through FACS sorting of TurboGFPbright cells. (c) Quantification
of GATA2 knockdown in stably-transduced GATA2-knockdown THP-1 cells incubated
with human oxLDL for 72 hrs compared to cells transduced with a scrambled shRNA
control by RT-qPCR. Image and graph are representative of (a, b) or quantifies (c) N = 3
biological replicates. Data are shown as mean (b) or mean ± SEM (c). *p < 0.05 by
unpaired, two-tailed Student’s t test.
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5.3.5 Perturbation of GATA2 expression does not alter macrophage
cholesterol metabolism
Following the generation of stably-transduced GATA2 overexpression and knockdown
THP-1 cell lines, we used these cells to examine the effect of perturbing GATA2
expression on macrophage cholesterol handling. Cholesterol loading in macrophages with
exposure to oxLDL was measured by observing accumulation of the lipophilic dye Nile
Red in THP-1 macrophages over a period of 8-12 hrs (Figure 5.9a). THP-1 macrophages
continually accumulate cholesterol over a period of 12 hrs, with the most rapid rate of
accumulation occurring between 4-8 hrs of oxLDL exposure and slowing down after 8 hrs
(Figure 5.9b).

197

Figure 5.9 Perturbation of GATA2 expression does not have a consistent effect on
macrophage cholesterol handling. (on opposite page)
Cholesterol handling was assessed in THP-1 cell lines with differing levels of GATA2
expression. (a) Accumulation of cholesterol in THP-1 macrophages imaged with live cell
Nile Red staining over a period of 12 hrs, and (b) quantification of these images
demonstrating intracellular cholesterol accumulation. (c) Accumulation of cholesterol over
8 hrs in THP-1 cells with differing levels of GATA2 expression. (d and e) Cholesterol
efflux from THP-1 macrophages grown under normal (Control) or hyperlipidemic
(oxLDL) conditions quantified using fluorescent BODIPY-labelled cholesterol shown as
percent efflux from baseline (d) or relative to the degree of cholesterol efflux in cells grown
in normal conditions (e). WT = wild type THP-1 cells, GATA = GATA2 overexpressing
THP-1 cells, shRNA = GATA2 knockdown THP-1 cells. Colours in (a) are representative
of Nile Red fluorescence intensity. Data are representative of (a) or quantifies (b - e) a
minimum of N = 3 biological replicates. Data are shown as mean ± SEM. (b) ***p < 0.001
and ****p < 0.0001 compared to Time = 0 hrs by 1-way ANOVA with Sidak multiple
comparisons test, (d, e) #p < 0.05 compared to the WT + Control condition and *p < 0.05
compared to Control condition in the same cell line by 2-way ANOVA with Tukey’s posthoc test. Scale bar = 10 µm.
We examined cholesterol accumulation by Nile Red staining of live wild type, GATA2
overexpressing and GATA2 knockdown THP-1 macrophages, and we did not find any
difference in the rate or degree of cholesterol accumulation between these cells over a
period of 8 hrs (Figure 5.9c), suggesting that perturbation of GATA2 expression does not
significantly affect the rate of cholesterol accumulation in macrophages. We also measured
the rate of cholesterol efflux in wild type, GATA2 overexpressing and GATA2 knockdown
THP-1 macrophages cultured normally or in the presence of human oxLDL. GATA2
overexpression significantly increased the rate of cholesterol efflux, suggesting that
GATA2 expression may be an adaptive response to elevated cholesterol stress. However,
this enhanced efflux was not retained in the presence of oxLDL, and unexpectedly, GATA2
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knockdown had no effect on the efflux rate (Figures 5.9d and 5.9e). Regardless of the level
of GATA2 expression, neither enhanced or impaired cholesterol efflux was observed under
hyperlipidemic conditions, suggesting that the enhanced efflux of cholesterol observed in
GATA2-overexpressing cells is suppressed by the presence of oxLDL via a non-GATA2
pathway (Figure 5.9e).

5.3.6 oxLDL exposure and perturbation of GATA2 expression alters
macrophage phagocytic/efferocytic capacity and phagosome/
efferosome maturation
We went on to determine the effect of perturbing GATA2 expression on macrophage
efferocytic capacity and efferosome maturation. We first examined the impact of GATA2
overexpression and knockdown on the capacity of macrophages to internalize IgG-coated
beads (Figure 5.10a). GATA2 has previously been shown to regulate phagocytic activity
in rat macrophages in the context of Pneumocystis carinii infection, where GATA2
downregulation resulted in decreased macrophage phagocytic capacity.59 In contrast, in our
hands human macrophages overexpressing GATA2 demonstrated significant impairment
in their capacity to internalize the IgG-coated beads. This impairment was even more
pronounced if the GATA2 overexpressing macrophages were cultured in the presence of
oxLDL. Conversely, downregulation of GATA2 expression did not result in any significant
impairment of phagocytic capacity and was actually sufficient to rescue the impairment in
phagocytosis seen when wild type macrophages were cultured in the presence of oxLDL.
The same trend was observed when we examined the capacity of our macrophages to
efferocytose PS-coated beads (Figure 5.10b). Culturing wild type macrophages in the
presence of oxLDL resulted in a decrease in efferocytic capacity, which is consistent with
previously published literature.69,70 GATA2 overexpressing macrophages showed impaired
efferocytotic capacity, regardless of whether they were cultured in the presence of oxLDL.
While GATA2 overexpressing macrophages cultured with oxLDL showed slightly
decreased efferocytic capacity compared to those cultured under normal conditions, this
was not statistically significant. Interestingly, as with phagocytosis, GATA2 knockdown
did not impair efferocytosis in macrophages cultured under normal conditions and restored
efferocytic capacity in macrophages cultured in the presence of oxLDL. The same
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observations held true when we used apoptotic Jurkat cells in place of PS-coated beads and
quantified the fraction of individual apoptotic cells internalized by macrophages (Figure
5.10c). Efferocytosis of apoptotic cells was markedly reduced both when wild type
macrophages were cultured in the presence of oxLDL and by GATA2 overexpression
independently of oxLDL levels. Again, no impairment in efferocytosis was observed in
GATA2 knockdown macrophages and critically, GATA2 knockdown protected
macrophages against the oxLDL-induced loss of apoptotic cell efferocytosis.

Figure 5.10 GATA2 overexpression impairs macrophage phagocytic and efferocytic
capacity.
Phagocytic and efferocytic capacity in THP-1 macrophages with perturbed GATA2
expression grown under normal (Control) or in the presence of human oxLDL (oxLDL)
was assessed by phagocytosis and efferocytosis assays using a variety of bead-based
phagocytic/efferocytic mimics and apoptotic cells. (a) Phagocytic index of THP-1
macrophages incubated for 30 min with IgG-coated 5-µm polystyrene beads was assessed
by fluorescence microscopy. (b) Efferocytic index of THP-1 macrophages incubated for
60 min with PS-coated 3-µm silica beads was assessed by fluorescence microscopy. (c)
THP-1 macrophages were co-incubated with fluorescently-labelled apoptotic Jurkat cells
for 90 min and the fraction of apoptotic materials internalized by macrophages was
assessed by microscopy. WT = wild type THP-1 cells, GATA = GATA2 overexpressing
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THP-1 cells, shRNA = GATA2 knockdown THP-1 cells. Data quantifies a minimum of N
= 3 biological replicates. Data are shown as mean ± SEM. #p < 0.05 compared to the WT
+ Control condition and *p < 0.05 compared to Control condition in the same cell line by
2-way ANOVA with Tukey’s post-hoc test.
In addition to efferocytic uptake, proper maturation of the efferosome is equally important
for proper processing of apoptotic cells, the avoidance of self-antigen presentation, and the
generation of autoimmunity.71 Therefore, beyond simply assessing efferocytic capacity, we
also sought to assess efferosome maturation in THP-1 macrophages with perturbed
GATA2 expression. There are multiple mechanisms involved in proper efferosome
maturation, including generation of superoxides within the efferosome through the action
of NADPH oxidase, efferosome acidification driving by vacuolar ATPases and fusion
between efferosomes and lysosomes (reviewed in detail in Chapter 5.1.3).
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Figure 5.11 GATA2 overexpression impairs macrophage efferosome maturation.
Efferosome maturation in THP-1 macrophages with perturbed GATA2 expression grown
under normal (Control) or in the presence of human oxLDL (oxLDL) was assessed using
a number of functional assays. (a, b) Nitro blue tetrazolium assay was used to measure
NADPH oxidase activity in THP-1 macrophages. Fluorescence intensity of diformazan
deposits was quantified as a measure of superoxide production. (c, d) Macrophages were
pulsed with tetramethylrhodamine-conjugated dextran to label cellular lysosomal
compartments and then allowed to internalize IgG-coated beads. Phagolysosomal fusion
was monitored by fluorescence microscopy as internalized beads that have accumulated
dextran. (e, f) Phagocytosis assays with pHrodo- and IgG-coated beads were imaged using
live cell fluorescence microscopy over a period of 60 min at 1 frame/min to determine
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terminal phagosome pH and phagosomal acidification rate for the first five minutes postcomplete phagosomal closure respectively. WT = wild type THP-1 cells, GATA = GATA2
overexpressing THP-1 cells, shRNA = GATA2 knockdown THP-1 cells. Images are
representative of (a, c) N =3 biological replicates. Graphs quantify N = 3 biological
replicates (d-f) or 30 individual cells across N = 3 biological replicates (b). White arrows
indicate beads that have been internalized (c). Data are shown as mean ± SEM. #p < 0.05
compared to the WT + Control condition and *p < 0.05 compared to Control condition in
the same cell line by 2-way ANOVA with Tukey’s post-hoc test. Scale bar = 10 µm.
To assess NADPH oxidase activity, we allowed macrophages to efferocytose apoptotic
Jurkat cells in the presence of nitro blue tetrazolium, which reacts with superoxide radicals
to form a fluorescent diformazan precipitate (Figure 5.11a and 5.11b). Macrophages
cultured in the presence of oxLDL show reduced NADPH activity, as do GATA2
overexpressing macrophages, even in the absence of oxLDL. GATA2 knockdown does not
significantly alter NADPH activity, however, in contrast to what was observed with
phagocytic and efferocytic capacity, GATA2 knockdown does not completely rescue the
defect in superoxide production in macrophages cultured with oxLDL.
To assess whether phagolysosomal fusion would also be impaired in our model system, we
performed a pulse-chase experiment with fluorescently-labelled dextran to assess fusion
between lysosomes and phagosomes containing IgG-coated beads (Figures 5.11c and
5.11d). Consistent with the previous observations, we noted a slight but statistically
significant decrease in phagolysosomal fusion in macrophages cultured with oxLDL and
in GATA2 overexpressing macrophages. In contrast, GATA2 knockdown macrophages
did not display any impairment in phagolysosomal fusion and indeed, GATA2 knockdown
was sufficient to prevent impaired phagolysosomal fusion in macrophages cultured with
oxLDL.
We assessed vacuolar ATPase activity by first assessing the terminal pH of maturing IgG
phagosomes (Figure 5.11e) following internalization of IgG- and pHrodo-coated beads (as
efferosome and phagosome acidification are thought to be driven by the same
mechanisms). We observed both a failure to reach an appropriate terminal phagosome pH
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in macrophages cultured with oxLDL. The same held true for GATA2 overexpressing
macrophages, regardless of whether or not they were cultured in the presence or absence
of oxLDL, and again, these impairments were rescued in GATA2 knockdown
macrophages.
Since lysosome fusion was impaired (Figure 5.11d), it is possible this lack of phagosome
acidification was due to poor lysosome fusion rather than decreased vATPase expression.
To assess this possibility, we quantified the rate of acidification in the first five minutes
following phagosome closure, which is prior to the time of phagosome-lysosome fusion.72
The same trends were observed in the early acidification rate as were observed with
phagosome terminal pH, confirming that oxLDL-driven GATA2 overexpression impairs
phagosome acidification, at least in part, through decreased expression of the vATPase
(Figure 5.11f).

5.3.7 oxLDL exposure but not perturbation of GATA2 expression alters
peptide citrullination in macrophages
Amongst the genes found to be upregulated in patient macrophages in our microarray
dataset was PADI3, a member of the peptide arginine deaminase (PAD) family of enzymes
that catalyze peptide citrullination and which play a central role in the pathogenesis of
rheumatoid arthritis.67,73 There is a well-established connection between rheumatoid
arthritis and increased cardiovascular disease risk, with aberrant presentation of selfantigen within the atherosclerotic plaque being a potential driver of autoimmune
disease.74,75 We therefore sought to assess whether peptide citrullination was occurring
with the atherosclerotic lesions in our patient aortic punch tissue samples and whether
GATA2 drives increased peptide citrullination in the context of atherosclerotic disease.
IHC staining of sectioned patient aortic punch tissue with an AMC antibody demonstrated
evidence of peptide citrullination specifically within the aortic intima (Figure 5.12a).
Experimental evidence shows that macrophages (and monocytes) in patients with
rheumatoid arthritis express increased levels of PAD enzymes.76 We therefore examined
PADI3 gene expression levels in both patient and control macrophages and PADI3 levels
were found to be significantly increased in patient macrophages (Figure 5.12b). As we
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have previously demonstrated, oxLDL is a crucial environmental ligand that induces
macrophages to become impaired in efferocytic uptake and efferosome maturation. Here,
we show that THP-1 macrophages cultured in the presence of oxLDL also showed
increased expression of PADI3 as compared to macrophages cultured under control
conditions (Figure 5.12c). Indeed, we could further demonstrate the exposure of THP-1
macrophages to oxLDL resulted in the generation of citrullinated peptides in vitro (Figure
5.12d).
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Figure 5.12 oxLDL exposure but not GATA2 expression drives PADI3 expression and
peptide citrullination in atherosclerotic macrophages. (on opposite page)
The degree of peptide citrullination and PADI3 enzyme expression was assessed in both
patient aortic punch tissues and atherosclerotic THP-1 macrophages. (a) FFPE patient
aortic punch tissue sections were immunostained for modified citrulline with an AMC
antibody (AMC) or an IgG isotype (IgG) as a negative control; AMC = anti-modified
citrulline. (b, c) Quantification of PADI3 expression by RT-qPCR in patient and control
macrophages (b) and THP-1 macrophages cultured under normal (Control) and
hyperlipidemic (oxLDL) conditions (c). (d) Immunofluorescence staining of THP-1
macrophages cultured for 72 hrs in the presence (oxLDL) or absence (Control) of human
oxLDL with an AMC antibody (AMC) or an IgG isotype (IgG) as a negative control.
Individual cells are labelled using a AF647-conjugated wheat germ agglutinin (WGA). (e
– g) Immunofluorescence staining of wild type THP-1 macrophages (e), GATA2
overexpressing THP-1 macrophages (f) and GATA2 knockdown THP-1 macrophages (f)
cultured under either normal (Control) or hyperlipidemic (oxLDL) conditions using an
AMC antibody (AMC) or IgG isotype (IgG) as a negative control. Images are
representative of either N = 3 individual patients (a) or N = 3 biological replicates (d).
Graphs are representative of N = 5 individual patients (b), N = 3 biological replicates (c)
or 30 cells across N = 3 biological replicates (e – g). Data are shown as mean ± SEM. *p <
0.05 by unpaired, two-tailed Student’s t test (b, c), ***p < 0.001 and ****p < 0.0001 by 1way ANOVA with Tukey’s post-hoc test (e – g). Black arrows indicate the vessel intima.
Scale bars = 100 µm (a) or 10 µm (d).
We then sought to determine the role of perturbed GATA2 expression on oxLDL-induced
peptide citrullination in THP-1 macrophages. The degree of peptide citrullination as
quantified by immunofluorescence staining of macrophages with the AMC antibody was
assessed in wild type THP-1 macrophages (Figure 5.12e), GATA2 overexpressing THP-1
macrophages (Figure 5.12f) and GATA2 knockdown macrophages (Figure 5.12g). In
each case, we found that little to no peptide citrullination occurred in the absence of oxLDL
regardless of the GATA2 expression level, whereas for cells cultured with oxLDL peptide
citrullination was observed at comparable levels regardless of GATA2 expression.
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5.3.8 GATA2 overexpression is driven by signaling through ERK and
the Src family kinases
We next sought to determine the upstream signaling pathways that contribute to GATA2
upregulation in response to stimulation with oxLDL. There are a number of canonical
oxLDL receptors that are expressed on the cell surface of human macrophages, including
members of the class A and B scavenger receptors (in particular CD36) and TLR4. CD36
and TLR4 are able to activate a number of distinct downstream signal transduction
pathways.13 Wu et al. have shown that stimulation of TLR4 by LPS drives GATA2
upregulation in a MEK/ERK-dependent pathway.32 This pathway may be specifically
inhibited using the small molecule inhibitor U0126.77 Heit et al. have demonstrated that
CD36 internalizes ligands through engagement with Src-family kinases (SFK’s) and Syk.78
The small molecule inhibitors protein phosphatase 1 (PP1) and Syk inhibitor (SykI) are
small molecule inhibitors of SFK’s and Syk respectively.78,79
Using these small molecule inhibitors, we inhibited in turn the activity of SFK’s (Figure
5.13a), MEK/ERK (Figure 5.13b) and Syk (Figure 5.13c) in THP-1 macrophages cultured
with human oxLDL for 72 hrs. Compared to a DMSO-treated control, macrophages treated
with PP1 or SykI exhibited significantly impaired GATA2 upregulation in response to
oxLDL stimulation. Treatment with U0126 had no effect on GATA2 upregulation.
Downstream of these signaling pathways, we did not determine experimentally which
transcription factor(s) are involved in oxLDL-driven GATA2 upregulation. However,
previous studies have suggested that SP1 is important in driving GATA2 expression. SP1
is phosphorylated downstream of the c-Src/Syk signaling pathway following ligand
engagement by CD36.80,81 Therefore, SP1 is a likely candidate for activating GATA2
transcription in response to oxLDL-driven signaling through the c-Src/Syk pathway
downstream of CD36 (Figure 5.13e).
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Figure 5.13 oxLDL-induced GATA2 upregulation requires signaling through the Src
pathway.
THP-1 macrophages were cultured in the presence of oxLDL for 72 hrs with 200 nM PP1
(a), 2 nM U0126 (b) or 10 µM SykI (c). GATA2 expression in these cells were compared
to THP-1 macrophages cultured for 72 hrs with oxLDL and a DMSO vehicle control (Veh).
(d) Schematic of oxLDL-induced GATA2 upregulation in human macrophages. Data are
shown as mean ± SEM and quantify N = 3 biological replicates. *p < 0.05 by unpaired,
two-tailed Student’s t test.
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5.3.9 GATA2 trends toward being elevated in Ldlr-/- mice fed a high-fat
diet
Finally, we examined Gata2 expression levels in the aorta of Ldlr-/- mice fed high-fat, highcholesterol (HFHC) or standard chow diet for 12 weeks by RT-qPCR (Figure 5.14). The
expression of Gata2 was consistently low in the plaques of Ldlr-/- mice fed a normal diet,
but underwent a highly heterogeneous response in response to a high-fat diet. These data
suggest that GATA2 may be upregulated in Ldlr-/- mice in response to a high-fat diet, but
this protocol requires further refinement before conclusive data can be generated.

Figure 5.14 Gata2 expression trends towards being increased in high-fat diet
atherosclerotic mice.
Ldlr-/- knockout mice were maintained for 12 weeks on a chow (CHOW) or high-fat (HDF)
diet. At 12 weeks, mice were sacrificed, and their aortas dissected for use in RT-qPCR
studies that measured Gata2 expression. Data summarize N = 3 mice in each group and are
presented as mean ± SEM. The difference in Gata2 expression was found to not be
statistically significant by a two-tailed, unpaired Student’s t test.
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5.4 Discussion
In this Chapter, we examined the impact of perturbing GATA2 expression on macrophage
cholesterol handling, peptide citrullination and efferocytosis/efferosome maturation using
an in vitro model of atherosclerotic macrophages. We found that GATA2 overexpression
was sufficient to impair macrophage efferocytotic uptake and efferosome maturation, even
in the absence of pro-atherogenic stimuli. Importantly, knockdown of GATA2 expression
using an shRNA normalized efferocytosis and efferosome maturation when macrophages
were exposed to oxLDL. Taken together, these data indicate that GATA2 acts as a master
regulatory factor that appears to be required for oxLDL-mediated impairment of
macrophage efferocytic uptake and efferosome maturation. However, we did not find any
effect of GATA2 perturbation on either cholesterol handling nor peptide citrullination,
suggesting that the effect of GATA2 is specific to macrophage apoptotic uptake and
degradation.
Our most interesting finding is the impact of perturbing GATA2 expression on efferocytic
uptake of apoptotic cells and on subsequent efferosome maturation and processing of
apoptotic cargo. We are able to replicate the finding that macrophage efferocytosis is
impaired following exposure to oxLDL, but our data show that this effect appears to be
dependent on the upregulation of GATA2 in response to this atherogenic stimulus. Indeed,
we find that when GATA2 expression is abrogated using a shRNA, macrophages retain
full efferocytic capacity. To date, mechanisms underlying impaired macrophage
efferocytic capacity in atherosclerosis remain poorly defined. Cai et al. showed that
ADAM17-mediated cleavage of a key efferocytic receptor, MerTK, results in increased
plaque necrotic core size in Ldlr-/- mice.82 Our finding that oxLDL-mediated GATA2
upregulation leads to impaired efferocytic capacity may represent an alternate mechanism
driving defective efferocytosis in atherosclerotic plaques. Importantly, we have also found
that perturbation of GATA2 expression had profound impacts on efferosome maturation in
addition to efferocytic capacity. Our data show that GATA2 upregulation drives
impairment in efferosomal NADPH oxidase activity and superoxide generation,
efferosomal acidification and potentially interferes with efficient efferosome-lysosome
fusion. Efficient efferosomal maturation and processing of cargo is essential for
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macrophages in maintaining a rapid rate of efferocytosis, and impaired efferosomal
maturation may partially explain how efferocytosis becomes defective in the course of
atherosclerotic disease. Impaired apoptotic cargo degradation may also result in the
generation of inflammation and autoimmunity. A number of investigators have identified
rapid cargo degradation as a key mechanism in limiting antigen presentation. For example,
Erwig et al. found that efferosomal maturation following apoptotic cell uptake by
macrophages proceeded much faster than following uptake of IgG-coated pathogen
mimics, while Yates et al. observed decreased phagosome degradative capacity following
macrophage activation.83,84 Impaired efferosomal maturation, in addition to interfering
with efficient apoptotic cell clearance, may also be a potential mechanism driving
autoantigen presentation and autoimmunity in atherosclerosis.
Another fascinating observation from our microarray dataset was the upregulation of the
PADI3 enzyme in patient macrophages. Here, we demonstrate through IHC that peptide
citrullination is present within the early atherosclerotic plaque. This is in agreement with
the findings of Sokolove et al., who identified the presence of citrullinated fibrinogen
within human atherosclerotic plaques by Western blot.85 While Sokolove et al. suggested
that intra-plaque citrullination is driven by PADI4,85 our data implicates PADI3 as another
player in this process. We demonstrated by RT-qPCR that PADI3 expression is upregulated
within both atherosclerotic lesion-resident macrophages and in macrophages treated in
vitro with oxLDL. While we did not find strong evidence that GATA2 affects the
expression of PADI3 or the degree of peptide citrullination that occurs in atherosclerotic
macrophages, exposure of macrophages to oxLDL is sufficient to induce citrullination in
vitro regardless of the level of GATA2 expression. Increased risk of cardiovascular disease
in patients with rheumatoid arthritis has been well established, thought to be the result of
elevated inflammation in these patients.75,86 However, there is some evidence that the
relationship is a reciprocal one, with atherosclerosis driving the genesis and/or progression
of rheumatoid arthritis and other forms of autoimmune disease.87,88 Autoantibodies against
oxLDL, HSP60 and ApoB100 (the major lipoprotein component of LDL) have been
identified in patients with atherosclerosis.87 Furthermore, various T cell subsets have been
isolated from human atherosclerotic plaques, with Th1 cells being the predominant type.88
Whether these lesion-resident T cells also recognize and respond to the presence of
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citrullinated peptides remains to be shown, but such a mechanism would help explain the
high degree of coincidence between rheumatoid arthritis and atherosclerosis.
There is some evidence that GATA2 could be involved in regulation of cholesterol
handling in macrophages. Cheng et al. showed that leptin-mediated activation of GATA2
expression and DNA binding resulted in the downregulation of the transcription factor
PPARγ.89 PPARγ plays a number of important roles in the context of atherosclerosis. First,
it is a major driver of anti-inflammatory activation and PPARγ agonists have been shown
to demonstrate some protective effects in animal models of atherosclerosis through
restraining inflammation within the atherosclerotic plaque.90,91 Simultaneously, Lee et al.
have demonstrated that activation of PPARγ results in upregulation of ABCA1 and
increases the rate of cellular cholesterol efflux.92 However, our data indicate that while
GATA2 expression does enhance cholesterol efflux, this effect is lost in the presence of
oxLDL and therefore cannot serve a protective function in the context of atherosclerosis.
This could be a result of the potent activation of multiple pathways related to cholesterol
metabolism as a result of oxLDL exposure that are antagonistic to either GATA2
expression or function. These results are interesting, however, in that they suggest that
GATA2 may be upregulated by macrophages in order to adapt to cellular stress, and that
the negative impacts on phagocytosis and efferocytosis are an unwanted side-effect of this
adaptive process. However, further work remains to be done in dissecting out the specific
role of GATA2 in cholesterol handling during atherogenesis in order to fully explore this
possibility.
We have begun to define the signaling pathways upstream of oxLDL-induced GATA2
upregulation. Inhibition of either Src family kinases or Syk results in decreased levels of
GATA2 expression in response to oxLDL. Src and Syk are recruited downstream of ligand
engagement by CD36, a class B scavenger receptor that plays a crucial role in recognition
and internalization of oxLDL in macrophages.78,93 CD36 is activated as a multi-unit
complex along with β1 and β2 integrins along with CD9 and CD81. This complex
phosphorylates the signaling adaptor FcRγ, which, via its phosphorylated ITAM motifs
and active SFKs, is capable of recruiting and activating Syk.78 While less well understood,
the Toll-like receptors TLR2 and TLR4 are also known to be activated by oxLDL, and to
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activate a similar Src/Syk pathway. The downstream targets of Src and Syk in the context
of CD36 and TLR activation are poorly understood. However, a few recent studies of novel
therapeutic agents in leukemia have shed light on one potential regulatory pathway that can
drive GATA2 activation.94,95 Yang et al. have shown that inhibition of GATA2 by the
proteasome inhibitor K-7174 results in sensitization of acute myeloid leukemia cells to
chemotherapy.94 K-7174 is known to exert its activity on GATA2 via degradation of the
transcription factor Sp1, which functions as a transactivator of class I histone deacetylases
and promotes transcriptional activation of GATA2.95 Sp1 may be activated by Src family
kinases or PI3K downstream of Syk signaling.80,96 Therefore, we propose a model whereby
activation of CD36 by oxLDL results in Src and Syk signaling, which activates Sp1 and
drives transcriptional activation and upregulation of GATA2. Whether Sp1 is able to
directly bind upstream of GATA2 and drive transcription or if it functions through its
chromosomal remodeling activity to allow other transcription factors to cooperatively drive
GATA2 expression remains to be determined.
To study the impact of GATA2 on efferocytosis, peptide citrullination and cholesterol
handling, we established an in vitro cell culture model of atherosclerotic macrophages by
incubating THP-1 cells with human oxLDL. We show that after 72 hrs of culture in the
presence of oxLDL, THP-1 macrophages adopt a distinctive foam cell-like appearance,
which is accompanied by upregulation of GATA2 expression. Culture of macrophages
with oxLDL or another modified LDL is a well-established method of generating foam
cells in vitro.10 While the precise type and concentration of lipoprotein as well as the culture
time varies between different investigators, multiple groups have shown that oxLDLtreated macrophages accumulate cholesterol and form lipid droplets in their
cytoplasm.14,97,98 Cholesterol loading of macrophage also induces production of
proinflammatory cytokines, including TNFα, IL-6 and IL-1β, as well as ER stress and the
unfolded protein response.16,99 While we did not examine generation of proinflammatory
cytokines and our in vitro system is certainly an oversimplification of the actual
atherosclerotic plaque microenvironment, we were able to observe significant cholesterol
accumulation and lipid droplet formation in our THP-1 macrophages. However, we are the
first to report upregulation of GATA2 in response to cholesterol accumulation in both THP1 macrophage-like cells and primary monocyte-derived human macrophages. This
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suggests that within the atherosclerotic plaque microenvironment, endogenous modified
lipoproteins such as oxLDL are sufficient to induce GATA2 upregulation.
In summary, we have identified the hematopoietic transcription factor GATA2 as a master
regulator of defective efferocytosis in atherosclerotic macrophages. GATA2 upregulation
impairs both the efferocytic uptake of apoptotic cells and multiple stages of the subsequent
catabolic process which degrades the efferosomal cargo. This impairment in efferosomal
maturation represents a previously unrecognized mechanism that not only drives defective
apoptotic cell clearance in atherosclerosis but may also contribute to autoantigen
presentation and the generation of inflammation and autoimmunity within the
atherosclerotic plaque. Therefore, GATA2 could prove to be an important therapeutic
target for enhancing efferocytosis within the atherosclerotic plaque, promoting
inflammation resolution, and limiting the development of the necrotic core of the plaque
to reduce plaque vulnerability in the setting of advanced atherosclerotic disease. In the
aftermath of the CANTOS trial demonstrating a role for therapies targeting the
inflammatory component of atherosclerotic disease,100 targeting inflammation through
improving efferocytosis within the plaque could hold the potential to address the unmet
residual inflammatory risk of atherosclerotic disease.
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Chapter 6

6

Summary, Discussion and Future Directions

6.1 Summary of major findings
The clearance of apoptotic cells by efferocytosis is an essential mechanism of limiting
inflammation and maintaining tissue homeostasis.1 In contrast to the phagocytosis and
clearance of pathogens, efferocytosis is immunologically silent and may promote the
generation of anti-inflammatory and pro-tolerogenic factors by professional efferocytes
such as macrophages.2,3 When efferocytosis becomes impaired, apoptotic cells are not
cleared and instead undergo secondary necrosis—resulting in the release of proinflammatory danger signals and self-antigens that are normally confined within the
cytoplasm of apoptotic bodies.4 In the context of atherosclerosis, efferocytic removal of
apoptotic cells and debris within the atherosclerotic plaque by lesion-infiltrating
macrophages is an important mechanism of limiting plaque growth and the development
of the necrotic core that is a pathological feature of late-stage disease.5,6 In this thesis, we
identified a Rab17-dependant vesicular trafficking pathway responsible for the
immunologically silent degradation of efferocytosed materials, and identified a GATA2driven transcriptional profile that drives efferocytic defects in early-stage atheroma
formation. This work provides new insights into the cellular mechanisms regulating
efferocytosis, and on how atherogenic conditions can drive defects in these processes.
In Chapter 3 of this thesis, we made use of an unbiased mass spectrometry approach to
identify proteins that differentially localize to the surface of efferosomes versus
phagosomes. Through this approach, we discovered several proteins that appeared to be
selectively recruited to the surface of the maturing efferosome. In particular, we identified
the small GTPase Rab17 as one of these efferosome-specific proteins. Rab GTPases act as
master regulators of intracellular trafficking, marking specific intracellular organelles and
compartments and recruiting effector molecules that mediate vesicular docking and fusion
in a highly-regulated fashion.7,8 We therefore examined whether Rab17 functioned as a
regulator of differentially cargo processing between efferosomes and phagosomes. First,
we saw that while Rab17 is transiently recruited to the surface of nascent phagosome and
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then quickly displaced, it is maintained on the surface of efferosomes throughout
efferosome maturation. Following fusion with lysosomes, the efferosome undergoes a
fission process, generating several smaller EDVs. Rab17-labelled EDVs subsequently
migrate to the cell periphery and fuse with the recycling endosome, presumably resulting
in exocytosis or recycling of degraded efferosomal cargo. Knockdown of Rab17 activity
using a dominant negative mutant disrupted this process. Efferosomes did not undergo
fission to the same degree but instead remained sequestered within the perinuclear region
of the cell, where they acquired MHC class II molecules and presumably matured into
MHC class II loading compartments. We therefore concluded that Rab17 is a central
regulator of immunologically silent efferosome maturation and is required to direct
efferosomal cargo to the recycling endosome in order to avoid the loading of apoptotic cellderived self-antigens onto MHC class II.
The onset of defective macrophage efferocytosis greatly accelerates plaque growth and the
development of large necrotic cores that are characteristic of unstable plaques.9,10 In
Chapter 4, we sought to perform gene expression profiling of lesion-resident macrophages
isolated from human atherosclerotic plaques to better characterize the molecule
mechanisms that drive the development of defective efferocytosis. We obtained tissue
samples from the ascending aorta of patients undergoing coronary artery bypass graft
surgery. Plaques identified in these tissue samples we found to have the histological
features of pre-atherosclerotic lesions. Macrophages from these early-stage lesions were
selectively isolated by laser capture microdissection using the scavenger receptor CD163
as a macrophage-specific marker. Purified patient macrophages were compared to in vitro
differentiated peripheral monocyte-derived macrophages from healthy individuals used as
controls by microarray. This revealed dramatic dysregulation in patient macrophage gene
expression, with approximately 3,000 protein-coding transcripts found to be differentially
expressed in these cells. Significantly, these genes clustered in pathways involved in
cellular lipid metabolism, cell stress responses, and intracellular trafficking. Gene set
enrichment analysis revealed specific defects in cholesterol handling, efferocytosis and
efferosome maturation. Of note, we identified three non-cell cycle transcription factors
genes to be significantly upregulated in patient macrophages: RARG, GATA2 and E4F1.
Amongst these, only GATA2 was previously associated with cardiovascular disease, is not
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normally expressed by mature myeloid cells, and is a known regulator of myeloid cell
development.11–13 We confirmed that GATA2 was upregulated nearly 50-fold in patient
macrophages by RT-qPCR. Together, these results suggest that lesion-resident
macrophages in early-stage human plaques possess a distinctive and previous
unappreciated phenotype characterized by impaired cholesterol handling and efferosome
maturation that may be driven by aberrant GATA2 expression.
As we had identified the hematopoietic transcription factor GATA2 as being significantly
upregulated in patient macrophages, we proceeded to determine in Chapter 5 whether
GATA2 was a master regulator of the unique macrophage phenotype we had previously
described. We confirmed that GATA2 was present in a significant proportion of CD68+
foam cells within patient aortic intima and that in vitro exposure of macrophages to the
pro-atherogenic molecule oxLDL resulted in GATA2 upregulation. Using stable GATA2overexpressing and -knockdown THP-1 macrophage cell lines we performed a number of
functional assays to assess the impact of perturbing GATA2 function on a variety of
macrophage functions, including efferocytosis and efferosome maturation. As expected,
both exposure to oxLDL and GATA2 overexpression independently resulted in markedly
impaired macrophage efferocytosis and efferosome maturation, but neither GATA2
overexpression or depletion had any effect on cholesterol influx or efflux. Critically,
shRNA-mediated knockdown of GATA2 expression was sufficient to prevent impaired
efferocytic uptake and efferosome maturation in macrophages cultured in the presence of
oxLDL, with GATA2 upregulation by oxLDL dependent on signaling pathways known to
be downstream of oxLDL signaling. Therefore, we concluded that GATA2 is a novel
transcription factor induced by exposure to modified lipoproteins, that is involved in the
pathogenesis of atherosclerosis through driving impaired apoptotic cell uptake and
degradation. GATA2 upregulation in response to oxLDL exposure drives both impaired
efferocytic internalization of apoptotic cells and the efficient degradation of apoptotic
cargo through efferosome maturation.
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6.2 Discussion
6.2.1 A novel mechanism of apoptotic cargo sorting following
efferocytosis
Despite the critical role of efferocytosis in restraining pathologic inflammation and
autoimmunity, there are many open questions on how professional efferocytes like
macrophages recognize and internalize apoptotic cells, and how these efferocytes then
process the apoptotic cargo to avoid an inflammatory response and self-antigen
presentation.4,14 We are beginning to develop a comprehensive understanding of the first
question, with researchers uncovering a host of apoptotic cell-derived signals and
corresponding efferocyte receptors that mediate the localization, recognition and
internalization of apoptotic cells by professional efferocytes.15 However, comparatively
less is known about how efferocytes then process efferosomal cargo following
internalization of the apoptotic cell. Much of what is currently known about the process of
efferosomal maturation has been inferred from studies on the maturation of
phagosome.8,16,17 Although these processes undoubtedly share many similarities,
degradation of pathogens within the phagosome ultimately leads to antigen presentation
and activation of an adaptive immune response.18 However, the same is not true of
efferocytosis and the molecular mechanisms that distinguish the ultimate fate of
phagosomal versus efferosomal cargo remain largely unknown.
Some previous studies have suggested that signaling from pattern recognition receptors
such as TLRs on the surface of phagosomes is responsible for discrimination between selfand non-self-antigens.19 Blander & Medzhitov describe a “phagosome-autonomous”
model whereby phagosomes containing TLR ligands undergo rapid maturation in order to
generate the hydrolytic environment necessary to successfully process the MHC class IIassociated invariant chain (Ii).20,21 Processing of Ii is required for generation of the class
II-associated invariant chain-associated peptide (CLIP) and proper binding of antigenic
peptides to MHC class II.22 Under this framework, efferosomes containing apoptotic cells
undergo terminal cargo degradation without creating the conditions necessary for antigenic
loading of MHC class II.20 However, these findings have been called into questions by
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Yates & Russell, who found that phagosome maturation proceeds at similar rates regardless
of whether TLR2 or TLR4 ligands were present.23
In this thesis, we have described a novel mechanism of sorting apoptotic versus pathogenderived cargo following internalization. In macrophages, we found that Rab17 is recruited
to the surface of nascent efferosomes and directs apoptotic cargo away from the MHC class
II loading compartment and towards the recycling endosome. Rab17+ efferosomes undergo
fission to form EDVs, which traffic to the cell periphery in process which is likely
dependent on the activity of kinesins. Importantly, when Rab17 function is disrupted,
apoptotic cargo is instead directed to the MHC class II loading compartment, presumably
without any TLR signaling from the efferosome. Whether TLR signaling from phagosomes
prevents Rab17 recruitment or actively removes Rab17 from the surface of pathogencontaining phagosomes remains to be seen, but our findings suggest that it is the presence
of Rab17 that prevents efferosomes from maturing into MHC class II loading
compartments and present apoptotic cell-derived self-antigens.

6.2.2 Defects in macrophage function develop early in atherosclerotic
disease
Altered macrophage function in atherosclerosis has been well-documented.24,25 Within the
plaque microenvironment, macrophages are exposed to hypercholesterolemic conditions
that reprogram their behaviour.26 Uptake of cholesterol by macrophages has several
important consequences. The accumulation of free cholesterol in the cytoplasm can
activate the unfolded protein response and drive the production of pro-inflammatory
cytokines, including IL-1β, TNFα and IL-6.27,28 Exposure to pro-inflammatory cytokines
polarizes lesion-resident macrophages to a M1-like phenotype, which drives the further
production of cytokines and a decrease in efferocytic capacity.29 Excess cholesterol is also
thought to inhibit the ability of macrophages to efficiently clear apoptotic cells, although
the mechanisms that underlie this phenomenon remain unclear.30
While the ontology of human aortic and cardiac macrophages are not as well understood,
macrophages with markers of M1-polarization (iNOS, CD86), M2-polarization (MR,
dectin-1), and TREM2+-polarization (TREM2, CD9hi) have been identified in human
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plaque31,32. Later in disease other macrophage sub-types may emerge. For example,
intraplaque hemorrhage gives rise to atheroprotective HA-mac and Mhem macrophages in
mice, which scavenge hemoglobin and are resistant to oxidative stress33,34. While multiple
macrophage polarization states have been identified in mouse models and in human
atheroma samples, very little is known of the transcription factors or the tissue- and
environment-specific cues which regulate their transcriptional programs. One of the best
characterized atheroma-resident macrophage populations is the Mox sub-type, which in
mice accounts for 30% of atheroma-resident macrophages35. Mox cells are characterized
by a transcriptional profile mediated by the transcription factor Nrf2 which, when knocked
out, delays atheroma formation36. Nrf2 upregulates several genes not normally expressed
in M1 or M2 polarized cells, including genes for processing heme, angiogenic factors, and
anti-oxidant mechanisms35.
In general, it has previously been thought that defects in apoptotic cell clearance only
occurs in advanced atherosclerotic plaques.4,10 Indeed, the accumulation of uncleared
apoptotic cells is a marker of late-stage disease and forced induction of macrophage
apoptosis during early stages of disease actually slows progression and promotes plaque
stabilization, at least in murine models of atherosclerosis.37,38 In human studies,
accumulation of TUNEL+ secondary necrotic cells have been documented in carotid plaque
samples obtained from endarterectomy.37 This stands in contrast to tissues where there is a
high rate of cell turnover but efferocytic capacity remains preserved, such as the tonsils. In
these tissues, TUNEL+ cells are almost undetectable.37 However, the carotid samples
commonly used in human atherosclerosis studies consist almost exclusively of late-stage
plaques where uncleared apoptotic and secondarily necrotic cells are known to accumulate.
To date, there have been very few studies that have studied early-stage atherosclerotic
plaques in humans.39,40 Furthermore, to the best of our knowledge none of these studies
have examined apoptotic cell clearance or macrophage function. Although animal studies
of plaque progression including early-stage plaque have been more comprehensive, studies
that have shown a benefit of macrophage apoptosis early in atherosclerosis have used
knockout mice lacking proteins involved in the intrinsic apoptotic pathways (Bax and
Bcl2).41 Deletion of these critical proteins may have resulted in off target effects that
complicates the interpretation of the experimental results.
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In our study, we studied primarily early-stage human atherosclerotic plaques as a result of
our use of aortic punch samples, which typically are excised from regions of the aorta that
have a comparatively lower degree of plaque burden. Although initially somewhat
discouraging, this strategy ultimately provided us with the rare opportunity to study earlystage human atherosclerosis lesions. Consistent with previous reports, we observed diffuse
intimal thickening along with sub-intimal lipid accumulation along with macrophage
accumulation in our patient samples.40 Surprisingly, we found that even in an early stage
of disease, macrophage gene expression was severely dysregulated in lesion-resident
macrophages. Genes involved in cellular cholesterol efflux, efferocytic uptake and
efferosome maturation were significantly downregulated in patient macrophages compared
to controls. However, despite the apparent downregulation of the core efferocytic
machinery in lesion-resident macrophages, we found very few necrotic TUNEL+ cells in
our patient tissue samples. One interpretation of these results is that the ability of
macrophages to clear apoptotic cells begins to decline early in atherosclerosis, but this
defect does not become severe enough for macrophage efferocytic capacity to be unable to
keep up with apoptotic cell turnover in the plaque until later on during disease progression.
These results could also mean that there is heterogeneity in macrophage function early in
atherosclerosis, with some macrophages developing impaired efferocytosis while others
remain fully functional. Unfortunately, our study was not designed to assess these
possibilities, but our data suggest that there is greater complexity in macrophage behaviour
in early atherosclerosis than has been previously appreciated.

6.2.3 Impaired efferosome maturation contributes to defective
efferocytosis in atherosclerosis
While defective efferocytic clearance of apoptotic cell is widely recognized as an important
driver of atherosclerotic disease progression through accelerating the growth of plaque
necrotic cores and increasing intra-lesion inflammation, how efferocytosis becomes
impaired in the context of atherosclerosis remains poorly understood.4 Several recent
studies have implicated decreased expression of key efferocytic receptors or their cleavage
from the macrophage cell surface within the inflammatory plaque microenvironment,
while other studies have shown that alleviation of “don’t eat me” signals in the plaque can
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delay disease progression.9,42,43 Other studies have found that excessive oxidation of
phosphatidylserine can actually inhibit CD36-mediated apoptotic cell clearance.44 A recent
seminal study from Cai et al. showed that ADAM17-mediated cleavage of the efferocytic
receptor MerTK leads to increased necrotic core size and plaque progression.9
Significantly, the authors of this study also demonstrated the presence of cleaved MerTK
in human carotid plaques, suggesting that this is a bona fide mechanism of impaired
efferocytosis in human atherosclerotic disease.9
Beyond the engagement between efferocytic receptor and target required for binding and
uptake of apoptotic cells, we now understand that efficient processing of internalized
apoptotic cargo is required to maintain efficient efferocytosis. Wang et al. have shown that
defects in Drp1, a protein involved in mitochondrial fission, leads to impaired apoptotic
cargo degradation and recycling.45 This in turn drove defective apoptotic cell clearance and
promoted the accumulation of necrotic cells in Drp1-/-/Ldlr-/- double-knockout mice.45
In this thesis, we uncovered evidence suggesting that macrophage efferosome maturation
and apoptotic cargo degradation are impaired in human atherosclerotic disease. We found
that several genes involved in efferosome maturation to be downregulated in patient
macrophages compared to controls. These included RAB7, which coordinates both
phagosome and efferosome maturation through regulating fusion with late endosome and
driving phagosome/efferosome fusion with lysosomes,46 and genes encoding the NADPH
oxidase and the vacuolar ATPase, both of which function to permit efficient degradation
of apoptotic cell cargo.8,47 We further determined that culturing macrophages in the
presence of a pro-atherogenic stimulus results in impairment of several key mechanisms
that are required for efficient apoptotic cargo degradation, including generation of
superoxides, efferosome acidification and efferolysosomal fusion. Therefore, our data
suggest that in addition to cleavage of efferocytic receptors, impaired efferosome
maturation in macrophages is an additional mechanism that drives defective efferocytosis
in human atherosclerotic disease.
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6.2.4 GATA2 is involved in driving macrophage dysfunction in
atherosclerosis
Our previous findings collectively support the conclusion that we have identified a
previously unappreciated macrophage phenotype that is unique to early-stage human
atherosclerosis. These macrophages are characterized by impaired cholesterol handling and
efferocytic capacity without demonstrating the features classically associated with M1-like
macrophages or other known atherosclerosis-associated subsets such as increased
production of proinflammatory cytokines.48,49 We sought to identify transcription factors
that were responsible for the induction of this phenotype. Only a few transcription factors
have been identified to be associated with atherosclerotic macrophages. These include the
PPARs, liver X receptor (LXR), retinoic acid receptor (RAR) and retinoid X receptor
(RXR).50–52 These receptors tend to be activated in respond to macrophage cholesterol
loading and function to modulate macrophage cholesterol metabolism and drive expression
of both proteins involved in cholesterol efflux such as ABCA1 and efferocytic receptors
such as CD36.53
In this thesis, we identified just three non-cell cycle transcription factors as being
upregulated in patient macrophages in our microarray dataset. Initially, we were excited to
see a member of the RAR family of transcription factors RARγ amongst these. However,
we could not confirm RARγ upregulation in an independent set of patient and control
macrophage samples. Therefore, we turned our focus to GATA2, a zinc finger transcription
factor best studied for its role in maintenance of the hematopoietic stem cell population
and in myeloid lineage specification during hematopoiesis.54 Interestingly, SNPs in
GATA2 have been implicated in previous genome-wide association studies to be involved
in coronary artery disease.11 We found that GATA2 overexpression in the absence of a proatherogenic trigger was sufficient to induce defects in efferocytotic uptake and in multiple
steps of efferosome maturation. Furthermore, knockdown of GATA2 could protect
macrophages against oxLDL-induced impairments in efferocytic uptake and efferosome
maturation. These data suggest that aberrant GATA2 expression drives efferocytic defects
in macrophages during the early stages of human atherosclerotic disease.
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Germline mutations in GATA2 in humans are exceedingly rare but when they do occur
result in a spectrum of diseases connected by aberrant development of the myeloid cell
lineage (macrophages and neutrophils) and a propensity for developing acute myeloid
leukemia (AML).55,56 Indeed, de novo mutations in GATA2 within the bone marrow have
been recognized as contributing to the development of AML.56 Recent work from Jaiswal
et al. demonstrated that mutations in genes that pre-dispose individuals to developing AML
also contributes to increased risk of atherosclerosis and coronary artery disease in a process
termed “clonal hematopoiesis of indeterminant potential” (CHIP).57 AML driver mutations
increase the rate of myeloid cell proliferation and accelerate the development of
atherosclerosis.58,59 In particular, work from Fuster et al. on the same phenomenon found
that in Ldlr-knockout mice lacking Tet2, an enzyme that regulates epigenetic modification
of DNA, atherosclerotic plaques were larger and lesion-resident macrophages produced
greater levels of IL-1β.58 Interestingly, GATA2 is recognized as another gene that is often
found to be mutated in AML.56,60 Although to date there have been no reported cases of
GATA2 mutations contributing to CHIP in humans, it is possible that de novo mutations
in GATA2 may increase the risk of coronary artery disease.

6.3 Limitations
6.3.1 Alteration in Rab17 expression or function in atherosclerotic
macrophages
Given the importance of Rab17 as a regulator of efferosomal maturation in macrophages,
and the broad array of maturation defects present in oxLDL-treated macrophages, we were
surprised to find that it was not differentially expressed in our patient macrophages.
Instead, impaired efferosome maturation in our patient atherosclerotic macrophages was
found to be mediated primarily through a downregulation of Rab7—which mediates
efferosome-lysosome fusion61—as well as efferosomal acidification, NADPH oxidase
activation, and efferolysosomal fusion. We did not initially examine Rab17 expression or
localization in our GATA2 overexpression and knockdown macrophage cell lines here
because its expression was not significantly altered in our microarray dataset. However,
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further investigation in this direction is warranted. Consequently, it is unclear at this point
whether Rab17 plays a role in macrophage dysfunction in atherosclerosis. While Rab17
expression may not be affected in atherosclerosis, its function or localization may well be.
Unfortunately, we do not currently have a clear picture of how Rab17 is recruited to the
surface of efferosomes, nor have we identified any potential downstream Rab17 effectors.
This makes studying Rab17 function in atherosclerotic macrophages challenging. Further
work is required in defining how Rab17 directs efferosomal cargo trafficking before we
will be able to unravel whether it plays a role in defective efferocytosis in atherosclerosis.

6.3.2 Sampling of patient atherosclerotic plaques
The choice to utilize aortic punch tissue as our source of atherosclerotic plaque presents
both advantages and drawbacks. Since plaque burden in the ascending aorta in humans is
relatively low and surgeons will select a region of the aorta that is macroscopically free
from plaque when performing the aortic punch biopsy, we were able to obtain early-stage
atherosclerotic plaque for our studies. Early stage plaque is understudied in the human
context because investigators to date have focused on the late-stage lesions that are readily
available from carotid endarterectomy procedures, while mouse studies into early plaque
are limited by the accelerated disease progression in these models.62,63 Moreover, while our
aortic biopsy samples contain plaque that is histologically classified as early plaque, this
material is recovered from patients with advanced disease. Consequently, while we propose
that this thesis has explored early-stage plaque, it is possible that some of the observed
gene expression patterns are a product of late-stage disease. Concordantly, we are in the
process of starting a new study to perform comparative gene expression studies of
monocytes and aortic plaque macrophages from the same patients, in order to trace the
ontology of the defects we have observed. Ideally, we would also liked to have accessed
advanced lesions in our original study as well. These plaques have been better studied and
are arguably more clinically-relevant to study because of they tend to be more vulnerable
and have an increased risk of rupture.64 Access to both early-stage and advanced plaque
from the same patient would have also offered us the possibility of comparing gene
expression changes between different stages of disease progression. Unfortunately,
limitations in current clinical practice (i.e. the same patient is unlikely to require both a
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CABG operation and a carotid endarterectomy within a reasonable timeframe) make it
difficult to access both early and advanced lesions from the same patient and precludes us
from doing these studies.

6.3.3 Utilization of CD163 as a macrophage-specific marker
The use of CD163 as our macrophage-specific marker is an undoubtedly controversial
choice. We selected this marker because the most commonly-utilized macrophage markers
in human studies, CD68, is abundantly expressed within the atherosclerotic plaque by
smooth muscle cells.66 In fact, recent studies suggest that more than half of the CD68+ cells
in atherosclerotic plaques are derived from smooth muscle cells rather than macrophages.67
CD163 is a hemoglobin/haptoglobin scavenger receptor that is typically thought of as a
marker of alternatively-activated M2-like macrophages.33,68 However, there is abundant
evidence that in humans CD163 expression is not restricted to M2 macrophages. CD163
expression has been detected in several populations in tissue-resident macrophages,
including Kupffer cells and splenic red pulp macrophages.68 Significantly, a study of 1,105
pathology specimens at Stanford University Medical Center found CD163 to be restricted
to cells of the monocyte/macrophage lineage, making it a highly specific marker of
macrophages.69 Furthermore, our own data showed that CD163 was detectable on the
surface of primary monocyte-derived macrophages in vitro regardless of whether these
macrophages were polarized to M0, M1 or M2 states (Figure 4.4a). We also observed that
CD163 was often co-expressed with CD68 expression in patient aortic intima (Figure
4.4b), suggesting that we were able to capture a majority of macrophages by CD163
staining. However, our approach did sacrifice sensitivity for specificity and it is unknown
whether this led to any bias in our microarray dataset. An alternative approach that could
be taken in future studies is to stain for CD45 along with CD68. CD45 expression is
restricted to leukocytes and therefore we can be reasonably certain that any CD68/CD45
double-positive cells within the plaque would be macrophages or macrophage-derived
foam cells.70
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6.3.4 Use of peripheral monocyte-derived macrophages as a control
in gene expression profiling
Finally, the most significant limitation of this thesis was the use of peripheral monocytederived macrophages from age- and sex-matched healthy individuals as the control for our
microarray study. This approach made it difficult to distinguish gene expression changes
specific to atherosclerotic macrophages from those arising from the in vitro differentiation
of monocytes into macrophages. Our rational for using these cells are four-fold. Firstly,
macrophages are present at extremely low density in non-diseased vascular intima – in our
samples, aortic biopsies lacking early-stage plaque had fewer than 1-2 intimal macrophages
per low-power field. Assuming those numbers are typical of what would be observed in
non-diseased individuals, the density of macrophages in healthy intima would be too low
to allow for recovery of enough cells for microarray analysis. Secondly, the resident
cardiac macrophages found in the healthy heart and adventitial macrophages found in
healthy arteries are largely of embryonic origin and therefore are of a completely different
ontology than plaque macrophages, the majority of which are hematopoietic in origin.71–73
Thirdly, low-level atherosclerosis is near-ubiquitous in the North American adult
population, making it questionable whether truly non-diseased tissue is available.74 Finally,
it is established that myeloid cells undergo significant changes in their gene expression
profiles as individuals age.75 As such, the choice to use monocyte-derived macrophages
recapitulates the correct ontology and age of the cells, in sufficient numbers to enable
experimentation, while allowing us to compare our patient samples to macrophages from
an environment free of atherogenic cues. That said, the lack of aortic intima-specific
developmental cues will have contributed some of the differentially-expressed genes we
observed in our microarray dataset. While we took pains to verify through functional assays
in vitro of GATA2-mediated impairment of efferocytosis and efferosome maturation, an
alternative source of control macrophages would have added to our confidence in the
macrophage phenotype we have described. Unfortunately, an appropriate population of
macrophages to serve as a control is lacking. An alternative approach would have been to
compare gene expression in macrophages isolated from early-stage and late-stage plaques,
or to compare the expression of genes between monocytes and lesion-resident macrophages
from the same patient. In our case this was not possible because of a lack of late-stage
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plaque from our aortic punch tissue samples and the inability to specifically identify the
patients from which each aortic punch sample was obtained due to the nature of our ethics
approval, which was limited to use discarded tissue.

6.4 Future Directions
6.4.1 Understanding the role of Rab17 in antigen presentation and
atherosclerosis
In this thesis, we have demonstrated that Rab17 is a crucial mediator of cargo trafficking
in efferocytosis. However, while we have demonstrated that interfering with Rab17
function results in mis-trafficking of apoptotic cargo to the MHC class II loading
compartment, whether this results in presentation of apoptotic cell-derived antigens
remains to be seen. Moving forwards, we will utilize model pathogens and apoptotic cells
expressing a fusion protein consisting of ovalbumin and the Eα peptide to study antigen
presentation in a Rab17 knockdown model. Ovalbumin-derived antigens are presented on
both MHC class I (SIINFEKL; H-2Kb) and MHC class II (OVA 323-339; I-A[d]), whereas
Eα peptide is presented exclusively on MHC class II (Eα 52-68; I-A[b]). Presentation of
ovalbumin-derived SIINFEKL peptide on MHC class I H-2Kb is readily detectable by the
25-D1.16 mouse monoclonal antibody whereas presentation of Eα 52-68 on MHC class II
I-A[b] can be detected using the Y-Ae mouse monoclonal antibody. Presentation of
ovalbumin-derived antigens on MHC class I and MHC class II may also be assessed by T
cell proliferation assays with naïve lymphocytes from OTI and OTII transgenic mice,
which express a limited T cell repertoire such that they are only responsive to ovalbuminderived antigens. Using these methods, we will be able to assess the impact on antigen
presentation following either phagocytosis of a pathogen or efferocytosis of an apoptotic
cell under normal conditions and with Rab17 functionally knocked down.
It will also be interesting to determine whether Rab17 has any biological role in
atherosclerosis. Our microarray and functional data show that efferosome maturation and
apoptotic cargo processing are dysregulated in atherosclerotic macrophages. Whether
Rab17 plays a role in this process remains unknown. It is well established that the
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development of plaque-reactive antibodies and T cells accelerates atherosclerosis disease.
This raises the interesting hypothesis that impaired or altered apoptotic cell processing in
atherosclerosis, potentially due to altered Rab17 activity, may drive the pro-atherogenic
presentation of atheroma-derived antigens–self-antigens which normally be restricted from
presentation by Rab17-mediated trafficking.76 We will seek to use live-cell fluorescence
imaging to assess the recruitment of Rab17 to efferosome under atherosclerotic conditions
and also to determine whether functional knockdown of Rab17 gives rise to any deleterious
effect in atherosclerotic macrophages.

6.4.2 Further elucidation of the biological role of GATA2 in
atherosclerosis
We have demonstrated thus far that GATA2 is upregulated in atherosclerotic macrophages
in early-stage lesions and that GATA2 upregulation appears to be required for oxLDLmediated impairment of efferocytic uptake and efferosome maturation in these
macrophages. We further demonstrated that signaling through the Src/Syk pathway
downstream of the oxLDL receptors CD36, TLR2 and TLR4 is required for GATA2
upregulation in response to oxLDL stimulus. However, there are still many unanswered
questions about the role of GATA2 in atherosclerosis.
First, there is a need to identify the mechanism(s) driving GATA2 upregulation. This could
be through oxLDL signaling via CD36 or other receptors, or in response to ER-stress
pathways activated in these cells—neither of which were explored in this thesis. This may
be achieved using receptor-specific shRNA and inhibitors of TLR and ER-stress signaling.
Second, it is still unclear how GATA2 upregulation results in impairment of efferocytosis
and efferosome maturation. Data from our microarray analysis suggests that this may be
through downregulation of signal transduction molecules required for efferocytic receptormediated apoptotic cell internalization (e.g. ILK, ITGAX) and downregulation of specific
genes required for efficient efferosome maturation (e.g. RAB7A, ATP6V1B1). However,
this remains to be demonstrated experimentally. One immediate first step is to perform a
ChIP-Seq assay in patient aortic punch macrophages or oxLDL-treated macrophages to
determine which genes GATA2 regulates in these cells. It may also be of interest to directly
compare gene expression in wild type macrophages compared to GATA2 overexpressing
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macrophages to identify the complete set of genes for which expression levels change with
increased levels of GATA2.
Fundamentally, it will also be necessary to directly demonstrate that GATA2 has a
biological role in atherosclerosis by studying the effect of GATA2 deletion on
atherosclerotic plaque development. This will require generating a monocyte/macrophagespecific Gata2 knockout mouse and either back-crossing this mouse onto a Ldlr-/background or performing bone marrow transplantation from the Gata2 knockout into Ldlr/-

mice. It is unclear at this time whether GATA2 is regulated the same in mice as in humans,

with preliminary experiments in Ldlr-/- mice fed a high-fat diet for 12 weeks compared to
chow diet-fed animals showing variable upregulation of GATA2 in the plaque. A myeloidspecific approach is necessary because whole body Gata2 knockout is embryonically lethal
due to hematopoietic and lymphatic collapse.54 Additionally, since GATA2 is required for
maintenance of the hematopoietic stem cell population and for myeloid-lineage
specification, it may be necessary create a floxed mouse where target gene recombination
is under the transcriptional control of a gene that is only expressed in terminallydifferentiated monocytes (e.g. CD11b), or where GATA2 excision is controlled by a
mature myeloid-restricted inducible knockout.54 We would then look at plaque size and
surface area, necrotic core size, macrophage numbers and phenotype within the plaque as
well as characterize plasma lipid levels and levels of circulating immune cells. Studying
myeloid-specific Gata2 knockout will be critical in establishing a biological role for this
transcription factor in atherosclerosis.

6.4.3 Characterizing changes in macrophage and monocyte gene
expression with atherosclerotic disease progression
A limitation in the present study is a lack of an appropriate population of control
macrophages to which atherosclerotic macrophage gene expression can be compared. One
way to circumvent this difficulty is to compare the gene expression profiles of macrophages
isolated from the plaques and monocytes isolated from the blood of patients with differing
atherosclerotic disease severities. There are many clinical scores that assess atherosclerotic
disease severity, including the Gensini score and the SYNTAX score.77,78 These scores
may be used to stratify patients into differing categories of disease severity. The gene
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expression profiles of macrophages and monocytes from patients from different categories
may then be compared against one another. This approach will allow us to identify genes
involved in atherosclerosis disease progression, at least within the latter stages of disease
in humans.
Another approach is to compare gene expression between lesion-resident macrophages and
circulating monocytes within the same patient. This would allow us to determine the
changes that occur in gene expression as monocytes migrate into the atherosclerotic plaque
and differentiate into macrophages. Such an approach has the potential to answer important
questions on the effect of the plaque microenvironment on macrophage function following
migration into the plaque.

6.4.4 Utilizing macrophage and monocyte gene expression profiling
to predict clinical outcomes in patients with coronary artery
disease
Understanding gene expression changes in macrophages and monocytes with progressive
atherosclerotic disease severity has the potential to allow us to identify important genes
and pathways involved in the underlying biology of plaque macrophages. This information
may then serve as a basis for determining whether differences in monocyte and macrophage
gene expression can be used to predict clinical outcomes in patients with significant
atherosclerotic disease (i.e. those patients who have experienced at least one cardiac or
cerebrovascular event as a result of atherosclerosis).
From a cohort of patients undergoing coronary artery bypass graft surgery for any reason,
the expression of a few genes of interest (e.g. GATA2), as determined on the basis of
characterizing the genes and pathways important for disease progression as outlined in the
previous section, will be quantified. These patients will then be followed for a period of
two years for cases of major adverse cardiovascular and cerebrovascular events (MACCE;
defined as a composite of myocardial infarction, ischemic stroke, need for repeat bypass
surgery and death).79 We will then determine whether gene expression in monocytes and/or
macrophages correlate with the incidence of MACCE. This will allow us to determine
whether the expression of certain genes in macrophages and/or monocytes can be used as
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a biomarker of adverse clinical outcomes in patients with high existing atherosclerotic
disease burden.

6.5 Concluding Remarks
In conclusion, the work presented in this doctoral thesis advances our understanding of
efferocytosis and the mechanisms by which efferocytosis becomes impaired in the setting
of atherosclerotic disease. We present three major findings: 1) the small GTPase Rab17
traffics degraded apoptotic cell contents from the phagolysosome to the recycling
endosome, likely preventing the presentation of apoptotic cell-derived antigens, 2)
macrophages isolated from early-stage plaque down-regulate many of the genes required
for efficient uptake and processing of apoptotic cells, and 3) upregulation of the
hematopoietic transcription factor GATA2 is required for the onset of impaired
efferocytosis and efferosome maturation in macrophages in response to oxLDL loading.
The findings presented here advance our fundamental knowledge of how apoptotic cells
are processed and degraded following internalization by an efferocyte. To date, how
macrophages discriminate between pathogens and apoptotic cells during cargo processing
is poorly understood. Previous studies have suggested that differences in TLR signaling
from the phagosome or in the inherent differences in kinetics between phagosome and
efferosome maturation are responsible for the divergent outcomes observed following
efferocytosis and phagocytosis.21,80 Our observation that Rab17 is required for efferosomal
cargo trafficking to the recycling endosome and that impaired Rab17 activity leads to mistrafficking of cargo to the MHC class II loading compartment (Chapter 3) suggests that
there is a phagocyte-intrinsic, TLR-independent pathway that plays a role in discrimination
between pathogens and apoptotic cell cargo.
Our findings also challenge some widely-held notions in the field about the development
of efferocytic defects in the setting of atherosclerosis. Our observation that lesion-resident
macrophages from early-stage human plaques already have dysregulated expression of
genes involved in efferocytosis (Chapter 4) suggest that the onset of impaired
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efferocytosis may be occurring much earlier than previously thought. We are also the first
to identify a potential defect in efferosome maturation in human lesion-resident
macrophages (Chapter 4), suggesting that defects in how macrophages process apoptotic
cargo, in addition to defects in recognition and efferocytic uptake of apoptotic cells, plays
a role in the development of defective efferocytosis. Finally, we are also the first to identify
a potential role for the hematopoietic transcription factor GATA2 in driving macrophage
dysfunction in human atherosclerotic disease. We observed that GATA2 is required for
oxLDL-mediated impairments in both efferocytic uptake and efferosome maturation
(Chapter 5), implicating this transcription factor as a major driver of dysregulated
macrophage function under atherosclerotic conditions.
Much work remains to be done in furthering our understanding of the role of macrophages,
defective apoptotic cell clearance and inflammation in atherosclerosis. Following decades
of clinical interest and success in treating the dyslipidemia component of atherosclerosis,
the results of the recent CANTOS trial have brought the inflammatory component of this
disease back into the primetime.81 The results presented in this thesis represent a just small
step forward in unraveling our understanding of the underlying mechanisms of how
apoptotic cell clearance becomes impaired in human atherosclerotic disease. Importantly,
our discovery of GATA2 as a potential master regulator of defective efferocytosis in earlystage human atherosclerotic macrophages merits further investigation. GATA2 and its
downstream targets may represent viable therapeutic targets in the development of novel
anti-inflammatory agents for the treatment of the residual inflammatory risk in
atherosclerosis.

6.6 References
1.

Nagata S. Apoptosis and Clearance of Apoptotic Cells. Annu Rev Immunol.
2018;361829(1):1-18. doi:10.1146/annurev-immunol

2.

Green DR, Oguin TH, Martinez J. The clearance of dying cells: table for two. Cell
Death Differ. 2016;23(6):915-926. doi:10.1038/cdd.2015.172

245

3.

Trahtemberg U, Mevorach D. Apoptotic Cells Induced Signaling for Immune
Homeostasis in Macrophages and Dendritic Cells. Front Immunol.
2017;8(October). doi:10.3389/fimmu.2017.01356

4.

Tabas I. Macrophage death and defective inflammation resolution in
atherosclerosis. Nat Rev Immunol. 2009;10(1):36-46. doi:10.1038/nri2675

5.

Van Vré E a., Ait-Oufella H, Tedgui A, Mallat Z. Apoptotic cell death and
efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(4):887893. doi:10.1161/ATVBAHA.111.224873

6.

Kojima Y, Weissman IL, Leeper NJ. The Role of Efferocytosis in Atherosclerosis.
Circulation. 2017;135(5):476-489. doi:10.1161/CIRCULATIONAHA.116.025684

7.

Stenmark H, Olkkonen VM. The Rab GTPase family. Genome Biol.
2001;2(5):REVIEWS3007. doi:10.1186/gb-2001-2-5-reviews3007

8.

Kinchen JM, Ravichandran KS. Phagosome maturation: going through the acid
test. Nat Rev Mol Cell Biol. 2008;9(10):781-795. doi:10.1038/nrm2515

9.

Cai B, Thorp EB, Doran AC, et al. MerTK receptor cleavage promotes plaque
necrosis and defective resolution in atherosclerosis. J Clini. 2017;127(2):564-568.
doi:10.1172/JCI90520.We

10.

Tabas I. 2016 Russell Ross Memorial Lecture in Vascular Biology. Arterioscler
Thromb Vasc Biol. 2016:ATVBAHA.116.308036.
doi:10.1161/ATVBAHA.116.308036

11.

Muiya NP, Wakil S, Al-Najai M, et al. A study of the role of GATA2 gene
polymorphism in coronary artery disease risk traits. Gene. 2014;544(2):152-158.
doi:10.1016/j.gene.2014.04.064

12.

Connelly JJ, Wang T, Cox JE, et al. GATA2 is associated with familial early-onset
coronary artery disease. PLoS Genet. 2006;2(8):1265-1273.
doi:10.1371/journal.pgen.0020139

246

13.

Bresnick EH, Katsumura KR, Lee HY, Johnson KD, Perkins AS. Master
regulatory GATA transcription factors: Mechanistic principles and emerging links
to hematologic malignancies. Nucleic Acids Res. 2012;40(13):5819-5831.
doi:10.1093/nar/gks281

14.

Ariel A, Ravichandran KS. ‘This way please’: Apoptotic cells regulate phagocyte
migration before and after engulfment. Eur J Immunol. 2016:1-4.
doi:10.1002/eji.201646505

15.

Henson PM. Cell Removal : Efferocytosis. Annu Rev Cell Dev Biol. 2017;33:1-18.

16.

Cui Y, Zhao Q, Gao C, et al. Activation of the Rab7 GTPase by the MON1-CCZ1
complex is essential for PVC-to-vacuole trafficking and plant growth in
Arabidopsis. Plant Cell. 2014;26(5):2080-2097. doi:10.1105/tpc.114.123141

17.

Rupper A, Grove B, Cardelli J. Rab7 regulates phagosome maturation in
Dictyostelium. J Cell Sci. 2001;114(13):2449-2460.

18.

Flannagan RS, Jaumouillé V, Grinstein S. The Cell Biology of Phagocytosis. Annu
Rev Pathol Mech Dis. 2011;7(1):61-98. doi:10.1146/annurev-pathol-011811132445

19.

Blander JM. Regulation of Phagosome Maturation by Signals from Toll-Like
Receptors. Science. 2011;1014(2004):1014-1018. doi:10.1126/science.1096158

20.

Blander JM, Medzhitov R. On regulation of phagosome maturation and antigen
presentation. Nat Immunol. 2006;7(10):1029-1035. doi:10.1038/ni1006-1029

21.

Magarian Blander J, Medzhitov R. Toll-dependent selection of microbial antigens
for presentation by dendritic cells. Nature. 2006;440(7085):808-812.
doi:10.1038/nature04596

22.

Schröder B. The multifaceted roles of the invariant chain CD74 - More than just a
chaperone. Biochim Biophys Acta - Mol Cell Res. 2016;1863(6):1269-1281.
doi:10.1016/j.bbamcr.2016.03.026

247

23.

Yates RM, Russell DG. Phagosome maturation proceeds independently of
stimulation of toll-like receptors 2 and 4. Immunity. 2005;23(4):409-417.
doi:10.1016/j.immuni.2005.09.007

24.

Moore KJ, Sheedy FJ, Fisher E a. Macrophages in atherosclerosis: a dynamic
balance. Nat Rev Immunol. 2013;13(10):709-721. doi:10.1038/nri3520

25.

Rojas J, Salazar J, Martínez MS, et al. Macrophage Heterogeneity and Plasticity:
Impact of Macrophage Biomarkers on Atherosclerosis. Scientifica (Cairo).
2015;2015:1-17. doi:10.1155/2015/851252

26.

Westover E. Cholesterol in Health and Disease. J Clin Invest. 2002;110(5):583590. doi:10.1172/JCI200216381.Imagine

27.

Li Y, Gerbod-Giannone MC, Seitz H, et al. Cholesterol-induced apoptotic
macrophages elicit an inflammatory response in phagocytes, which is partially
attenuated by the Mer receptor. J Biol Chem. 2006;281(10):6707-6717.
doi:10.1074/jbc.M510579200

28.

Li Y, Seitz H, Cui D, et al. Cholesterol-induced Apoptotic Macrophages Elicit an
Inflammatory Response in Phagocytes , Which Is Partially Attenuated by the Mer
Receptor *. J Bacteriol. 2006;281(10):6707-6717. doi:10.1074/jbc.M510579200

29.

Seo J-W, Yang E-J, Yoo K-H, Choi I-H. Macrophage Differentiation from
Monocytes Is Influenced by the Lipid Oxidation Degree of Low Density
Lipoprotein. Mediators Inflamm. 2015;2015:1-10. doi:10.1155/2015/235797

30.

Cui D, Thorp E, Li Y, et al. Pivotal advance: macrophages become resistant to
cholesterol-induced death after phagocytosis of apoptotic cells. J Leukoc Biol.
2007;82(5):1040-1050. doi:10.1189/jlb.0307192

31.

Stöger JL, Gijbels MJJ, van der Velden S, et al. Distribution of macrophage
polarization markers in human atherosclerosis. Atherosclerosis. 2012;225(2):461468. doi:10.1016/j.atherosclerosis.2012.09.013

248

32.

Cochain C, Vafadarnejad E, Arampatzi P, et al. Single-Cell RNA-Seq Reveals the
Transcriptional Landscape and Heterogeneity of Aortic Macrophages in Murine
Atherosclerosis. Circ Res. 2018;122(12):1661-1674.
doi:10.1161/CIRCRESAHA.117.312509

33.

Boyle JJ, Harrington H a, Piper E, et al. Coronary intraplaque hemorrhage evokes
a novel atheroprotective macrophage phenotype. Am J Pathol. 2009;174(3):10971108. doi:10.2353/ajpath.2009.080431

34.

Boyle JJ, Johns M, Kampfer T, et al. Activating transcription factor 1 directs
Mhem atheroprotective macrophages through coordinated iron handling and foam
cell protection. Circ Res. 2012;110(1):20-33.
doi:10.1161/CIRCRESAHA.111.247577

35.

Kadl A, Meher AK, Sharma PR, et al. Identification of a novel macrophage
phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ
Res. 2010;107(6):737-746. doi:10.1161/CIRCRESAHA.109.215715

36.

Sussan TE, Jun J, Thimmulappa R, et al. Disruption of Nrf2, a key inducer of
antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice. PLoS
One. 2008;3(11):e3791. doi:10.1371/journal.pone.0003791

37.

Schrijvers DM, De Meyer GRY, Kockx MM, Herman AG, Martinet W.
Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis.
Arterioscler Thromb Vasc Biol. 2005;25(6):1256-1261.
doi:10.1161/01.ATV.0000166517.18801.a7

38.

Gautier EL, Huby T, Witztum JL, et al. Macrophage apoptosis exerts divergent
effects on atherogenesis as a function of lesion stage. Circulation.
2009;119(13):1795-1804. doi:10.1161/CIRCULATIONAHA.108.806158

39.

Pulanco MC, Cosman J, Ho M, et al. Complement Protein C1q Enhances
Macrophage Foam Cell Survival and Efferocytosis. J Immunol. 2016;198.
doi:10.4049/jimmunol.1601445

249

40.

Nakashima Y, Chen YX, Kinukawa N, Sueishi K. Distributions of diffuse intimal
thickening in human arteries: Preferential expression in atherosclerosis-prone
arteries from an early age. Virchows Arch. 2002;441(3):279-288.
doi:10.1007/s00428-002-0605-1

41.

Liu J, Thewke DP, Su YR, Linton MF, Fazio S, Sinensky MS. Reduced
macrophage apoptosis is associated with accelerated atherosclerosis in low-density
lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol. 2005;25(1):174179. doi:10.1161/01.ATV.0000148548.47755.22

42.

Zhang S, Yeap XY, Grigoryeva L, et al. Cardiomyocytes induce macrophage
receptor shedding to suppress phagocytosis. J Mol Cell Cardiol. 2015;87:171-179.
doi:10.1016/j.yjmcc.2015.08.009

43.

Kojima Y, Volkmer J-P, McKenna K, et al. CD47-blocking antibodies restore
phagocytosis and prevent atherosclerosis. Nature. 2016;536(7614):86-90.
doi:10.1038/nature18935

44.

Kimani SG, Geng K, Kasikara C, et al. Contribution of defective PS recognition
and efferocytosis to chronic inflammation and autoimmunity. Front Immunol.
2014;5(NOV):1-9. doi:10.3389/fimmu.2014.00566

45.

Wang Y, Subramanian M, Yurdagul A, et al. Mitochondrial Fission Promotes the
Continued Clearance of Apoptotic Cells by Macrophages. Cell. 2017;171(2):331345.e22. doi:10.1016/j.cell.2017.08.041

46.

Kinchen JM, Ravichandran KS. Identification of two evolutionarily conserved
genes regulating processing of engulfed apoptotic cells. Nature.
2010;464(7289):778-782. doi:10.1038/nature08853

47.

Bagaitkar J, Huang J, Zeng MY, et al. NADPH oxidase activation regulates
apoptotic neutrophil clearance by murine macrophages. Blood. 2018.
doi:10.1104/pp.111.188953

48.

de Gaetano M, Crean D, Barry M, Belton O. M1- and M2-Type Macrophage

250

Responses Are Predictive of Adverse Outcomes in Human Atherosclerosis. Front
Immunol. 2016;7(July). doi:10.3389/fimmu.2016.00275
49.

Mills CD, Lenz LL, Ley K. Macrophages at the fork in the road to health or
disease. Front Immunol. 2015;6(February):1-6. doi:10.3389/fimmu.2015.00059

50.

Röszer T. Transcriptional control of apoptotic cell clearance by macrophage
nuclear receptors. Apoptosis. 2016;0(0):0. doi:10.1007/s10495-016-1310-x

51.

Doran AC, Ozcan L, Cai B, et al. CAMKIIγ suppresses an efferocytosis pathway
in macrophages and promotes atherosclerotic plaque necrosis. J Clin Invest.
2017;(16):1-15. doi:10.1172/JCI94735

52.

Costet P, Lalanne F, Gerbod-Giannone MC, et al. Retinoic Acid ReceptorMediated Induction of ABCA1 in Macrophages. Mol Cell Biol. 2003;23(21):77567766. doi:10.1128/mcb.23.21.7756-7766.2003

53.

Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko A V., Orekhov AN.
Mechanisms of foam cell formation in atherosclerosis. J Mol Med.
2017;95(11):1153-1165. doi:10.1007/s00109-017-1575-8

54.

Lim KC, Hosoya T, Brandt W, et al. Conditional Gata2 inactivation results in HSC
loss and lymphatic mispatterning. J Clin Invest. 2012;122(10):3705-3717.
doi:10.1172/JCI61619

55.

Shih AH, Jiang Y, Meydan C, et al. Mutational cooperativity linked to
combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell.
2015;27(4):502-515. doi:10.1016/j.ccell.2015.03.009

56.

Luesink M, Hollink IHIM, van der Velden VHJ, et al. High GATA2 expression is
a poor prognostic marker in pediatric acute myeloid leukemia. Blood.
2012;120(10):2064-2075. doi:10.1182/blood-2011-12-397083 LK http://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=00064971&id=doi:10.1182%2
Fblood-2011-12397083&atitle=High+GATA2+expression+is+a+poor+prognostic+marker+in+ped

251

iatric+acute+myeloid+leukemia&stitle=Blood&title=Blood&volume=120&issue=
10&spage=2064&epage=2075&aulast=Luesink&aufirst=Maaike&auinit=M.&auf
ull=Luesink+M.&coden=BLOOA&isbn=&pages=20642075&date=2012&auinit1=M&auinitm=
57.

Jaiswal S, Natarajan P, Silver AJ, et al. Clonal Hematopoiesis and Risk of
Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377(2):111-121.
doi:10.1056/NEJMoa1701719

58.

Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated
with Tet2 deficiency accelerates atherosclerosis development in mice. Science (80). 2017;1381(January).

59.

Xie M, Lu C, Wang J, et al. Age-related cancer mutations associated with clonal
hematopoietic expansion. Nat Med. 2015;20(12):1472-1478.
doi:10.1038/nm.3733.Age-related

60.

Zhang S-J, Ma L-Y, Huang Q-H, et al. Gain-of-function mutation of GATA-2 in
acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci.
2008;105(6):2076-2081. doi:10.1073/pnas.0711824105

61.

Harrison RE, Bucci C, Vieira O V, Schroer TA, Grinstein S. Phagosomes fuse
with late endosomes and/or lysosomes by extension of membrane protrusions
along microtubules: role of Rab7 and RILP. Mol Cell Biol. 2003;23(18):64946506. doi:10.1128/MCB.23.18.6494

62.

Chai JT, Ruparelia N, Goel A, et al. Differential Gene Expression in Macrophages
From Human Atherosclerotic Plaques Shows Convergence on Pathways
Implicated by Genome-Wide Association Study Risk Variants. Arterioscler
Thromb Vasc Biol. 2018;38(11):2718-2730. doi:10.1161/ATVBAHA.118.311209

63.

Getz GS, Reardon C a. Animal models of Atherosclerosis. Arterioscler Thromb
Vasc Biol. 2012;32(5):1104-1115. doi:10.1161/ATVBAHA.111.237693

64.

Yahagi K, Kolodgie FD, Otsuka F, et al. Pathophysiology of native coronary, vein

252

graft, and in-stent atherosclerosis. Nat Rev Cardiol. 2015;advance on.
doi:10.1038/nrcardio.2015.164
65.

Trogan E, Choudhury RP, Dansky HM, Rong JX, Breslow JL, Fisher E a. Laser
capture microdissection analysis of gene expression in macrophages from
atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S
A. 2002;99(4):2234-2239. doi:10.1073/pnas.042683999

66.

Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA.
Contribution of intimal smooth muscle cells to cholesterol accumulation and
macrophage-like cells in human atherosclerosis. Circulation. 2014;129(15):15511559. doi:10.1161/CIRCULATIONAHA.113.005015

67.

Wang Y, Dubland JA, Allahverdian S, et al. Smooth Muscle Cells Contribute the
Majority of Foam Cells in ApoE (Apolipoprotein E)-Deficient Mouse
Atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39(5):876-887.
doi:10.1161/ATVBAHA.119.312434

68.

Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and
therapeutic aspects. Antioxid Redox Signal. 2013;18(17):2352-2363.
doi:10.1089/ars.2012.4834

69.

Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y.
Expression of CD163 (hemoglobin scavenger receptor) in normal tissues,
lymphomas, carcinomas, and sarcomas is largely restricted to the
monocyte/macrophage lineage. Am J Surg Pathol. 2005;29(5):617-624.
doi:10.1097/01.pas.0000157940.80538.ec

70.

Nakano A, Harada T, Morikawa S, Kato Y. Expression of Leukocyte Common
Antigen (CD45) on Various Human Leukemia/Lymphoma Cell Lines. Pathol Int.
1990;40(2):107-115. doi:10.1111/j.1440-1827.1990.tb01549.x

71.

Epelman S, Lavine KJ, Beaudin AE, et al. Embryonic and adult-derived resident
cardiac macrophages are maintained through distinct mechanisms at steady state

253

and during inflammation. Immunity. 2014;40(1):91-104.
doi:10.1016/j.immuni.2013.11.019
72.

Ensan S, Li A, Besla R, et al. Self-renewing resident arterial macrophages arise
from embryonic CX3CR1+ precursors and circulating monocytes immediately
after birth. Nat Immunol. 2015;17(2):159-168. doi:10.1038/ni.3343

73.

Rahman K, Vengrenyuk Y, Ramsey SA, et al. Inflammatory Ly6Chimonocytes
and their conversion to M2 macrophages drive atherosclerosis regression. J Clin
Invest. 2017;127(8):2904-2915. doi:10.1172/JCI75005

74.

Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of
Atherosclerosis and the Potential to Reduce the Global Burden of
Atherothrombotic Disease. Circ Res. 2016;118(4):535-546.
doi:10.1161/CIRCRESAHA.115.307611

75.

Lissner MM, Thomas BJ, Wee K, Tong AJ, Kollmann TR, Smale ST. Age-related
gene expression differences in monocytes from Human Neonates, Young Adults,
and Older Adults. PLoS One. 2015;10(7):1-18. doi:10.1371/journal.pone.0132061

76.

Abdolmaleki F, Farahani N, Hayat SMG, et al. The role of efferocytosis in
autoimmune diseases. Front Immunol. 2018;9(JUL):1-13.
doi:10.3389/fimmu.2018.01645

77.

Sianos G, Morel M-A, Kappetein AP, et al. The SYNTAX Score: an angiographic
tool grading the complexity of coronary artery disease. EuroIntervention.
2005;1(2):219-227. doi:EIJV1I2A36 [pii]

78.

Kashani H, Zeraati H, Mohammad K, et al. Analyzing gensini score as a semicontinuous outcome. J Tehran Univ Hear Cent. 2016;11(2):55-61.

79.

Serruys PW, Ong ATL, van Herwerden LA, et al. Five-Year Outcomes After
Coronary Stenting Versus Bypass Surgery for the Treatment of Multivessel
Disease. J Am Coll Cardiol. 2005;46(4):575-581.
doi:http://dx.doi.org/10.1016/j.jacc.2004.12.082

254

80.

Erwig L-P, McPhilips KA, Wynes MW, Ivetic A, Ridley AJ, Henson PM.
Differential regulation of phagosome maturation in macrophages and dendritic
cells mediated by Rho GTPases and ezrin–radixin–moesin (ERM) proteins. Proc
Natl Acad Sci USA. 2006;103(34):12825-12830. doi:10.1155/2015/359153

81.

Ridker PM, Dellborg M, Kastelein JJP, et al. Antiinflammatory Therapy with
Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):11191131. doi:10.1056/nejmoa1707914

255

Appendices
Appendix A List of all constructs used in this thesis
Gene

18S
CD14
SMA
GATA2
E4F1
RARG
ABCA1
NPC1
NPC2
RAB7A
ITGAX
CD44
ILK
PADI3
mGata2
mGapdh

GATA2
Rab17
DN-Rab17

Sequence
qPCR primers
5’-GAGGGAGCCTGAGAAACGG-3’
5’-GTCGGGAGTGGGTAATTTGC-3’
5’-AGCCAAGGCAGTTTGAGTCC-3’
5’-TAAAGGACTGCCAGCCAAGC-3’
5’-CCGACCGAATGCAGAAGGA-3’
5’-ACAGAGTATTTGCGCTCCG-3’
5’-GTCACTGACGGAGAGCATGA-3’
5’-GGCACATAGGAGGGGTAGGT-3’
5’-ACACCACACAGGCGAGA-3’
5’-TCCTCAGACACCAGCAAC-3’
5’-CTGCCAGTACTGCCGGCTAC-3’
5’-TCTGCACTGGAGTTCGTGGTATACT-3’
5’-GCACTGAGGAAGATGCTGAAA-3’
5’-AGTTCCTGGAAGGTCTTGTTCAC-3’
5’-AGCCAGTAATGTCACCGAAAC-3’
5’-CCGAGGTTGAAGATAGTGTCG-3’
5’-TATCCCTCTATAAAACTGGTGGTG-3’
5’-CCAGATGCACCGAACTCAAT-3’
5’-CATCCTGGGAGATTCTGGAGTC-3’
5’-TGTGTCCCATATCTGCATTGTG-3’
5’-GCTGAAGGCACACTGTGAAA-3’
5’-AGGGAGGCCGTGAAGTATCT-3’
5’-TGGCACCCGCTATGTCCAG-3’
5’-GTAGCAGGGATTCTGTCTG-3’
5’-ATGTACTACATGAAGGCACCAATTTC-3’
5’-CCCCTTGCCATGTCCAAAG-3’
5’-GGAGACCCTCGTGGACATTT-3’
5’-CTCCAAAGTCGCGTCAAAGC-3’
5’-GCAGAGAAGCAAGGCTCGC-3’
5’-CAGTTGACACACTCCCGGC-3’
5’-CTCCCACTCTTCCACCTTCG-3’
5’-GCCTCTCTTGCTCAGTGTCC-3’
PCR primers
5’-TATTTCCGGTGAATTCATGGAGGTGGCGGCCGAGCA-3’
5’-CGGGATCCGCGGCCGCTAGCCCATGGCGGTCACCATGCT-3’
5’- AAAAAAAAAGAATTCGATGGCACAGGCACACAGGACCCC-3’
5’-TTTTTTTTTGGATCCCTAGTGGGCGCAGCATTTGGCCT-3’
5’-GCCCACCAGCATCACCAGGACTTC-3’
5’-ATCAAGACGGACCTCAGCCAGGAGCGG-3’
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GATA2

shRNA sequences
5'-AAGGATCCAGCAAGGCTCGTTCCTGTTCATCAAG
AGTGAACAGGAACGAGCCTTGCTTTTTTACCGGTAA-3'
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Appendix B List of all primers and oligos used in this thesis.
Construct

Backbone

Enzyme Cut
Sites

Sequencing
Primer(s)

PM-RFP

pcDNA3

HindIII; XbaI

PM-GFP

pcDNA3

HindIII; XbaI

Rab5-GFP

pEGFP-C1

EcoRI; BamHI

Rab7-RFP

pmCherry-C1

EcoRI; BamHI

SV40pA-R

Rab17-GFP

pEGFP-C1

EcoRI; BamHI

EGFP-C;
SV40pA-R

Rab17-RFP

pmCherry-C1

EcoRI; BamHI

SV40pA-R

DN-Rab17-RFP

pmCherry-C1

EcoRI; BamHI

SV40pA-R

Rab6b-GFP

pEGFP-C1

EcoRI; BamHI

Rab45-GFP

pEGFP-C1

EcoRI; BamHI

pLVX-IRESZsGreen1 GATA2
pGFP-C-shLenti
GATA2 shRNA1

pLVX-IRESZsGreen1

EcoRI

CMV

pGFP-C-shLenti

BamHI; AgeI

CMV

CMV;
SV40pA-R
CMV;
SV40pA-R
EGFP-C;
SV40pA-R

EGFP-C;
SV40pA-R
EGFP-C;
SV40pA-R

258

Appendix C List of the 100 most up-regulated genes from the patient macrophage
microarray
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

Gene Symbol
OR2T12
LRRC3C
ZNF705E
LOC646743
CLEC18A
TCEA2
GPRC5D
OR52I1
OR2A42
KRTAP12-4
LINC01562
CHFR
OR51S1
PGM5
C10orf53
BAGE4
CAMK2N2
C7orf65
OR2T3
OR51B4
ZNF648
ZNF675
NBPF4
KRTAP4-8
TMEM200C
TPBGL
PRAMEF8
AVP
LOC101930023
RAB44
KCNK18
CNTNAP3
CHST3
C3orf18
OR10H4
FOXF2
CACNG5
OR5F1
C9orf62
FAM26E

Fold Change
9.62722
6.74565
4.42287
3.85502
3.84465
3.78658
3.78366
3.7386
3.50104
3.42346
3.33314
3.22888
3.20428
3.16232
3.12336
3.07173
3.05843
3.05369
3.02501
2.93111
2.92935
2.86593
2.86195
2.73692
2.73062
2.66528
2.66506
2.66329
2.65457
2.63632
2.61918
2.60335
2.55363
2.54441
2.53899
2.53369
2.52677
2.50943
2.48851
2.48581
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41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84

ZACN
HPCA
OLFM1
LGALS14
YAP1
MSX2
KRT81
CHST5
GATA2
ANKRD63
TMEM98
C5orf60
MYH7
KIR3DL2
CFAP77
LOC162137
NANOS3
S100A7A
ARID3C
GOLGA7B
LINC00355
SNORA78
TMEM74B
E4F1
SPRN
RARG
LOC101929469
PADI3
FOXD4L5
MTRNR2L10
LDB3
MAGIX
PNMA5
FKRP
LAGE3
ANKRD60
HOXA7
SBK3
MOSPD3
PSKH2
ANTXRL
LMX1B
LOC101927503
C1orf116

2.48312
2.47082
2.4674
2.46699
2.45382
2.45281
2.43951
2.43565
2.42342
2.42284
2.42282
2.41695
2.40692
2.37758
2.37248
2.37207
2.36682
2.36563
2.36417
2.3582
2.34773
2.3349
2.32943
2.32076
2.3178
2.30969
2.30961
2.30731
2.30638
2.2982
2.29628
2.2868
2.2776
2.27714
2.27668
2.27227
2.25975
2.25707
2.24509
2.24342
2.23942
2.23414
2.22992
2.22789
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85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

CGN
HSFX1
TRPC7
HNF4A-AS1
ST6GALNAC5
KCNJ14
HCRTR1
BHLHB9
CYP2A13
TCEAL3
DRD3
MMRN1
LOC100287477
KDM4D
DNAJB7
RUNX1T1

2.22447
2.21322
2.21214
2.2089
2.20807
2.20672
2.20412
2.19662
2.19164
2.18544
2.184
2.18251
2.18245
2.18208
2.17999
2.17761
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Appendix D List of the 100 most down-regulated genes from the patient
macrophage microarray
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Gene Symbol
TXN
C15orf48
FTL
SUMO2
HLA-DRA
PLAUR
RAB7A
CTSS
OAZ1
TMSB10
CYBB
FCER1G
POMP
PRDX1
LAPTM5
CCL4
CXCL16
SLC7A11
NPC2
RPL27
MMP9
PSAP
SQRDL
ATP6V0E1
IGSF6
IFI30
CD68
COX4I1
SRGN
SLAMF7
LYZ
RPL41
CHI3L1
RPS2
CBWD2
ATP6V1F

Fold Change
-411.775
-304.907
-273.736
-251.54
-249.226
-213.088
-181.069
-175.483
-161.761
-155.19
-142.868
-125.149
-117.743
-117.17
-114.969
-112.871
-111.563
-106.723
-103.934
-99.386
-94.4103
-90.8828
-88.5736
-87.0824
-86.649
-86.0078
-85.0816
-84.5514
-84.234
-81.9502
-81.1264
-81.035
-80.5382
-79.1202
-77.2671
-76.9367
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37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80

BCL2A1
PLA2G7
PSMA3
ARPC5
RPS2
COX8A
AQP9
ACTG1
RAB31
ATP5B
GMFG
TNFAIP6
ANXA5
NBEAL1
UBA52
SEP15
SPP1
DAD1
CD44
LAPTM4A
SOD1
EIF4G2
ADAMDEC1
AHR
CES1P1
ITGAX
WSB1
ACTR3
FDX1
NDUFA1
UBE2K
PSMB3
KYNU
RPS2
MSN
SERINC3
ANXA1
RPS28
CYB5A
GLIPR1
CALR
TIMM23
ITM2B
RAB1A

-70.9492
-70.2001
-69.3309
-68.7327
-68.2021
-67.5268
-66.065
-65.3203
-64.7101
-61.2968
-60.7423
-58.9338
-57.8008
-57.4835
-56.6651
-56.6403
-56.5101
-56.3629
-55.613
-55.4191
-53.6316
-53.1141
-52.9579
-52.8631
-51.9996
-51.7944
-51.2909
-50.372
-50.1473
-49.7039
-48.7071
-48.5966
-48.1175
-47.79
-47.2697
-46.8628
-46.2265
-45.5
-45.3311
-44.9408
-44.1832
-43.4285
-42.5918
-42.1434
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81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

RPS11
GRN
CCL2
VAMP8
APLP2
MMP7
HIST1H2AC
IL1A
VMP1
DRG1
ATP6AP2
IL1B
ATP6V1C1
YBX1
CSGALNACT2
ERP44
NOP10
CXCR4
CCL3L3
ELF1

-42.0848
-41.6052
-41.4591
-41.3574
-41.1694
-40.7584
-38.9235
-38.9067
-38.8178
-38.6188
-38.5816
-37.4948
-37.2856
-37.2772
-36.9458
-36.484
-36.1277
-35.7405
-35.4365
-35.0605
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